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 A. Introduction 1 
A. INTRODUCTION 
1 Cytomegalovirus as a herpesvirus 
1.1 The group of herpesviruses 
Cytomegalovirus (CMV) is a member of the herpesvirus family which consists of more 
than 100 members. Eight of these infect humans: herpes simplex virus I and II, varicel-
la-zoster virus, cytomegalovirus, human herpesvirus 6 and 7, Epstein-Barr virus, and 
human herpesvirus 8. The name “herpes” is derived from the Greek word “herpein” that 
means “to creep like a snake”. This term describes the capacity of eczemas to slowly 
spread on the skin of individuals infected with the herpes simplex or varicella-zoster 
virus. 
Herpesviruses share biological features and particle morphology. They have double-
stranded DNA genomes with a high coding capacity and all herpesviruses can establish 
latent infection. Herpesviruses can be subdivided into α-, β- und γ-herpesviruses de-
pending on host spectrum, replication time and cell tropism. CMV is the principal 
member of the β-herpesvirus subgroup. It exhibits a number of biological characteris-
tics, common to all β-herpesviruses, including salivary gland tropism, strict species spe-
cificity, and slow growth in cultured cells (Ho et al., 1991; Roizman et al., 1981). Hu-
man herpesvirus 6 and 7 are also members of the β-herpesviruses. γ- and β-
herpesviruses display strict species specificity, but the length of the replication cycle 
varies between the different members of the two families. The γ-species infects B- and 
T-cells of the lymphoid system. Prominent members of this family are the Epstein-Barr 
virus and the human herpesvirus 8. α-herpesviruses have a broad host spectrum and 
short replication cycle in contrast to γ- and β-herpesviruses. They have the capacity to 
establish latency in ganglia and contiguous neural tissue. Herpes simplex virus I and II 
and the varicella-zoster virus belong to this family. 
HCMV is an important human pathogen that causes disease in the immunologically 
immature or the immunocompromised host, such as premature infants, newborns, trans-
plant recipients and individuals infected with human immunodeficiency virus. 
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1.2 Cytomegalovirus 
The term cytomegalia was first used in 1921 and describes the prominent cell enlarge-
ment induced by the cytomegalovirus (Goodpasture and Talbot, 1921). Cells infected 
with CMV show virus-induced cytopathic effects (CPE) with characteristic nuclear and 
cytoplasmic inclusions and cell rounding. 
1.2.1 Structure of the cytomegalovirus virion 
CMVs resemble morphologically other members of the herpesvirus family. Mature vi-
rions have a diameter of 150 to 200 nm. The CMV virion (see Fig. A 1) consists of an 
icosahedral capsid encasing a double-stranded linear DNA genome with a core sur-
rounded by a tegument (a fairly unstructured matrix of viral proteins) and is enveloped 
in a lipid bilayer, which carries a large number of virus-encoded glycoproteins (Britt 
and Mach, 1996). Purified virus particles of HCMV have been estimated to contain 30 
to 40 polypeptides with molecular weights ranging from 20 to over 300 kDa in size 
(Baldick and Shenk, 1995). The capsid is composed of seven proteins, all of which are 
homologous to those identified in HSV and at least 25 proteins are located in the tegu-
 
Fig. A 1 The CMV virion. The nucleocapsid containing the core, the linear DNA and the 
icosahedral capsid, is surrounded by tegument. The viral envelope is composed of a lipid 
bilayer with viral glycoproteins. 
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ment between the virion capsid and the envelope (Gibson 1996). The virion envelope 
carries two prominent herpesvirus-conserved glycoprotein complexes (one composed of 
dimers of glycoprotein B (gB) and the other of gH, gL, and gO) embedded in a host li-
pid bilayer derived from intracellular membranes (Britt and Mach, 1996). 
Apart from infectious virions, non-infectious enveloped particles and dense bodies 
are produced in HCMV-infected cells (Irmiere and Gibson, 1983). Dense bodies do not 
contain viral DNA or capsid. They mainly constitute of the tegument protein pp65 
(Craighead et al., 1972), while the less abundant non-infectious particles do have a cap-
sid but lack DNA. In murine CMV infected cells dense bodies are not produced, but vi-
rions that contain several capsids have been observed (Chong and Mims, 1981). 
1.2.2 Organization of the cytomegalovirus genome 
The linear molecules of HCMV and MCMV are significantly larger than those of other 
herpesviruses and are among the largest and most complex virus genomes (Fig. A 2) 
(Chee et al., 1990; Rawlinson et al., 1996). 
The HCMV genome has two unique components, the unique long (UL) and unique 
short (US) sequences, flanked by inverted repeats b (TRL/IRL) and c (IRS/TRS) (Fig. A 
2). Different orientations of the inverted repeats can establish four isomers of HCMV. 
The HCMV open reading frames (ORFs) are numbered sequentially and designated by 
their location within the unique and repeated regions of the viral genome (Chee et al., 
1990). 
The MCMV genome comprises of a single unique sequence (Ebeling et al., 1983). 
Direct terminal repeats are present at the ends of the MCMV genome and multiple other 
direct and inverted repeats of different lengths are found (in a higher quantity than in 
other herpesviruses) at different positions of the genome (Rawlinson et al., 1996). 
MCMV ORFs that show sequence similarity to HCMV ORFs are designated with up-
per-case letters (e.g. M36), whereas those not conserved in HCMV are represented by 
lower-case letters (e.g. m152). Families of ORFs that result from gene duplication 
events are present in HCMV and MCMV (Chee et al., 1990; Rawlinson et al., 1996). 
These also show sequence homology to other herpesviruses. Before DNA replication is 
initiated, the linear genomes of HCMV and MCMV both circularize in the nucleus of 
infected cells. 
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Fig. A 2 CMV genome structure. (A) Representation of lengths of different virus genomes. 
The line below shows a size scale in kbp. (B) HCMV genome structure. The first line depicts the 
two unique sequences of HCMV, the unique long (UL) and unique short (US) sequences, 
flanked by inverted repeats b (TRL/IRL) and c (IRS/TRS). The sequences a, b and c represent 
terminal and internal repeats. HCMV has four isomers depending on the orientation of the inter-
nal and terminal repeats. The oriLyt depicts the origin of replication. (C) MCMV genome struc-
ture. The MCMV genome is flanked by terminal repeats. The line below depicts the size in kbp. 
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1.2.3 Gene expression and replication of cytomegalovirus 
The CMV replication cycle and that of all other herpesviruses is stringently regulated 
and follows a downwelling organization. HCMV penetrates cells by fusion between the 
virus envelope and the host cell plasma membrane (Compton et al., 1992). Attachment 
and penetration at the cell surface is rapid and efficient in permissive as well as in non-
permissive cell types, suggesting that cellular receptors for CMV are widely distributed. 
To date, molecular details underlying the mechanism of CMV entry into host cells re-
main elusive. The major cell surface proteoglycan heparan sulfate has been implicated 
in the initial interaction between the virus and the cell (Compton et al., 1993), and 
coiled-coil domains in glycoproteins B and H, and the epidermal growth factor receptor 
play a role in membrane fusion (Kinzler and Commpton 2005; Lopper and Compton, 
2004; Wang et al., 2003). After penetration and uncoating, viral nucleocapsids migrate 
to the nucleus where the linear genome circularizes as an episome. Gene expression and 
replication of the CMV genome both take place in the nucleus. 
Viral gene expression follows different kinetic classes depending on the time of ex-
pression: immediate early (IE), early (E), and late (L). The complete replication cycle is 
long compared to other herpesviruses: 48 to 72 hours for HCMV and 24 hours for 
MCMV. During the IE-phase, regulatory proteins are expressed which induce, as tran-
scriptional activators, the expression of E- and L-proteins as well as cellular proteins 
(Kowalik et al., 1993; Nicholas, 1996). During the E-phase, proteins which are neces-
sary for the viral genome replication are expressed, and during the late phase mostly 
structural proteins or proteins involved in the assembly of the virus are expressed. The 
DNA replication starts during the E-phase and is probably enabled by viral proteins on-
ly. 
After circularization of the parental genome, DNA synthesis takes place according 
to the “rolling-circle” mechanism and results in the formation of a single double-
stranded DNA molecule, which contains several copies of the viral genome (concate-
mers). The concatemers are cleaved between the a-sequences at the cleavage-sites and 
packaged into the capsid. Capsids and tegument proteins associate at the inner nuclear 
membrane. Egression of the capsid from the nucleus and gain of the envelope occurs 
according to the “double envelope theory”: by leaving the nucleoplasm, the viral capsid 
obtains a first envelope, which is lost by fusion with the outer nuclear membrane. The 
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final envelope is acquired during migration through the endoplasmic reticulum and the 
Golgi apparatus (Mettenleiter 2002; Radsak et al., 1996). 
1.2.4 Pathogenesis of cytomegalovirus infection: mechanisms of dissemination 
and tissue tropism 
The cellular pathway of host entry by CMV has not been fully delineated. Epidemiolog-
ic evidence suggests that the entry of CMV follows contact between infectious virus 
and mucosal surface. The site of entry seems to be the epithilium of the genitourinary 
tract, the upper alimentary tract, or the respiratory tract (Sinzger and Jahn, 1996). How-
ever, CMV infection can also be established by transplanted organs, blood transfusion 
or by the hematogenous route during fetal development. Although the key pathways for 
spread of human CMV from the initial site of replication have not been clearly proven, 
circulating virus is usually found in leukocytes (Dankner et al., 1990; Saltzmann et al, 
1988). The virus may be carried by peripheral monocytes and circulating endothelial 
cells to reach different organs (Gerna et al., 2000). A wide range of tissues and often 
multiple cell types within an organ are involved in CMV infection (Plachter et al., 
1996). Cells with cytopathology typical of CMV have been described in the epithelium 
of salivary gland, bile duct epithelium, bronchial epithelium, islet cells, renal tubular 
epithelium, capillary endothelium, astrocytes, neurons, and epithial cells of the inner ear 
(Ho, 1995). Not only epithelial and endothelial cells of different organs, but also fibro-
blasts, macrophages, and smooth muscle cells have been shown to support productive 
replication of CMV (Sinzger et al., 1995). 
1.2.5 Immune response and latency in cytomegalovirus infection 
Despite the response of the innate and adaptive immune system the CMV-infected host 
does not achieve viral clearance. In most cases CMV establishes latent infection by 
evading the immune system. There are multiple mechanisms by which CMV can 
achieve this and apparently during latency CMV transcripts can be detected in the blood 
of infected individuals (Kondo et al., 1994). CMV can compromise antiviral host de-
fence mechanisms by expressing a diversity of proteins focused on mimicking and alter-
ing the major histocompatibility complex protein function (Ahn et al., 1996; Gewurz et 
al., 2001; Kavanagh et al., 2001a; Kavanagh et al., 2001a; Tomaszin et al, 1999), leuko-
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cyte migration (Penfold et al., 1999; Saederup et al., 2002), activation and cytokine res-
ponses (Akdis and Blaser, 2001; Kotenko et al., 2000), and host cell susceptibility to 
apoptosis (Zhu et al., 1995; Brune et al., 2001: Menard et al., 2003). The evidence for 
molecular mechanisms by which CMVs avoid detection and elimination is rapidly 
growing. 
Specific cellular and humoral immunity all play important roles in the control of 
CMV disease. Shellam et al. (1981) showed that mice devoid of NK cells are more sus-
ceptible to MCMV infection. Indirect evidence for the importance of NK cells in de-
fense of CMV infection also comes from the observation that the viral gene products 
that appear to be conserved can protect against NK cell-mediated lysis (Tomasec et al., 
2000). Nearly all immune human sera have antibody to envelope glycoproteins gB 
(UL55) and gH (UL75), to the tegument phosphoprotein pp150 (UL32) and to a non-
structural DNA binding phosphoprotein pp 52 (UL44) (Greijer et al., 1999; Schoppel et 
al., 1997). Neutralizing antibody is mainly directed against envelope proteins gB and 
gH (Britt, 1991). 
CMV disease is seen almost exclusively in patients with profoundly impaired cell-
mediated immunity, such as patients undergoing bone marrow transplantation or pa-
tients with AIDS. The severity of disease due to CMV infection parallels the degree of 
impairment of T-lymphocyte response. The suppression of T-lymphocyte function led 
to reactivation and dissemination of the natural infection in a murine model. An impor-
tant role for CD4+ T-lymphocytes in γ-interferon production has also been suggested 
(Hengel et al., 1994). Although CD4+ T-lymphocyte response to envelope glycoprote-
ins gB and gH, to lower matrix protein pp65, and to immediate-early proteins, are most 
commonly detected, responses to other proteins have been also reported (Alp et al., 
1991; Beninga et al., 1995). It is likely that more targets for CTL will be identified 
among CMV proteins. At present proteins pp65 (UL83) and IE1 (UL123) appear to be 
major targets. 
CMV not only establishes a latent state of infection and restricts the number of viral 
genes expressed in order to minimize exposure to the immune system, but also uses 
specific tissues for replication, that have a less stringent immune surveillance. There is 
growing evidence that cells in bone marrow and peripheral blood are a key reservoir for 
CMV through latent infection. A small percentage of peripheral blood monocytes from 
subjects with past infection harbor CMV DNA, but viral gene expression is limited to 
 A. Introduction 8 
early genes (Danker et al., 1990; Ibanez et al. 1991; Taylor-Wiedemann et al., 1991). 
However, tissue macrophages express early and late CMV antigens (Sinzger et al., 
1996). These observations led to propose a model for human CMV persistence and 
reactivation in which bone marrow precursors are a key site of latency; peripheral blood 
monocytes provide a means to disseminate virus, and differentiation of latently infected 
monocytes into macrophages leads to reactivation and productive infection. The expe-
rimental evidence supports a model of CMV persistence in which myelomonocytic stem 
cells resident in bone marrow maintain latent infection, and latently infected CD 14+ 
monocytes circulate in peripheral blood. Differentiation of latently infected monocytes 
into tissue macrophages as a result of allogenic stimulation, or triggering of proinflam-
matory cytokines as occurs with intercurrent infections, may lead to productive CMV 
infection (Hahn et al., 1998; Ibanez et al., 1991; Soderberg-Naucler et al., 1997). 
2 Clinical aspects of cytomegalovirus infection  
2.1 Epidemiology and transmission of cytomegalovirus  
Human cytomegalovirus has a worldwide distribution and infection occurs from human 
to human. Depending on the socioeconomic status and living conditions, the rate of se-
ropositive individuals varies between 50% to 100% in the adult population (Mustakan-
gas et al., 2000; Wong et al., 2000). In general, prevalence is higher and CMV is ac-
quired earlier in life in developing countries and in the lower socioeconomic strata of 
developed countries (Britt and Alford, 1996; Pass, 1985). 
Despite these high rates of CMV infection, CMV is not highly contagious. Excretion 
of the virus after primary infection can be detected for months to years and the virus can 
generally be detected in oropharyngeal secretions, breast milk, feces, urine, cervical and 
vaginal secretions, semen and blood (Dworsky et al., 1983; Handsfield et al., 1985; 
Montgomery et al., 1972). Transmission appears to require frequent contact with body 
fluids from humans excreting the virus and can occur perinatally, intrapartally, through 
breast milk, between sex partners, between children in day care centers, between pre-
school-aged children and their care givers, and through organ transplantations and 
blood transfusions (Pass et al., 1990; Pereira et al., 1990). 
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CMV infection is the most common congenital viral infection in developed coun-
tries (Demmler, 1991), overtaking rubella since the introduction of the rubella immuni-
zation. Approximately 3000 infants in Germany (Scholz, 2000) and 40 000 infants in 
the United States are born with congenital CMV infection annually (Stagno and Whit-
ley, 1985). This corresponds to approximately 1% of newborns that are infected in utero 
during maternal viremia. The occurrence of congenital infection is unique in CMVs 
among the human herpesviruses and congenital infection plays an important role in 
maintaining CMV infection in the population. Mothers are mostly infected by young 
infants and children shedding the virus after primary infection. Around 5% to 25% of 
newborns with congenital CMV infection are symptomatic (Fig. A 3). The incidence of 
perinatal (up to 1 month after birth) and postnatal (up to 12 months after birth) infection 
is still higher than that of intrauterine infection. Typically, the infant is exposed to virus 
shed from the cervix, excreted in breast milk, or, less commonly, shed from other in-
fants infected with the virus. Although the incidence of perinatal and postnatal CMV 
infection is higher, these infants have asymptomatic or self-limited disease but do not 
have the neurologic sequelae seen in some congenitally infected infants (Demmler, 
1991). 
primary infection
develop sequelae
5 - 15%
40% transmit infection to fetus
(0.2 - 1% of all newborns)
90% asymptomatic infants 10% clinically apparent disease(mild to severe)
90%
 
Fig. A 3 Characteristics of cytomegalovirus infection during pregnancy. 
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For horizontal spread close or even intimate contact is required. Sexual transmission 
is common in adolescents and the adult population. Patients with multiple sexual part-
ners are attributed with a higher risk (Jordan et al., 1973). In immunocompromised pa-
tients in terms of malignancy, acquired immunosuppression or immunosuppression in 
transplant recipients, CMV reactivation develops more frequently. The sources of in-
fecting virus in allograft recipients include the transplanted organ and reactivation of 
endogenous virus of the transplant recipient. CMV infection can also be acquired during 
the use of blood products containing an increased amount of leukocytes at a frequency 
of 0.9% (Preiksaitis et al., 1988). 
2.2 Clinical manifestations of cytomegalovirus  
Most infections with HCMV are clinically inapparent. Symptomatic infections occur 
more commonly in preterm infants, newborns and immunocompromised patients. In 
immunocompetent individuals, primary infection is usually without clinical manifesta-
tions or can cause symptoms that resemble those of mononucleosis with prolonged high 
fevers, sometimes accompanied with chills, profound fatigue and malaise. 
Congenital CMV infection involves damage to the central nervous system and or-
gans of perception (eyes, ears) and neonatal death in around 10% symptomatic new-
borns (Boppana et al., 1999). Protracted interstitial pneumonitis has been associated 
with perinatally acquired CMV infection, particularly in premature infants. Five percent 
of fetuses develop cytomegalic inclusion disease. Common symptoms of cytomegalic 
inclusion disease are petechiae, hepatosplenomagaly, jaundice, microcephaly, intraute-
rine growth retardation, and prematurity (Fig. A 4). 
 
Fig. A 4 Congenital HMCV infection. Premature infant with clinical findings of petechial rash 
and hepatosplenomegaly (Neonatal Intensive Care Unit, Children´s Hospital Munich). 
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However, the majority (50% to 100%) of symptomatic newborns will have some 
combination of deficits, including mental retardation, cerebral palsy, sensorineural loss, 
and impaired vision (Bale et al., 1990) (Fig. A 3). Approximately 5% to 15% of infants 
with asymptomatic congenital CMV infection will have CNS sequelae, mainly sensori-
neural hearing loss (Ivarsson et al., 1997). 
Depending on the immune status of the host, reinfection with a novel exogenous 
strain or reactivation of the latent strain can occur. Patients who are immunosuppressed 
can develop life threatening disease such as pneumonitis, gastrointestinal ulceration or 
severe hepatic dysfunction. Primary infection acquired from a transplanted organ is 
generally more severe than reactivation of the recipient’s latent virus and can lead to 
impaired graft function. In recipients of allogenic bone marrow transplants, pneumonitis 
is a clinically significant CMV disease (Boeckh and Bowden, 1995). In patients with 
AIDS, risk of CMV disease is linked closely to the immune impairment as reflected by 
low CD4(+) T-cell counts. 
The major clinical manifestations among AIDS patients with CMV disease are reti-
nitis, esophagitis and colitis, and CMV has also been suspected to be a cofactor in the 
development of AIDS (Kovacs et al., 1999; Ostrowski et al., 1998). Furthermore, it has 
been reported that CMV-infected cardiac transplant patients have higher rates of graft 
rejection, more severe coronary atherosclerosis, and higher death rates (Danesh et al., 
1997; Grattam et al., 1989; Zhou et al., 1996). HCMV may play a causal role in resteno-
sis by interacting with the tumor suppressor p53 (Spier et al., 1994). Further investiga-
tions will be needed to establish a more comprehensive relationship of CMV infection 
and atherosclerosis. 
2.3 Diagnosis of cytomegalovirus infection 
HCMV infection can be diagnosed by serological tests and direct detection. Acute 
HCMV infection is probable when HCMV-specific IgM antibodies and a fourfold in-
crease in HCMV-specific IgG antibody titers are present. Serologic results require a 
comparison to baseline titers. Since these are often not available, serologic testing is 
limited in its utility. Previously, cultures had to be held for one to six weeks until cyto-
pathic effects were observed (Chou, 1990). To surpass slow viral growth, detection of 
HCMV can be achieved within 24 to 72 hours by detecting immediate early proteins 
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using immunofluorescence staining. This overnight tissue-culture method (shell vial 
assay) involves centrifugation enhancement and an immunochemical detection tech-
nique employing monoclonal antibodies to an immediate early CMV antigen (pp65 pro-
tein). HCMV can be detected from multiple sites, including blood, urine, throat wash-
ings, cerebrospinal fluid, bronchial washings, and biopsy specimens. Employing PCR 
one can detect viral DNA of immediate early and glycoprotein genes. Prenatal diagnos-
tic is performed with transabdominal ultrasound and if necessary is followed by analysis 
of amniotic fluid in the early-to-mid trimester for viral DNA. 
2.4 Therapy of cytomegalovirus infection  
There are several agents that are available for the systemic therapy of CMV infection. 
These include ganciclovir, and its prodrug valganciclovir, foscarnet and cidofovir. Gan-
ciclovir is phosphorylated intracellularly by a viral kinase to a triphosphate, which 
competively inhibitis the incorporation of dGTP by the viral DNA polymerase. This 
disrupts viral DNA synthesis. Ganciclovir is used in the therapy of HIV positive pa-
tients with CMV retinitis, CMV gastrointestinal tract disease, CMV pneumonitis, and 
CMV neurologic disease. In transplant recipients of solid organs and bone marrow, 
ganciclovir is also used as a preemptive treatment. As an alternative, foscarnet or cido-
vir can be used in cases with kinase mutations that lead to ganciclovir resistance. Fos-
carnet, another agent, is a pyrophosphate that stops DNA chain elongation and has addi-
tional antiretroviral activity. Cidovir is a nucleotide analogue and its incorporation into 
viral DNA disrupts further chain elongation. It is mainly used in the treatment of CMV 
retinitis in patients with AIDS. 
Currently, there is no effective intervention for a primary CMV infection during 
pregnancy. A nonrandomized study by Nigro et al. (2005) showed that hyperimmune 
globulin therapy was associated with a significantly lower risk of congenital CMV in-
fection (adjusted odds ratio 0.32; 95% confidence interval, 0.10 to 0.94; p = 0.04). 
Treatment of pregnant women with CMV-specific hyperimmune might be effective in 
prevention of congenital CMV infection. A controlled trial of this agent will follow. 
In the future vaccines against CMV could help to control CMV disease in high-risk 
patient populations. Evidence from several animal models of CMV infection indicates 
that a variety of vaccine strategies are capable of inducing immune responses sufficient 
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to protect against CMV-associated illness following viral challenge (Cicin-Sain et al., 
2003; Gonzalez-Armas, et al., 1996; MacDonald et al., 1998). Currently, CMV vaccines 
are in various stages of preclinical and clinical testing and include: protein subunit vac-
cines, DNA vaccines, vectored vaccines using viral vectors such as attenuated pox- and 
alphaviruses, peptide vaccines, and live attenuated vaccines (Schleiss and Heineman, 
2005). 
3 Generation of recombinant cytomegalovirus  
Functional characterization of viral genes, by generating virus mutants and investigating 
the resulting changes in phenotype, is important for understanding the molecular aspects 
of herpesvirus replication and pathogenesis, and to provide a basis for the development 
of new vaccines and chemotherapeutics. 
3.1 Methods of mutagenesis used before bacterial artificial chromosome technolo-
gy 
3.1.1 Chemical mutagenesis in infected cells 
Genetic alterations, which result in phenotypic alterations, are of great importance to 
gain insight into the functional role of viral genes. The classical genetic approach using 
mutagenic chemicals to introduce random mutations was applied 30 years ago and al-
lowed the production of a large number of mutants that can be screened for interesting 
phenotypes (Fig. A 5). Characterization of conditional alleles, such as temperature-
sensitive (ts) mutants (Schaffer, 1975), was favored because operational viability of the 
virus of interest is a prerequisite for analysis. Generating such mutants is straightfor-
ward, but the most demanding and difficult step of this forward genetic approach is 
mapping the mutations and excluding second-site mutations. 
3.1.2 Site-directed mutagenesis by homologous recombination in CMV-infected 
cells 
In the early 1980s, a method for reverse genetics by the targeted mutation of individual 
genes was developed for HSV (Mocarski et al., 1980, Post and Roizman, 1981) and lat-
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er adopted for other members of the herpesvirus family (Manning and Mocarski; 1988; 
Spaete and Mocarski, 1987). In this method, the mutation together with a marker gene 
is introduced into the target sequence by the cellular recombination machinery (Fig. A 
5). 
As the wild-type virus is over-represented in the resulting virus pool, selection pro-
cedures are required. This step is laborious and, if the mutant has a growth deficit, iso-
lating the recombinant virus can be difficult. Null mutants of genes that are indispensa-
ble for viral growth (essential genes) can only be produced on complementing cell lines, 
that provide the essential gene product in trans (DeLuca et al., 1985). 
 
Fig. A 5 Methods of herpesvirus mutagenesis before BAC technology. (A) Chemical 
mutagenesis. Mutagenic chemicals introduce large number of random mutations. (B) Site-
directed mutagenesis in eukaryotic cells. A linear DNA fragment that contains the mutation, a 
marker gene (red box) and flanking homologies to the viral target sequence is transfected into 
infected cells. The marker gene is inserted into the viral genome by homologous recombination 
(dashed lines). Recombinant and wt virus need further separation. (C) Production of infectious 
virus from overlapping cosmids. Overlapping fragments spanning the entire viral genome are 
linearized and transfected into permissive cells, in which the viral genome is reassembled by 
homologous recombination and viral progeny is produced. 
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3.1.3 Regenerating virus from overlapping cosmid clones  
In the late 1980s, a novel approach was introduced for mutating herpesvirus genomes 
(van Zijl et al., 1988). The large viral genomes were subcloned in E. coli as a set of 
overlapping clones. Mutations were introduced into one of the subcloned fragments. 
After cotransfection of cells with the cosmid set, infectious virus can be reconstituted by 
multiple homologous recombinations via the overlapping sequences (Fig. A 5). Because 
only the mutant genome is reconstituted using this method, the introduction of markers 
and selection against wild-type virus is not required. Limitations of this system include 
the difficulty of finding suitable restriction sites in large cosmids and of mutating re-
gions of cosmid overlap. In addition, because many recombination events are needed to 
reassemble the full-length genome in the target cell and because recombination proce-
dures in cells cannot be controlled, mutagenesis is often associated with unwanted mu-
tations. Extensive post-mutagenesis analysis of the isolated mutants is therefore re-
quired. Finally, it is not easy to construct revertants, which are needed to prove that the 
altered property is a function of the targeted mutation and not of an unwanted mutation 
elsewhere in the genome, with the cosmid technology. 
3.2  Cytomegalovirus mutagenesis with bacterial artificial chromosomes in E. coli  
Until recently, mutagenesis of the large CMV genomes was difficult because most mu-
tagenesis procedures were performed in eukaryotic cells and recombinant virus was on-
ly obtained after these poorly controlled recombination events occurred. Production of 
null mutants was not possible. The genetic analysis of the mutant virus for illegitimate 
mutations could only start after the virus had been reconstituted and isolated, which 
could take several months. 
3.2.1 Cloning herpesvirus genomes as bacterial artificial chromosomes 
Cloning a complete herpesvirus genome as a single plasmid was difficult as the size of 
the herpesvirus genome exceeds the cloning capacity of conventional plasmids and 
cosmids. Yeast artificial chromosomes (YACs) were the first cloning vectors with a 
coding capacity of up to 2 Mbp. However, YACs were not suitable for cloning the 
herpesvirus genome. They are not easy to handle and they cause deletions and frequent 
spontaneous rearrangements between the repetitive sequences contained in herpesvirus 
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genomes (Ramsay, 1994). To simplify and accelerate mutagenesis of herpesvirus ge-
nomes, Messerle and colleagues (Messerle et al., 1997) chose a completely new ap-
proach. They used F-factor-derived bacterial artificial chromosomes (BACs), which can 
maintain foreign DNA of up to ~ 300 kb in E. coli, to clone the MCMV genome. In 
contrast to YACs or cosmids, BACs showed surprising stability (Shizuya et al., 1992). 
The strict control of the F-factor replicon maintains a single copy of the BAC per bacte-
rial cell, reducing the risk of recombination events via repetitive DNA elements present 
in herpesvirus genomes. To clone the herpesvirus genome as a BAC, MCMV infected 
cells were transfected with a linearized BAC, flanked by sequences homologous to the 
desired insertion site into the viral genome. The sequences for the BAC vector are thus 
introduced into the herpesvirus genome by conventional homologous recombination 
into infected cells. The linear double-stranded DNA genome circularizes during replica-
tion. By isolating the circular replication intermediate of the BAC mutant and transfect-
ing it into E. coli, the herpesvirus BAC can then be propagated and mutated in E. coli. 
Because inserting the BAC cassette resulted in an overlength of the MCMV genomes (8 
kbp) that are not well packaged, spontaneous deletions occurred within the MCMV-
BAC genomes. To obtain a stable BAC-clone, 8 kbp of non essential sequences had to 
be deleted. Once in E. coli, the deleted viral sequences were reintroduced into the viral 
BAC-genome in a way that allows excision of the BAC cassette upon virus reconstitu-
tion (Wagner et al., 1999). Methods of prokaryotic genome engineering can now be 
used and adapted to mutate the virus genome. Infectious virus is simply reconstituted by 
transfecting the mutated viral BAC into permissive eukaryotic cells. In the last years, 
the strategy of cloning an entire viral genome as a BAC has been adopted for the Ep-
stein-Barr virus, HSV, pseudorabies virus, human CMV, and others (Adler et al., 2000; 
Borst et al., 1999; Delecluse et al., 1998; Horsburgh et al., 1999; McGregor et al., 2001; 
Rudolph et al., 2002; Schuhmacher et al., 2000; Smith and Enquist 1999). BAC-
technology has been employed in forward and reverse genetics. 
3.2.2 Random mutagenesis of cytomegalovirus BACs with transposons 
BAC-technology has been applied to transposon mutagenesis. Transposons are mobile 
genetic elements that insert randomly into the genome (Berg et al., 1998). Using trans-
posons that insert preferably into plasmid DNA (BAC DNA), a forward genetics proce-
 A. Introduction 17 
dure was developed (Brune et al., 1999) for constructing transposon libraries (Fig. A 6). 
After reconstitution of the mutant virus, genes of interest can be identified based on the 
resulting phenotype. This is a fast and straightforward method to identify essential and 
nonessential genes. 
 
Fig. A 6 Random transposon mutagenesis of MCMV BAC plasmids. The MCMV BAC and 
the transposon donor plasmid are maintained in E. coli at 30°C. The BAC is selected for by 
chloramphenicol (cam), and the transposon is selected for by ampicillin (amp). To select for 
transposition events, bacteria are plated on agar plates and incubated at 42°C selecting with 
cam and kanamycin (kan, red box). The Tn donor plasmid does not replicate at 42 °C, only 
those bacteria in which a transposition event occurred were able to form colonies. BAC DNA 
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extracted from bacteria can be analyzed by restriction enzyme digestion and direct sequencing. 
Finally, mutant virus is reconstituted by transfection of mutated genomes into fibroblasts. 
3.2.3 Allelic exchange using linear DNA fragments 
In 1998, Stewart and colleagues described a one-step mutagenesis method named ET 
cloning (Zhang et al., 1998). This method uses the recombination functions of recombi-
nation proteins recET from prophage Rac or redαβ from bacteriophage λ to introduce 
mutations into a circular DNA molecule by DNA fragments (Muyrers et al., 2000; 
Zhang et al., 1998). Recently, our group adapted this method to introduce mutations in-
to viral BACs (Wagner et al., 2003; Wagner et al., 2002a). A linear fragment, contain-
ing a selectable marker and homologous sequences to the target sequence, is transferred 
into recombination-proficient E. coli with redαβ under the control of an inducible pro-
moter (Fig. A 7). To circumvent degradation of the linear DNA, exonuclease-negative 
bacteria must be used or the exonuclease inhibitor redγ (gam) from bacteriophage λ 
must be expressed. The selectable marker is introduced along with the mutation by a 
double cross-over event. This one-step recombination method has several advantages 
compared to the RecA-mediated two-step recombination with shuttle plasmids (see 
Wagner et al., 1999). The recombination functions used allow homologous recombina-
tion between homologies as short as 25-50 nucleotides. These sequences can be pro-
vided by the synthetic oligonucleotides used to amplify the linear DNA fragment and 
therefore no cloning is required. The mutagenesis is independent of the presence of re-
striction enzyme recognition sites and the homology sequences can be chosen freely. 
This method allows the deletion of sequences starting from very few bps (such as an 
ATG) to up to several hundreds of kbps within a few days. In addition, sequences with 
short tags or large genes can be introduced. The drawbacks of the method are the poten-
tial instability of the viral BAC and the need to insert a selectable marker along with the 
mutation. But the marker gene can be removed after mutagenesis with flanking FLP 
recognition target (FRT) (Macleod et al., 1986) or loxP (locus of crossing over P1 
phage) sites. These sites allow excision of the marker by expression of the site-specific 
recombinases FLP (Cherepanov et al., 1995) or Cre, leaving only 48 or 34 nucleotides 
of bacterial sequence at the mutation site. 
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Fig. A 7 MCMV BAC mutagenesis. (A) A contiguous primer pair is used for PCR amplification 
of a selectable marker gene (red box). The primers contain homologies to the viral sequence at 
their 5´- ends (dashed lines) and priming regions to the selectable marker. (B) The linear PCR 
fragment is transformed into E. coli with the MCMV BAC genome and the plasmid pBADαβγ 
that expresses recombinases redα, redβ and exonuclease inhibitor redγ. (C) Transfection of the 
mutated MCMV BAC plasmid into permissive cells leads to reconstitution of recombinant virus 
only. The BAC sequence is efficiently removed by homologous recombination. Thus, the MCMV 
vector genome is devoid of any residual bacterial sequence. 
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4 Murine cytomegalovirus as a model for human cytomegalovirus infection 
4.1 Murine cytomegalovirus infection 
HCMV infects only humans and thus cannot be studied in animals. Murine, guinea pig, 
rat, and rhesus macaque CMVs have been employed as surrogate models of human 
CMV infection, latency and disease, providing insights into CMV pathogenesis. Among 
these, MCMV is the best analyzed and mostly used model system since MCMV and 
HCMV share great homology and a similar course of infection (Hudson, 1979). As in 
HCMV infection, infection of immunocompetent mice with MCMV is controlled by the 
immune system and leads to latent infection. Infection of immunosuppressed mice leads 
to life-threatening disease with interstitial pneumonia, hepatitis, and inflammation of the 
adrenal glands (Brody et al., 1974; Mayo et al., 1977; Sutherland et al., 2001). Further-
more, it has been shown that MCMV can be reactivated from latency through special 
reactivation protocols (Hamilton and Seaworth, 1985; Jordan et al., 1978; Reddehase et 
al., 1994). By generating MCMV mutants with functional deletions of individual genes 
and investigating them in cell culture and the mouse, it is possible to identify new gene 
functions which are important for viral pathogenesis of MCMV and possibly HMCV 
infection. 
4.2 Function of open reading frames in human and murine cytomegalovirus 
Despite the fact that members of the β-herpesviruses have significantly diverged in dif-
ferent animal species, as well as within the same animal species, significant amino acid 
sequence homology in approximately 80 ORFs in the central region of the β-herpesvirus 
genomes can be found. Similarly, amino acid sequence homology in as many as 46 her-
pesvirus-common ORFs controlling DNA replication, genome packaging, and virion 
morphogenesis, shows that β-herpesviruses are related to all mammalian herpesviruses 
(Chee et al., 1990). The right and left termini of the MCMV genome contain multiple 
genes with mainly nonessential and unknown functions. 
CMVs have a high coding capacity compared to other viruses. Their genome com-
prises approximately 230 kb and represents the largest mammalian virus genome. Sev-
eral herpesviruses genomes have been sequenced (Chee et al., 1990; Gompels et al., 
1995; Nicholas, 1996; Rawlinson et al., 1996; Vink et al., 2000), and after sequencing 
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of the HCMV laboratory strain AD169, 208 potential ORFs were predicted to encode 
polypeptides containing more than 100 amino acids (Chee et al., 1990). In the original 
and less passaged HCMV strains Toledo and Towne, 22 additional ORFs were identi-
fied, which were lost during the frequent passages of the laboratory strain AD169 (Cha 
et al., 1996). Sequencing of the MCMV Smith strain resulted in 170 potential ORFs 
(Rawlinson et al., 1996).  
The function of the majority of the CMV genes is still unknown. Altogether, about 
49% of the MCMV ORFs share homology to other known proteins, and between 
MCMV and HCMV 80 genes share significant homology to each other (Rawlinson et 
al., 1996). Among these 80 genes, 46 genes are conserved in all herpesviruses (Chee et 
al., 1990). Some of the CMV genes probably arise from gene duplication (Chee et al., 
1990; Mocarski et al., 2001; Rawlinson et al., 1996). A specific function was experi-
mentally proven for about 26% of the ORFs in HCMV and 25% in MCMV. For many 
genes it is not known whether they are essential or nonessential for virus replication in 
cell culture or in vivo. Essentiality has been proven for approximately 35% of the genes 
in HCMV and 36% in MCMV.  
Because of the complex interplay between the CMVs with their host, it is likely that 
only a minority of the many genes are required for virus morphogenesis, whereas the 
others are committed to evade the host immune response, optimize viral growth, and 
promote viral dissemination and latency. Constructing single gene knock-out mutants 
and analyzing them in vitro and in vivo compared to wild-type-MCMV are important 
goals for identifying new gene functions and understanding the biology of CMVs 
(Wagner et al., 2002b). 
4.3 Gene families in human and murine cytomegalovirus 
HCMV and MCMV contain families of ORFs that result from gene duplication events 
during evolution that are present in all β-herpesviruses (Chee et al., 1990; Mocarski et 
al., 2001; Rawlinson et al., 1996). HCMV encodes nine gene families, with the six larg-
est clustered at each end of the genome. MCMV has four gene family homologs in 
HCMV. Two families are unique to MCMV. MCMV sequence has revealed homologs 
to the HCMV gene families US22, UL25, UL 82 and GCRs. Not much is known about 
the function of these gene families. Given the conservation of gene families in β-
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herpesviruses it seems reasonable to assume that their functions are important in the in-
fection of the natural host and that gene duplication may account for the larger size of β-
herpesviruses (Weston and Barrell, 1986). 
 
Tab. A 1 US 22 gene family homologs in MCMV and HMCV. 
HCMV ORF MCMV homolog Gene products in HCMV and MCMV 
UL 23 
M23 
m25.1 
HCMV: tegument 
UL 24 M24 HCMV: tegument 
UL 28 no homolog unknown function 
UL 29 no homolog unknown function 
UL 36 (Exon 1) 
UL 36 (Exon 2) 
M36 (Exon 1) 
M36 (Exon 2) 
HCMV: tegument, inhibitor of apoptosis 
UL 43 M43 HCMV: tegument, cell tropism 
US 22 
m25.2 
m128 
m139 
unknown function 
HCMV: tegument, immediate early gene 
MCMV: macrophage cell tropism 
US 23 
m140 
m143 
MCMV: macrophage cell tropism 
MCMV: essential for viral replication 
US 24 m141 MCMV: macrophage cell tropism 
US 26 m142 MCMV: essential for viral replication 
TRS 1 no homolog 
HCMV: tegument, transcriptional trans-
activator 
 
The US22 gene family comprises twelve members in both HCMV and MCMV (see 
(Tab. A 1) and eleven in rat CMV. The product of the HCMV US22 gene is a nuclear 
protein which is expressed at early and late times (Mocarski et al., 1988). Members of 
the US22 gene family are characterized by stretches of hydrophobic and charged resi-
dues, as well as up to four conserved sequence motifs which are specific for β-
herpesviruses (Hanson et al., 1999b; Kouzarides et al., 1988). The functions of most of 
the US22 genes are unknown. For some of these, TRS1/IRS1 and UL36 of HCMV, and 
m128 of MCMV, a transcriptional transactivation function was described (Cardin et al., 
1995; Colberg, 1996; Colberg et al., 1992; Iskenderian et al., 1996; Romanowski and 
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Shenk, 1997). The ie2 gene product of m128 has been shown to be dispensable for 
growth of MCMV in vitro and in vivo (Cardin et al., 1995). The report on the combined 
failure of macrophage growth in vitro and altered tissue type distribution in vivo of mu-
tants RV7 (encompassing genes m137 through m141) and RV10 (encompassing US22 
family genes m139 to m141) (Cavanaugh et al., 1996; Hanson et al., 1999) prompted us 
to study the US22 gene family members for cell tropism and to analyze their growth in 
macrophages. 
5 Goal of this thesis 
To test the role of all US22 members in cell tropism, Menard et al. (2003) analyzed the 
growth properties of MCMV mutants carrying transposon insertions in all 12 US22 
gene family homologs in different cell types. Growth in macrophages of mutants with 
insertions in genes m139, m140, and m141 was severely affected while mutants of 
genes m142 and m143 did not show viral growth. These results indicated that mutant 
genes m139, m140 and/or m141 can confer macrophage tropism and that gene m142 
and/or m143 is essential for viral growth. Genes m139 to m143 represent a complex 
transcriptional unit (Hanson et al., 1999b). Since genes m139 to m141 and genes m142 
to m143 are transcribed collinearly, a transposable unit introduced into a gene upstream 
of this unit could influence the transcription or transcript stability of the downstream 
gene or genes. The goal of this thesis was to construct and to analyze additional targeted 
mutants of the genes m139, m140 and m142 in order to exclude polar effects on the 
downstream genes and to define the gene functions (cell tropism, essentiality) attributa-
ble to genes m139, m140 and m142. 
5.1 Generation of US 22 gene homolog mutants m139, m140, and m142 in MCMV 
Mutagenesis of viral genes is the basic strategy to investigate the function of the her-
pesvirus ORFs. Due to the large genome size and the slow replication kinetics in vitro 
of CMV, mutagenesis of viral genes in the context of the viral genome by conventional 
recombination methods in cell culture has been difficult. That is why the recently de-
veloped BAC-technology was employed. This technique allows the maintenance of vir-
al genomes as a plasmid in E. coli and the reconstitution of viral progeny by transfec-
tion of the BAC plasmid into eukaryotic cells. Using prokaryotic recombination pro-
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teins in E. coli it is possible to introduce any genetic modification of the viral genome. 
This allows the generation of mutant viruses and facilitates the analysis of herpesvirus 
genomes cloned as infectious BACs.  
Targeted mutants were constructed by site-directed BAC mutagenesis of the MCMV 
BAC to analyze the gene functions of ORF m139, m140 and m142. In order to mini-
mize possible effects on transcript or protein stability the introduced mutation was re-
stricted to the start codon or at most to the second ATG, resulting in the deletion of a 
few base pairs. 
5.2 Characterization of MCMV mutants m139, m140 and m142 
Once recovered, mutants of the US22 gene family were analyzed for replication in fi-
broblasts and macrophages. Macrophages play a major role in the pathogenesis of CMV 
infection. They presumably initiate early antiviral immune response (Heise et al., 1998; 
Orange and Biron, 1996), but have also been shown to serve as target cells in infected 
organs, as disseminators of the virus throughout the host and to harbor latent MCMV 
DNA (Michelson, 1997; Pollock et al., 1997). Because they play a key role in CMV 
dissemination as well as in tissue tropism and latency, viral gene products, which regu-
late growth in this cell type, are of great interest and are predicted to significantly affect 
MCMV pathogenesis in vivo. Analysis of the proteins expressed from ORF m139, 
which contributes to the common macrophage phenotype of mutants of m139, m140, 
and m141, was performed. 
Transposon mutants of genes m142 and m143, also homologs to the HCMV US 22 
gene family, were shown to be essential for viral replication. By definition essential 
genes are imperative for replication of CMV. The insertion of a transposon into an open 
reading frame usually results in truncation or functional inactivation of the correspond-
ing gene product. Due to the complex transcriptional unit of genes m142 and m143 and 
the possible polar effects of the 3-kb transposable unit on the neighboring genes, it was 
not possible to attribute essentiality to m143 and m142. That is why a targeted mutant 
of gene m142 needed to be constructed and analyzed for potential viral growth in cell 
culture. In case of absent viral growth, revertants were constructed. 
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B. MATERIALS AND METHODS 
1 Materials 
1.1 Reagents 
acrylamide/bisacrylamide (ProtoGel) National Diagnostics, USA 
agar Life Technologies, Germany 
agarose Biozym, Germany 
ammonium persulphate (APS) Bio-Rad, USA 
ampicillin Roche, Germany 
arabinose Roth, Germany 
bacto yeast and tryptone Life Technologies, Germany 
BCA protein assay kit Pierce, USA 
bromphenol blue Serva, Germany 
carboxymethylcellulose Sigma, Germany 
chloramphenicol Life Technologies, Germany 
dimethylsulfoxide (DMSO) Serva, Germany 
DNA purification kit Qiagen, Germany 
DNA-ladder (marker III) Roche, Germany 
dNTPs Roche, Germany 
Dulbecco´s modified Eagle´s medium (DMEM) Gibco, USA 
ECL Western blotting detection reagents kit Roche, Germany 
ethanol Riedel-de Haen, Germany 
ethylenediamintetraacetate sodium acid (EDTA) Roth, Germany 
Expand high fidelity PCR system polymerase Roche, Germany 
fetal calf serum (FCS) PAA, Germany 
films (BioMax MR) Kodak, USA 
GFX microplasmid prep kit Amersham, England 
GFX PCR DNA and gel band purification Amersham, England 
glycerol Roth, Germany 
glycine Serva, Germany 
HEPES  Roth, Germany 
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high-copy plasmid kit Amersham, England 
isopropanol Riedel-de Haen, Germany 
Klenow polymerase New England Biolabs, USA 
methylcellulose Fluka, Schweiz 
10 x modified eagle medium Life Technologies, Germany 
newborn calf serum (NCS) PAA, Germany 
N,N-methylenbisacrylamide Roth, Germany 
Nucleobond BAC-DNA purification kit) Machery & Nagel, Germany 
penicillin Life Technologies, Germany 
phenol/chloroform Roth, Germany 
phosphate buffered saline (PBS) Gibco, Germany 
potassium acetate Riedel-de Haen, Germany 
potassium chloride Riedel-de Haen, Germany 
protein kd ladder Bio-Rad, USA 
proteinase K Roche, Germany 
QiaEx gel purification kit Qiagen, Germany 
Qiaprep spin plasmid miniprep kit Qiagen, Germany 
Qiaprep spin plasmid maxiprep kit Qiagen, Germany 
QiaQiuck PCR purification kit Qiagen, Germany 
rapid ligation kit Roche, Germany 
restriction enzymes Roche, Germany and NEB, USA 
RNAse A Roche, Germany 
RPMI 1640 Life Technologies, Germany 
sodium dodecyl sulphate (SDS) National Diagnostics, USA 
shrimp alkaline phosphatise (SAP) Roche, Germany 
sodium acetate Riedel-de Haen, Germany 
sodium hydroxide J.T. Baker B.V., Holland 
Superfect reagent Qiagen, Germany 
T4-DNA ligase Roche, Germany 
Taq-DNA polymerase Roche, Germany 
trypsin Life Technologies, Germany 
tryptone Difco, Germany 
Western blue Promega, USA 
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zeocin Invitrogen, USA 
All other chemicals were purchased from Merck (Darmstadt) und Sigma 
(Deisenhofen). 
1.2 Bacteria 
DH10B (recA-) Life Technologies, Germany 
DH5-α Life Technologies, Germany 
1.3 Plasmids 
Commercially available plasmids 
pUC19  New England Biolabs, USA 
pCR3 Invitrogen, Germany 
pEGFP-C1 Clontech, USA 
 
Plasmids from cooperating institutions 
pBADαβγ Zhang et al., 1998 
pCP20 Cherepanov et al., 1995 
pSLFRTkan Atalay et al., 2002 
pSM3fr Messerle et al., 1997 
 
Plasmids from our institution 
pSM3fr/GFP  Mathys, S., LMU Munich, unpublished 
pUCHindIII-I Menard, C., LMU Munich 
pORI6kZeo  Bubeck, A., LMU Munich 
 
Generation of plasmids 
a) High-copy plasmids 
plasmid pORI6kZeo-m142 
Fragment HindIII-I was used as template DNA in order to amplify ORF m142 by 
PCR with primers 200748 up-m142-Eco and 199441down-m142-Xba. The 
amplified PCR fragment was inserted into the EcoRI and XbaI restriction sites of the 
multicloning site of plasmid pCR3. Digestion with restriction enzyme DrdI resulted 
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in a 2.6 kb fragment with the wild-type m142 ORF under the control of the human 
CMV immediate-early promoter-enhancer and a polyadenylation site. The fragment 
was treated with the blunt cutter EcoRV and inserted into plasmid pORI6kZeo with 
the zeocin resistance gene and a 48-bp FRT site. Thus, plasmid pORI6kZeo-m142 
contains the wild-type m142 ORF under the control of the human CMV immediate-
early promoter-enhancer, a conditional origin of replication, a zeocin resistance gene 
and a 48-bp FRT site. 
 
b) MCMV BAC plasmids 
MCMV plasmids were generated by site-directed mutagenesis in E. coli. The 
technique is based on homologous recombination of a linear PCR fragment flanked 
by 45 to 50-nucleotide sequences homologous to the up- and downstream regions of 
the target gene sequence of the MCMV BAC plasmid pSM3fr or pSMfr/GFP.  
 
BAC plasmid pΔATG-m139 (parental MCMV BAC: pSM3fr) 
For the deletion of the first two ATGs of ORF m139, the PCR fragment m139-PCR 
that contains the kanamycin cassette flanked by 34-bp minimal FLP recombinase 
recognition target (FRT) sites  was generated using plasmid pSLFRTkan (Atalay et 
al., 2002) as the DNA template. For PCR the following primers were used: primer 
5´-ΔATG-m139 (5´ - GGG GGA AGG CTC CTC TCG TCC ACG CCG CCG TAT 
TCT CCG AAC TTC TGG TCC GTC GTG GAA TGC CTT CGA ATT - 3´) and 
primer 3´-ΔATG-m139 (5´ - CGT GAG TTG ACG GCG CCG GCG CCA GAC 
GGA GCA GAC AGA GAG AGA GAA GGA CAA GGA CGA CGA CGA CAA 
GTA A - 3´). E.coli with the parental MCMV BAC plasmid pSM3fr were used for 
the generation of plasmid pΔATG-m139. Subsequently, the kanamycin resistance 
cassette, flanked by the minimal FRT sites, was excised by the FLP recombinase. 
The first two ATGs of ORF m139 (84 bp apart) were replaced with an 86-bp 
extraneous sequence. 
 
BAC plasmid pΔATG-m142 (parental MCMV BAC: pSM3fr) 
For the deletion of the first ATG of ORF m142, the PCR fragment m142-PCR that 
contains the kanamycin cassette flanked by 34-bp minimal FRT sites  was generated 
using plasmid pSLFRTkan (Atalay et al., 2002) as the DNA template. For PCR the 
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following primers were used: primer 5´-ΔATG-m142 (5´ - CTG GTC TCT GAA 
GTG ATC CGA TCG GAT CGC CGC GCA CAG GGC GTC CGT CGT GGA 
ATG CCT TCG AAT TC - 3´) and primer 3´-ΔATG-m142 (5´ - CCA CCC TTC 
TCC ACC CGT GTT CCC GCT GCC GCC CGT CGC CCT CGC CAC AAG GAC 
GAC GAC GAC AAG TAA - 3´). E.coli with the parental MCMV BAC plasmid 
pSM3fr were used for the generation of plasmid pΔATG-m142. The kanamycin 
resistance cassette, flanked by the minimal FRT sites, was excised by FLP 
recombinase. The native ATG of ORF m142 was deleted and replaced with an 86-bp 
extraneous sequence. 
 
BAC plasmid pΔATG-m142/FRT (parental MCMV BAC: pSM3fr/GFP) 
The pSM3fr BAC, that contains a FRT site and the GFP gene in position of the 
nonessential gene m152 (pSM3fr/GFP), was first subjected to site-directed 
mutagenesis to delete the native ATG of ORF m142 with the same PCR fragment 
used for the generation of the ΔATG-m142 mutant genome. The kanamycin 
resistance cassette was excised by FLP recombinase. This generated plasmid ΔATG-
m142/FRT 
 
BAC plasmid pΔATG-m142/m142E (parental MCMV BAC: pSM3fr/GFP) 
Plasmid pORI6kZeo-m142 with a conditional origin of replication, a zeocin 
resistance gene, a 48-bp FRT site and the wild-type m142 ORF under control of the 
human CMV immediate-early promoter-enhancer from plasmid pEGFP-C1 
(Clontech, USA) was inserted into the FRT site of ΔATG-m142/FRT. This 
generated plasmid  ΔATG-m142/m142E. 
 
BAC plasmid pSM3fr/GFP 
The m152 gene of pSM3fr was deleted and replaced by the GFP gene under the 
control of the HCMV promotor from the pEGFP-C1 plasmid and a FRT sequence. 
This plasmid was constructed by Sybille Mathys. 
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1.4 Antibodies 
Primary antibodies 
MCMV m139 rabbit polyclonal antiserum Hanson et al., 2001 
rabbit polyclonal m140* antibodies Eurogentec, Belgium 
rabbit polyclonal m141* antibodies Eurogentec, Belgium 
*15-amino-acid peptides from the C terminus (SVLTTRPDRNRDTRT, amino acid 
position 431 to 446) and the N terminus (ATGGDQNARRRAIER, amino acid 
position 25 to 40) were used to generate rabbit polyclonal antibodies for the m140 
and m141 proteins. 
 
Secondary antibodies 
Pox conjugated goat anti-rabbit antiserum Eurogentec, Belgium 
1.5 Cells and viruses 
Cells 
IC-21* simian virus 40-transformed murine macrophages from 
C57BL/6-mice (ATCC TIB-186) 
MEF murine embryo fibroblasts from BALB/c-mice, prepared 
according to Wagner et al.(2002), see chapter B. 2.11 
M210B4* b1 marrow stromal line (ATCC CRL-1972) 
NIH3T3* murine fibroblasts from BALB/c-mice (ATCC CRL-1658) 
*purchased from the American Type Culture Collection (ATCC). 
 
Viruses 
M97.01 derived from plasmid pSM3fr (Messerle et al., 1997) 
M152/GFP-MCMV derived from plasmid pSM3fr/GFP (Sybille Mathys) 
Tn-m152 Menard et al., 2003 
Δ-m139 Menard et al., 2003 
ΔATG-m139-MCMV MCMV with deletion of the first 2 ATGs of m139 
ΔATG-m142-MCMV MCMV with deletion of the first ATG of m142 
ΔATG-m142/FRT-MCMV MCMV with deletion of the first ATG of m142 
ΔATG-m142/m142E-MCMV MCMV revertant for ORF m142 
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1.6 Oligonucleotides 
Oligonucleotides purchased from Metabion (Germany) were used for cloning, 
mutagenesis and sequencing. Oligonucleotides longer than 50 base pairs were purified 
by HPLC. The sequences of the oligonucleotides are listed in Tab. B 1. 
 
Tab. B 1 Sequences of oligonucleotides. 
oligonucleotide sequence nt 
5´-m140-nt-197427 
5´ - GCT CCC CGC GGT TCG ACT GGT GGC GGT 
AGA AGT CGC GGA ACG CGA GCG TCG TGG AAT 
GCC TTC GAA TTC - 3´ 
69 
3´-m140-nt-197517 
5´ - CCC GTT TTT CTC TAG ACC ATT ATC ACC ATC 
ATC TCA TCC GGC GAG ACA AGG ACG ACG ACG 
ACA AGT AA - 3´ 
68 
3´-m140-nt-197477 
5´ - GAT CCG GCA CCC TAT CGG CAC GCC ACC 
CGC TCA TCG TTT CTC CGC GTG ACA AGG ACG 
ACG ACG ACA AGT AA - 3´ 
71 
5´-ΔATG-m139 
 
5´ - GGG GGA AGG CTC CTC TCG TCC ACG CCG 
CCG TAT TCT CCG AAC TTC TGG TCC GTC GTG GAA 
TGC CTT CGA ATT - 3´ 
72 
3´-ΔATG-m139 
5´ - CGT GAG TTG ACG GCG CCG GCG CCA GAC 
GGA GCA GAC AGA GAG AGA GAA GGA CAA GGA 
CGA CGA CGA CAA GTA A - 3´ 
73 
5´-ΔATG-m142 
 
5´ - CTG GTC TCT GAA GTG ATC CGA TCG GAT CGC 
CGC GCA CAG GGC GTC CGT CGT GGA ATG CCT 
TCG AAT TC - 3´ 
68 
3´-ΔATG-m142 
5´ - CCA CCC TTC TCC ACC CGT GTT CCC GCT GCC 
GCC CGT CGC CCT CGC CAC AAG GAC GAC GAC 
GAC AAG TAA - 3´ 
69 
5´-m139-nt 195739 5´ - CGC GAT CTA TGA ACA GGT CAG AC - 3´ 23 
3´-m139-nt-196200 5´ - CAA CCG AGA CAC CCG AAC CCT - 3´ 21 
200748up-m142-Eco 
 
5´- GTG AAT TCA TGG ACG CCC TGT GCG CGG-3´ 28 
199441down-m142-
Xba 
5´- CTT CTA GAT CAG TCG TCA TCG TCG GCG TC-3´ 29 
m142-199541 up 5´-ACG TCG AGG TGG CGG ACG CGT-3´    21 
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2 Methods 
The following methods were carried out according to the procedures in Sambrook et al. 
(1989) if not stated otherwise. The standard protocols were used with the purchased 
kits. The components of the required solutions are shown below in boxes. 
2.1 Isolation und purification of nucleic acids 
2.1.1 Analytical isolation of plasmid DNA from bacteria (mini preparation of 
plasmid DNA) 
We used the GFX Micro Plasmid Prep Kit from Amersham to extract plasmid DNA. 1.5 
ml of Luria Bertani (LB) medium with the appropriate antibiotics were inoculated with 
the bacterial colony and incubated overnight at 37°C or at 30°C for temperature-
sensitive plasmids. 1.5 ml of the overnight culture was transferred to a 1.5 ml 
microcentrifuge tube and centrifuged at 14,000 rpm for 30 s to pellet the cells. The 
pellet was completely resuspended with vigorous vortexing in 150 µl of solution I (25 
mM Tris/HCl and 10 mM EDTA, pH 8.0), an isotonic solution that contains RNase, 
after removal of the supernatant. For alkaline lysis and denaturation of chromosomal 
DNA and proteins 150 µl of solution II (0.2 M NaOH, 1% SDS) was added for a few 
minutes and mixed by inverting the tubes 10-15 times. 300 µl of solution III (3 M 
potassium acetate, pH 4.8) was added and mixed by inverting the tube until a flocculent 
precipitate appeared and was evenly dispersed. After centrifugation at 14,000 rpm for 5 
min to pellet the cell debris the supernatant was loaded onto a glass matrix column, 
incubated for 1 min and then centrifuged at full speed for 30 s. The flow-through was 
discarded and 400 µl of washing buffer (Tris-EDTA buffer) was added to the column. 
The column was centrifuged at 14,000 rpm to remove the buffer and dry the matrix and 
incubated for 1 min at room temperature. The plasmid DNA was eluted with 100 µl of 
distilled water by centrifugation at 14,000 rpm for 1 minute. Yields are typically 3-6 µg 
of plasmid DNA/ml of culture. 
LB medium 
 
10 g bacto tryptone 
5 g yeast extract 
5 g sodium chloride 
dissolve in 1 l water 
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2.1.2 Quantitative isolation of plasmid DNA from bacteria (maxi preparation of 
plasmid DNA) 
The QIAGEN Plasmid Maxiprep Kit from Qiagen was used for the preparation of up to 
500 µg of high-copy plasmids. 100 ml of LB medium was inoculated with 100 µl of a 
bacterial starter culture and was then incubated overnight at 37°C or 30°C. The bacterial 
cells were harvested by centrifugation at 4,000 rpm with a Sorvall 1500 centrifuge for 
15 min at 4°C. The bacterial pellet was resuspended in 10 ml of resuspension buffer P1 
(50 mM Tris Cl pH 8.0, 10 mM EDT, RNase A). The bacteria were lysed with vigorous 
inverting in 10 ml of the lysis buffer P2 (200 mM NaOH, 1 %SDS w/v) and a 5 min 
incubation at room temperature. Precipitation of SDS, chromosomal DNA and protein is 
enhanced with chilled neutralization buffer P3 (potassium acetate pH 5.5) and 
incubating on ice for 15 min, followed by centrifugation at 13,000 rpm with a Sorvall 
centrifuge (SS-34 Rotor) for 30 min at 4°. Ion-exchange columns previously 
equilibrated with 10 ml of equilibration buffer QBT (750 mM NaCl, 50 mM MOPS pH 
7.0, 15% isopropanol (v/v), 0.15% TritonX-100 (v/v)) were loaded with the supernatant. 
The columns were washed twice by gravity-flow with 30 ml of washing buffer QC (1.0 
M NaCl, 50 mM MOPS pH 7.0, 15% isopropanol (v/v)). After elution of the DNA with 
15 ml of elution buffer QF (1.25 M NaCl, 50 mM Tris·Cl pH 8.5, 15% isopropanol 
(v/v)) the DNA was precipitated with room-temperature isopropanol at 11,000 rpm for 
30 min at 4°C. The pellet was washed with 5ml of 70 % ethanol, centrifuged at 11,000 
rpm for 10 min, dried on air for 5-10 min and redissolved in 200 µl of Tris-EDTA (TE) 
buffer. 
 
TE buffer 10 mM Tris/HCl (pH 8.0) 
1 mM EDTA 
2.1.3 Analytical isolation of BAC DNA from bacteria (mini preparation of BAC 
DNA) 
We used the solutions P1, P2 and P3 from the Qiagen Plasmid Maxiprep Kit for the 
isolation of BAC DNA. To reduce shear to the large MCMV BAC DNA (size of over 
200 kbp), we generally omitted vigorous shaking. 10 ml of LB medium was inoculated 
with a bacterial colony and incubated overnight at 37°C. The overnight bacterial 
suspension was transferred to a 15 ml tube and centrifuged at 3,500 rpm with a Heraeus 
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centrifuge for 5 min. The pellet was resuspended in 300 µl of solution P1 and 
transferred to a 2 ml microcentrifuge tube. 300 µl of solution P2 was added and efficient 
alkaline lysis was achieved by gentle inversion and incubation for max. 5 min. Then 
SDS, chromosomal DNA, and protein were precipitated on ice with 300 µl of solution 
P3. After centrifugation at 14,000 rpm with a 5415 Eppendorf centrifuge for 10 min at 
4°C, the supernatant (ca. 1 ml) was extracted with an equal volume of 1 ml of 
phenol/chloroform (1:1). The phases were mixed by gentle rocking for 10 min and to 
separate the phases centrifuged at 14,000 rpm for 5 min at 4°C. The aqueous layer was 
recovered avoiding the interface and the DNA was precipitated with isopropanol and 
centrifuged at 14,000 rpm for 20 min. The pellet was washed with 70% ethanol, dried 
on air and dissolved in 100 µl TE buffer. 
2.1.4 Quantitative isolation of BAC DNA from bacteria (maxi and midi 
preparation of BAC DNA) 
We used the Nucleobond Kit from Macherey & Nagel to extract BAC DNA. First 400 
ml (maxi prep) or 100 ml (midi prep) LB medium was inoculated with approximately 
100 µl of a bacterial culture and incubated overnight at 37°C. The bacteria were 
centrifuged at 6,000 rpm in a Kontron-Hermle centrifuge (Centrikon H-401) for 10 min 
at 4 °C. The appropriate solution volumes were used as stated in the manufacturer’s 
protocol for BAC maxi and midi preparation. The pellet was resuspended in solution S1 
(50 mM Tris/HCl, 10 mM EDTA, RNase A 100 µg /ml, ph 8.0). Solution S2 (200 mM 
NaOH, 1% SDS) was added for cell lysis and incubated for 2-3 min, and SDS, 
chromosomal DNA and protein was precipitated with pre-cooled solution S3 (KAc 2.8 
M, pH 5.1) and incubated on ice for 5 min. The bacterial lysate was clarified by 
filtration with a folded filter. The ion-exchange column was then equilibrated with 
solution N2 (100 mM Tris, 15% ethanol, 900 mM adjusted with H3PO4 to pH 6.3, 
0.15% Triton X-100). The cleared lysate was loaded twice onto the column, washed 
with solution N3 (100 mM Tris, 15% ethanol, 1150 mM potassium chloride, adjusted 
with H3PO4 to pH 6.3) and eluted with preheated solution N5 (100 mM Tris, 15% 
ethanol, 1000 mM potassium chloride adjusted with H3PO4 to pH 8.5). After DNA 
precipitation with isopropanol and the DNA was washed with 70% ethanol, the DNA 
pellet was resuspended in 200 µl or 100 µl TE buffer. 
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2.1.5 Concentration of DNA by ethanol precipitation 
Sodium acetate at a final concentration of 300 mM and two volumes of ethanol were 
added to the DNA solution in order to precipitate the DNA. The DNA was recovered by 
centrifugation at 14,000 rpm for 20 min at 4°C and the resulting pellet was washed with 
70% ethanol to remove residual salts. The pellet was dried on air to evaporate residual 
ethanol and finally redissolved in the desired buffer.  
2.1.6 Determination of DNA concentration 
The DNA concentration was determined by UV spectrophotometry at a wavelength of 
260 to 280 nm with a spectral photometer from Amersham. An absorption quotient of 
1.8 to 1.95 that was measured at 280 and 260 nm indicated pure DNA solutions. 
2.2 Cloning of DNA 
2.2.1 Digestion of DNA with restriction enzymes 
The digestion of plasmid DNA was performed in a total volume of 40 - 60 µl. 1 µg of 
DNA was incubated for 1-2 h at the recommended temperature with 10 units of 
restriction enzyme and 1/10 of the volume of a compatible 10x restriction enzyme 
buffer. 1 µg of DNA was incubated for 3-4 h with 20-40 units of restriction enzyme for 
the digestion of BAC DNA with restriction enzymes. If necessary the restriction 
enzyme was heat inactivated according to the catalog information. In most cases heat 
inactivation was performed at 65°C for 15 min. 
2.2.2 Dephosphorylation of DNA 
Alkaline phosphatases are said to prevent recircularization and religation of linearized 
cloning vehicle DNA by removing phosphate groups from both 5′ termini. Shrimp 
Alkaline Phosphatase (SAP) catalyzes the dephosphorylation of 5′ phosphates from 
DNA. SAP is active on 5′ overhangs, 5′ recessed and blunt ends. Per pmol of linear 
DNA at least 1 unit of SAP (Boehringer Mannheim) was added to the restriction 
enzyme digest. The DNA was incubated for 1 h at 37°C and SAP was inactivated at 
65°C for 15 min prior to ligation. 
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2.2.3 Treatment of DNA with Klenow polymerase  
DNA with non-complementary sticky ends can be treated with Klenow polymerase to 
create blunt ends. Klenow polymerase represents the subunit of the DNA polymerase 
and fills in the 5´-protruding ends of DNA fragments with dNTPs to generate blunt end 
DNA. For the reaction 1 µg of DNA in an aqueous solution was incubated with 1/10 of 
the volume of the 10x Klenow buffer (10 mM Tris/HCl, pH 7.5; 50 mM NaCl, 10 mM 
MgCl2, 1 mM DTT), 1/10 of the volume of a 40 mM dNTP solution and 1 unit of 
Klenow polymerase (Gibco) for 30 min at 37°C. If necessary, the enzyme was 
inactivated at 65°C for 15 min. 
2.2.4 Purification of DNA fragments from agarose gels 
Digested DNA was separated on a 0.6-1.5% agarose gel stained with ethidium bromide 
(1 µg/ml was added to the agarose gel) and visualized by UV light. The desired DNA 
band was then cut out and purified with the PCR DNA and Gel Band Purification kit 
from Amersham according to the standard protocol. 
2.2.5 Ligation of DNA 
DNA fragments were ligated with T4 DNA ligase at a molar vector:insert ratio of 1:4. 
The DNA was incubated with 1 unit of T4 DNA ligase and 1/10 of the supplied 10x 
buffer for 3 h at room temperature. Blunt end DNA was incubated overnight at 16°C. 
2.2.6 Preparation of electro-competent bacteria  
200 ml of LB medium with the appropriate antibiotics were inoculated with 2 ml of a 
fresh overnight culture and incubated at 37°C for the preparation of electrocompetent 
bacteria. After 2 h the optical density (OD600) of the bacterial culture was first 
measured. Once an OD600 of 0.5 to 0.6 was reached, the bacteria were chilled on ice for 
15 min and then centrifuged at 7,000 rpm for 10 min at 0°C. All further steps were 
performed on ice. The supernatant was decanted and the pellet was resuspended in 10 
ml of cold 10% glycerol to remove salts and centrifuged at 7,000 rpm for 10 min at –
4°C. This step was repeated twice. The resulting bacterial suspension was dispensed in 
60 µl aliquots, flash frozen with liquid nitrogen and stored at –80°C. 
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2.2.7 Preparation of chemical-competent bacteria 
50 ml of LB medium was inoculated with 1 ml of an overnight culture and incubated at 
37°C for the preparation of chemically competent bacteria. The diluted culture was 
grown to an optical density (OD600) of 0.25 to 0.5 and the bacteria were spun down at 
2,300 rpm for 10 min at 4°C. All further steps were performed on ice. The supernatant 
was decanted and the pellet was resuspended in 15 ml of ice cold transformation buffer 
(TfB) I and incubated on ice for 40 min. The cells were centrifuged at 2,300 rpm for 10 
min at 4°C and the pellet was cautiously resuspended in 2 ml of prechilled TfB II buffer 
and incubated on ice for 15 min. The bacteria were dispensed to 60 µl aliquots, flash 
frozen with liquid nitrogen and stored at –80°C. 
 
TfB I buffer  100 mM RbCl2 
10 mM CaCl2 
30 mM KAc 
50 mM MnCl2 
15% glycerol 
adjust pH to 5.8, filter sterilize 
 
TfB II buffer  10 mM RbCl2 
75 mM CaCl2 
10 mM MOPS (pH 7.0) 
15% glycerol 
filter sterilize 
2.2.8 Electroporation of bacteria  
The DNA solution was first dialysed on a 200 µm filter membrane on water for 30 min 
to reduce the salt concentration. The electro-competent cell aliquots were then thawed 
on ice. Less than 2 µl of DNA was added to the 60 µl aliquots of electrocompetent 
bacteria on ice, gently mixed and transferred to a chilled cuvette (diameter 0.2 µm). The 
bacteria were pulsed at 2.5 kV, 400 Ω und 25 µFD with the Gene Pulser from Perkin 
Elmer. 200 Ω were used for electroporation of MCMV BAC DNA into DH10B. The 
cuvette was removed from the chamber and immediately 1 ml of LB medium was 
added. The cells were transferred to a microcentrifuge tube and incubated with shaking 
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at 37°C or 30°C for 1 h. The cells were plated onto selective agar plates and incubated 
overnight at 37°C or 30°C. 
2.2.9 Chemical transformation of bacteria 
The 60 µl aliquots with chemical-competent bacteria were thawed on ice for chemical 
transformation. DNA was added onto the competent cells and incubated on ice for 30 
min. The cells were heat shocked for 1 minute at 42°C and incubated on ice for 2 min in 
1 ml of LB medium and incubated at 37°C or 30°C for 1 h. Then the cells were 
centrifuged at 6,000 rpm for 1 minute, the supernatant was decanted and were plated 
onto selective LB plates. 
2.2.10 Preservation of bacteria 
An overnight culture was mixed with 50% glycerol to a final concentration of 20% (v/v) 
and stored at –80°C for the long-term storage of bacteria. 
2.3 Analysis of DNA 
2.3.1 Agarose gel electrophoresis 
DNA was separated and analyzed on non-denaturating agarose gels with gel 
concentrations 0.6-1.5%. BAC DNA was separated on 0.8% gels. Ethidium bromide 
was added to the gels to a final concentration 1 µg/ml in order to visualize the DNA 
with an ultraviolet transilluminator after electrophoresis. Either Tris-acetate-EDTA 
(TAE) or Tris-borate-EDTA (TBE) buffer was used to prepare and run the agarose gel 
electrophoresis and 1/10 a 10x running buffer (200 mM EDTA, 40% ficoll 400, 0.02% 
(w/v) bromphenol blue) was added to the DNA samples before loading the samples onto 
the solidified agarose gels. The gels were run with voltages of 70-120 mV for 1-2 h and 
MCMV BAC DNA was run with 70 mV for 14-16 h. 
 
TAE buffer 40 mM Tris/HCl 
20 mM glacial acetic acid 
1 mM EDTA 
adjust pH to 8.0 
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TBE buffer 90 mM Tris 
90 mM boric acid 
1 mM EDTA 
pH 8.3 
2.3.2 Sequencing of DNA 
The sequencing services of sequiserve (Germany) were used to sequence cloned DNA 
and PCR products. The sequencing reaction required 1 µg of plasmid DNA and 5 µg of 
MCMV BAC DNA. BAC DNA in 200 µl of TE buffer was additionally treated with 
ultrasound (120 W) for 3 s. The DNA was then ethanol-precipitated and resuspended in 
10 µl of distilled water. 
2.4 Polymerase-chain reaction (PCR) 
We used the Expand High Fidelity PCR System polymerase from Roche for all PCR 
reactions. PCR was performed in the thermocycler T 2400 from Perkin Elmer. Each 
PCR sample was prepared with 10 ng to 100 ng of template DNA, 300 nM of each 
primer, 200 µM of dATP, dCTP, dGTP, dTTP, 1/10 of 10x Expand HF buffer and 3.5 
units of Expand High Fidelity PCR System polymerase. See table B 2 for PCR 
conditions. Chapter B 2.5.1 describes the PCR conditions for the amplification of PCR 
products for site-directed BAC mutagenesis. 
 
Tab. B 2 Conditions for PCR. 
cycles conditions for PCR 
1 at 95°C for 5 min 
28 
at 94°C for 30 s 
at TH* for 1minute 
at 68°C or 72°C** for 1 – 3 min (elongation time***) 
1 at 68°C or 72°C** for 6 min 
* The temperature for hybridization (TH) of a primer was calculated using this simplified 
equation: 
 TH (°C) = 60 + [(G + C) x 41 / Nt Number] – (600/NtNumber) 
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(G + C equals the number of cytosine und guanidine in a primer sequence, NtNumber  
corresponds to the length of the primer). The temperature for hybridization was 2°C 
lower than the smaller TH of both primers. 
** For DNA fragments smaller/larger than 1 kbp 72°C/68°C was chosen. 
*** For each 500 bp of template DNA an elongation time of 30 s was set, with a minimum of 
1 min. 
2.5 Mutagenesis of MCMV BAC plasmids 
The mutagenesis of the parental and mutated MCMV BAC plasmid was performed by 
homologous recombination in E.coli bacteria with the one-step mutagenesis according 
to Zhang et al. (1998). 
2.5.1 Generation of PCR fragments with viral homologies 
68 to 73 base pair large synthetic oligonucleotides were used as primers for PCR. These 
contained 22 to 23 base pair recognition sites at their 3´-end that are complementary to 
sequences of the template DNA pSLFRTkan. The 5´-end contained a 45-50-bp 
homology to the desired MCMV sequence. The following conditions were used to 
amplify the PCR fragment with the kanamycin resistance gene and the chosen viral 
homologies: We used the Expand High Fidelity PCR system polymerase from Roche at 
a temperature of 68°C and PCR was performed with a maximum of 10 ng of template 
DNA. PCR was performed in principal as described in chapter B 2.4 for conventional 
PCR, but touch-down conditions were applied to avoid unspecific binding. During the 
first 18 cycles the annealing temperature was decreased every round from 62°C to 45°C 
by 1°C. This was followed by 17 cycles at 45°C and an elongation time of 2 min. 
2.5.2 Purification of PCR fragments 
First, 4 µl of the 100 µl PCR reaction were analyzed by agarose gel electrophoresis to 
confirm successful amplification. The remaining 96 µl were purified with the Qiaquick 
PCR Purification kit from Qiagen according to the standard protocol and eluted in 50 µl. 
The eluted DNA was digested with 20 units (1 µl) of restriction enzyme DpnI for 1.5 h 
at 37°C. DpnI digests methylated DNA of bacteria and thus removed the template DNA. 
The DNA was then precipitated with 6 µl of 3 M sodium acetate and 180 µl of ethanol 
(3 vol.) at –80°C and centrifuged at 14,000 rpm for 15 min at 4°C. The pellet washed 
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with 70% ethanol, dried on air and resuspended in 10 µl of water. The DNA was stored 
at –20°C. 
2.5.3 Generation of electro-competent and arabinose-induced DH10B bacteria 
5 ml of LB medium with 25 µg/ml of chloramphenicol and 100 µg/ml of ampicillin 
were inoculated with 5 µl of a glycerol culture of DH10B bacteria that contained the 
MCMV BAC and the pBADαβγ plasmid. After overnight incubation at 37°C 2 ml of 
the starter culture were used to inoculate 200 ml LB medium with 25 µg/ml of 
chloramphenicol and 100 µg/ml of ampicillin. 2 ml of fresh arabinose solution (10% 
w/v) was added to a final concentration of 0.1 % (w/v) at an optical density (OD600) of 
0.15-0.18. The cells were further incubated at 37°C until the required OD600 was 
between 0.25-0.35. The appropriate OD600 was reached after 30 min in most cases. All 
materials and solutions were cooled to temperatures slightly below 0°C in the following 
steps. The bacterial culture was incubated on ice for 15 min and centrifuged at 7,000 
rpm in a prechilled (-5°C) GSA Sorvall rotor for 10 min. The supernatant was decanted 
and the bacterial pellets were resuspended in 10% glycerol. The bacteria were 
centrifuged and resuspended in glycerol again. Finally, the supernatant was discarded 
and the residual supernatant was cleared with a paper towel. The pellet was resuspended 
in the residual supernatant in the tube and was dispensed into 60 μl aliquots that were 
frozen at –80°C. 
2.5.4 Transformation of the PCR fragment into the arabinose-induced bacteria 
The electrocompetent DH10B bacteria were thawed on ice and transferred to a chilled 
cuvette. Then, 5 µl of the PCR fragment were added to the bacteria and pulsed with a 
gene pulser from Perkin Elmer at 2.5 kV, 200 Ω and 25 µFD. 1 ml of LB medium was 
added immediately and the bacteria were incubated with shaking at 37°C for 1.5 h. The 
transformed bacteria were plated onto selective agar plates with chloramphenicol and 
kanamycin (25 µg/ml) and incubated overnight at 37°C. 
2.5.5 Deletion of the FRT-flanked selection marker 
Plasmid pCP20 was transformed into electro-competent bacteria with previously 
mutated MCMV BAC. The pCP20 plasmid expresses the FLP recombinase that can 
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excise sequences between two FRT sites. The transformed bacteria were incubated at 
30°C for 1 h and then 1/10 vol. of bacteria was plated onto selective agar plates with 
chloramphenicol (25 µg/ml) und ampicillin (100 µg/ml) and incubated overnight at 
30°C. The FLP recombinase encoded on plasmid pCP20 excised the kanamycin cassette 
between the flanking FRT sites at 30 °C. The next day, 4 colonies were plated onto agar 
plates with chloramphenicol and incubated overnight at 43°C to loose plasmid pCP20 
(Fig. B 1). Then 50 colonies were tested for sensitivity for the previously excised 
kanamycin cassette. 
 
Fig. B 1 Efficacy of the excision of the kanamycin cassette. The plasmid pCP20 was 
transformed into electro-competent bacteria with the mutated MCMV BAC and incubated on LB 
agar with chloramphenicol und ampicillin overnight at 30°C. Four colonies were plated on agar 
plates with chloramphenicol the next day and incubated at 43°C overnight leading to the loss of 
the pCP20 plasmid. Then 50 colonies were tested for sensitivity for the previously excised 
kanamycin cassette. 
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2.5.6 Viral reconstitution of MCMV BAC plasmids 
Wild-type and mutant viruses were reconstituted by transfection of BAC DNA into 
MEFs with calcium-phosphate precipitation (see chapter B2.7.3) or into NIH 3T3 cells 
with the Superfect transfection reagent from Qiagen (see chapter B2.7.4). 1-2 µg of 
plasmid DNA was transfected into 80% confluent MEFs for the reconstitution of 
recombinant MCMVs from the MCMV BAC plasmid with calcium precipitation. 3-15 
viral plaques were formed after 4 (wt virus) to 10 days (attenuated virus). After a couple 
more days all cells showed a cytopathic effect. Alternatively, transfection with 
Superfect transfection reagent from Qiagen was performed according to the 
manufacturer's instructions (see chapter B 2.7.4). One ml of the viral supernatant was 
used to infect 30% confluent NIH3T3 fibroblasts to subsequently make larger viral 
stocks (see chapter B 2.8). The residual supernatant was stored at –80°C as a primary 
viral stock. 
2.6 Proteins in infected cells 
2.6.1 SDS-PAGE gel electrophoresis 
Proteins were separated on 12.5% polyacrylamide gels under denaturing conditions 
(SDS-PAGE). A ready-to-use 30% acrylamide stock solution with 0.8% bisacrylamide 
was used to pour gels. The stacking gels were poured with 4x stacking gel buffer while 
the resolving gel was poured in 4x resolving buffer. The samples were heated at 95°C 
for 5 min and loaded into the sample wells in a maximum volume of 40 µl of a 1X 
sample buffer. The gels were run in running buffer at a maximum of 180 V. 
 
4x stacking gel 
buffer  
0.5 M Tris 
0.4% SDS 
pH 6.8  
 
4x resolving 
buffer  
1.5 M Tris 
0.4% SDS 
pH 8.8 
 
 
 B. Materials and Methods 44 
1x sample 
buffer 
2% SDS 
20% glycerol 
25 mM Tris pH 6.8 
1% β-mercaptoethanol 
0.02% bromphenol blue 
 
running buffer 25 mM Tris 
10% SDS 
250 mM glycin 
2.6.2 Western blotting 
The cell lysate of 2x105 infected cells was used for Western blot analysis. After 
electrophoresis of the protein samples on an acrylamide gel, the gel was blotted onto a 
Hybond P PVDF membrane that was pre-wetted in blotting buffer and swiped in 
methanol. Three layers of Whatman paper equilibrated with blotting buffer were placed 
above and below the gel and membrane. The transfer was conducted with a semidry-
blotting apparatus from Bio-Rad (USA) for 30 min at 18 V. If necessary, the transfer of 
proteins was confirmed with ponceau dye. 
 
10x blotting 
buffer 
390 mM glycine 
480 mM Tris/HCl pH 8.3 
0.37% SDS 
 
ponceau dye 0.2% Ponceau-S 
3% acetic acid 
 
To block unabsorbed protein binding sites the membrane was placed in 5% BSA or 
milk in Tris Buffered Saline with Tween (TBST) buffer for 30 min at room temperature 
or at 4°C overnight. The membrane was then incubated with the primary antibody 
(diluted 1:1000 to 1:3000) for 1 h and washed at least five times with TBTS at room 
temperature. Then the secondary antibody (diluted 1:2000 to 1:7000 in TBST) was 
added for 1 h at room temperature. After washing the membrane another five times, the 
peroxidase that is conjugated to the secondary antibody was visualized photochemically 
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with the ECL Western blotting detection reagents kit from Roche according to the 
manufacturer’s instructions. To detect the protein bands, the membrane was placed on 
an X-ray film for 1-5 min. 
 
TBST buffer 150 mM NaCl 
10 mM Tris/HCl (pH 8.0) 
0.02% Tween 20 
2.7 Cell culture 
All cell lines were cultured with 5% CO2, 95% humidity and at 37°C in a Heraeus 
incubator. NIH3T3 fibroblasts were cultured in DMEM supplemented with newborn 
calf serum (NCS). IC-21 and MEFs were cultured in DMEM supplemented with fetal 
calf serum (FCS). Confluent cells were subcultured 1:3 to 1:5 every 3 to 4 days. MEFs 
were subcultured 1:2 every 6 days. First, the cells were washed in phosphate-buffered 
saline (PBS), incubated with trypsin/EDTA for 3 min at room temperature, harvested, 
and added to 10 ml of DMEM. Then, the cells were centrifuged with a Heraeus 
centrifuge at 12,000 rpm for 3-5 min at room temperature, resuspended in supplemented 
DMEM and transferred to an appropriate cell culture dish. 
 
trypsin/EDTA 0.5 g trypsin in 1:250 in PBS 
0.2 g EDTA/l 
 
supplemented 
DMEM 
90% DMEM 
10% FCS or NCS 
0.3 mg/ml L-glutamine 
1.3% (w/v) streptomycin 
0.6% (w/v) penicillin 
2.7.1 Thawing cells 
Frozen cells were thawed rapidly at 37°C and were then added to supplemented 
DMEM. After centrifugation for 5 min with a Heraeus centrifuge at 1,200 rpm and room 
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temperature the cells were resuspended in supplemented DMEM and transferred to cell 
culture dishes. 
2.7.2 Freezing cells  
Cells that were approximately 90% confluent were trypsonized, pelleted, and added to 1 
ml of freezing medium. The cells were first frozen at –80°C overnight and then in liquid 
nitrogen. 
 
Freezing 
medium 
50% FCS 
40% DMEM 
10% dimethyl sulfoxide 
(DMSO) 
2.7.3 Transfection of eukaryotic cells with calcium-phosphate precipitation and 
glycerol shock 
Mouse embryonic fibroblasts (MEF) were freshly thawed from –80°C, seeded on 10 cm 
tissue culture dishes and subcultured two days later to produce 40-80% confluent cells 
on the day of transfection. Then, 1 to 2 µg of MCMV BAC DNA were added to 31 µl of 
2 M CaCl2 and TE buffer was added to a final volume of 250 µl. After careful mixing 
250 µl 2x HEPES buffered saline (HBS) solution was added and the solution was mixed 
again. The suspension of calcium-phosphate precipitated DNA was incubated at room 
temperature for 15 min and pipetted drop by drop onto 40-80% confluent cells in a 6 cm 
cell culture dish. 
The cells were glycerol shocked to increase the amount of transfected DNA. The 
cells were washed with PBS after 5 h and the supernatant was removed. 1 ml of a 15% 
glycerol solution in 1x HBS solution was added to the cells for 2.5 min. The glycerol 
solution was then aspirated and the cells were rinsed twice with PBS and new 
supplemented DMEM was added. 
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2x HBS 
solution 
50 mM HEPES 
1.5 mM Na2HPO4 x 2 H2O 
0.28 M NaCl 
pH 7.13 
2.7.4 Transfection of eukaryotic cells with Superfect transfection reagent 
Wild-type and mutant viruses were reconstituted by transfection of BAC DNA into 
NIH3T3 cells with the Superfect transfection agent from Qiagen according to the 
manufacturer’s instructions. 2 to 3 μg of BAC DNA was incubated with 100 μl of 
medium without serum and 10 μl of Superfect transfection reagent. The mixture was 
added to approximately confluent 3 x 105 NIH3T3 fibroblasts. Cells were washed with 
phosphate-buffered saline 4 h later, cultured with fresh medium, and passaged when 
necessary. Plaques usually appeared 4 to 7 days after transfection. 
2.8 Generation of MCMV viral stock 
Ca. 30% confluent M2-10B4 cells in 14.5 cm tissue culture dishes were infected with an 
MOI of 0.1 to generate 8-10 MCMV viral stocks. 1 ml of viral supernatant from a 10 
cm cell culture dish of cells with a complete cytopathic effect was used to generate first-
time viral stocks. The cells and the supernatant were harvested after 3-5 days and 
transferred to a 250 ml centrifugation tube. The following steps were performed at 4°C 
or on ice. The supernatant with the virions was stored on ice and the cell pellet was 
resuspended in 4 ml of DMEM after centrifugation at 6,000 rpm with a Sorvall 
centrifuge for 15 min. The cells were homogenized 20 times with a glass dounce 
homogenisator to isolate cell-associated virions from the cells. The suspension was 
centrifuged again at 12,000 rpm for 10 min with a Sorvall centrifuge to remove cell 
debris and the supernatant was added to the previously stored supernatant. The 
combined supernatants were centrifuged at 13,000 rpm with a Sorvall centrifuge for 3 h 
to pellet the virions. The resulting viral pellet was covered with 1 ml of DMEM and was 
stored at 4°C overnight. After resuspending the viral pellet in 4 ml DMEM, the virions 
were dounced 20 times with the homogenisator and then transferred to 7 ml of 15% 
sucrose in VSB buffer in a SW28 centrifuge tube. The pure viral pellet was resuspended 
in VSB buffer and dounced again 20 times with the homogenisator after 1 h of 
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centrifugation at 20,000 rpm with a Beckmann SW 28 rotor. The viral preparation was 
stored in 50 µl aliquots at –80°C. 
 
VSB buffer 0.05 TRIS/HCl 
0.012 M KCl 
0.005 M EDTA 
pH 7.8 
2.9 Viral titration of MCMV with standard plaque assay 
MEFs were prepared in 48 well plates and after reaching 100% confluence were 
infected with dilutions of the viral suspension (1/104 to 1/109 in DMEM) to determine 
viral titers. After 1 h of adsorption, the cells were washed with phosphate-buffered 
saline and covered with carboxymethylcellulose medium to prevent formation of 
secondary plaques. Growth of each virus was quantified at least twice or in triplicate. At 
6 days post infection (p.i.) the plaques were counted under the light optical microscope 
and viral titers were calculated with the following equation: 
 
dilutionvirusofvolume
 wellcounted ofdilution  plaques counted (PFU/ml) titer Viral ×=  
 
 
carboxy-
methylcellulose 
medium (for 0.5 l) 
15% glycerol solution (in 1x HBS solution) 
3.75 g carboxymethylcellulose 
25 ml FCS 
50 ml 10x MEM 
5 ml L-glutamine 
2.5 ml solution of non-essential a.a. 
5 ml penicillin/streptomycin 
425 ml water 
24.7 ml of a 7.5% NaHCO3 solution 
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2.10 Viral titration of MCMV with the TCID50 (median tissue culture infectious 
dose) method 
Viral stock titers were determined by plaque assay on monolayers of NIH3T3 
fibroblasts. Confluent NIH 3T3 fibroblasts from a 10 cm tissue culture dish were 
subcultured 1:15 and seeded on 96 well microplates. The next day dilutions of the wild-
type or mutant virus (104 to 109) were added to each lane. 1 to 2 h after viral adsorption, 
the viral supernatant was aspirated and replaced by new DMEM. The TCID50 is defined 
as the dilution of virus required to infect 50% of the cell culture inoculated. Once CPE 
was obtained and the results were recorded, the virus infectivity titers were calculated to 
determine the 50% endpoint. 
2.11 Isolation of mouse embryonic fibroblasts from the mouse 
Mouse embryonic fibroblasts had been isolated from BALB/c mice as described 
previously (Wagner et al., 2002a, Wagner et al., 2000) and were cultured in Dulbecco's 
modified Eagle's medium supplemented with 10% (vol/vol) fetal calf serum, 100 U/ml 
penicillin, and 100 µg/ml streptomycin. These cells were used for virus reconstitution 
from recombinant MCMV BAC plasmids. 
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C. RESULTS 
1 Mutants ΔATG-m139 and ΔATG-m142 were generated by site-directed muta-
genesis 
In 2003 Menard et al. had generated, a transposon library of mutant BACs in order to 
analyze the members of the US 22 gene homolog family in MCMV. Transposon mu-
tants for the US22 gene homolog members m139, m140, m141, and m143 were gener-
ated rapidly. ORFs m139 to m141 and m142 to m143 represent a complex translational 
region and are transcribed collinearly. The insertion of a transposon donor plasmid into 
an upstream ORF of this region can destabilize the ORFs downstream. This could lead 
to difficulties in attributing a phenotype to a specific ORF. 
Additional site-directed mutants with a minimal genetic change were generated in 
this thesis. Linear PCR fragments with the kanamycin resistance marker flanked by vir-
al homologies were transformed into recombination-deficient bacterial strains that con-
tain the MCMV BAC DNA. The desired mutation was introduced by homologous re-
combination between the viral sequences of the linear PCR fragment and the MCMV 
genome. The mutation was successfully introduced if the kanamycin cassette replaced 
the desired sequences of ORF m139, m140 and m142 and was later excised by recom-
binases from Saccharomyces cerevisiae. 
1.1 PCR fragments with flanking viral homologies to ORF m139, m140 and m142 
were generated 
The generation of linear PCR products was the first step in the PCR-based mutagenesis 
of MCMV. 68 to 73 base pair large synthetic oligonucleotides were used as primers to 
generate the linear PCR fragments for site-directed BAC mutagenesis of ORF m139, 
ORF m140 and ORF m142. The primers contained 22-23 bp recognition sites at their 
3´-end that were complementary to sequences of the template plasmid pSLFRTkan. 
Plasmid pSLFRTkan contains the kanamycin resistance cassette and minimal FRT sites 
with 34 bp. These minimal FRT sites are sufficient for homologous recombination 
(McLeod et al., 1986). The 5´-end of the primers contained 45-50 bp homologies to the 
MCMV sequence of ORF m139, ORF m140 and ORF m142. Thus, the linear fragments 
generated by touch-down PCR with plasmid pSLFRTkan (Atalay et al., 2002) as tem-
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plate DNA contained the kanamycin resistance gene flanked by Flp recognition target 
sites (FRT), non-coding priming regions, and viral homologies (see Fig. C 1). The viral 
homologies were chosen so that the kanamycin resistance cassette replaced the ATG of 
ORF m139, m140 and 142 in MCMV. The resistance marker was introduced into the 
PCR fragment in order to select for the rare event of homologues recombination in E. 
coli. This selection marker was later excised by the flanking FRT. 
This one-step mutagenesis method based on double crossing-over does not require 
any prior cloning steps. Only synthetic oligonucleotides have to be generated in order to 
construct the desired mutant MCMV genome. 
3´ MCMV homology5´ MCMV homology
PCR
primer
kan
FRT FRTMCMV homology MCMV homology
pSLFRTkan
priming region in pSLFRTkanpriming region in pSLFRTkan
1.2 kbp
(45-50 bp)
(22-23 bp)
(1000 bp)
(34 bp)
 
Fig. C 1 Generation of linear PCR fragments. The plasmid pSLFRTkan was used as a tem-
plate for PCR. All primers (blue arrows) had a priming region (grey box) to plasmid pSLFRTkan 
and viral homologies (green box) to the desired MCMV sequence. The amplified PCR frag-
ments contained the kanamycin cassette (red box) flanked by Flp recognition target sites (FRT, 
yellow box), the priming regions in pSLFRTkan, and viral homologies. 
Successful amplification of the PCR fragments was confirmed by electrophoresis on 
ethidium bromide-stained agarose gels (see Fig. C 2). Approximately 1.2 kbp large li-
near PCR fragments were generated. The purified PCR fragments were digested with 
DpnI to remove methylated template DNA from the dam positive bacteria. 
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kan
A
1 2 3
B
1
2
3
195 930 nt 196 017 nt195 880 nt 196 066 nt
200 745 nt 200 749 nt200 701 nt 200 794 nt
197 478 nt
197 518 nt
197 431 nt
197 561 nt197 381 nt 197 426 nt
kan
kan
 
Fig. C 2. Linear PCR fragments. (A) The ethidium bromide-stained agarose gel shows linear 
DNA fragments amplified for the generation of site-directed mutants ΔATG-m139 (lane 1), 
ΔATG-m140 (lane 2) and ΔATG-m142 (lane 3). (B) PCR fragments PCR-m139 (1), PCR-m140 
(2), and PCR-m142 (3) are shown with the respective viral homologies (green box). The priming 
regions are shown as grey and the FRT sites as yellow boxes. 
1.2 Site-directed mutants of ORF m139 and m142 were generated 
Plasmid pSM3fr in E. coli was used for homologous recombination between the linear 
PCR fragments PCR-m139, PCR-m140, PCR-m142 and the MCMV BAC (Wagner et 
 
 
Fig. C 3 Plasmid pBADαβγ. Plasmid pBADαβγ contains the inducible recombination enzymes 
of phage λ. The redα−gene is under the control of the BAD promoter that can be inhibited by 
the regulatory protein araC. Arabinose activates the release of araC from the BAD promoter. 
The redβ−gene is under the control of promoter EM7 and the redγ−gene is under constitutive 
control of promoter Tn5. 
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al. 2002a; see also Materials and Methods). The MCMV BAC plasmid pSM3fr contains 
the entire MCMV genome and the BAC backbone. The construct loses the bacterial se-
quences and virus MV97.01 is reconstituted with wild-type properties after transfection 
into fibroblasts or infection of mice. 
For site-directed mutagenesis 1 μg of a PCR fragment was transformed into electro-
competent DH10 B that contain the plasmids pSM3fr and pBADαβγ (Fig. C 3). Plasmid 
pBADαβγ expresses the inducible recombination enzymes of phage λ. The PCR frag-
ment was inserted by the flanking 45-50 bp homologies to the viral target sequences. 
Viral homologies 25 to 60 bp long are sufficient for homologous recombination (Mur-
phy et al., 1998). The double crossover between the viral homologies of the PCR frag-
ment and the MCMV BAC plasmid was conferred by the transiently arabinose-induced 
recombinases redα and redβ, expressed by plasmid pBADαβγ. 
The transformation reaction was streaked out onto agar plates with chloramphenicol 
and kanamycin for selection of the mutant MCMV BAC plasmid. Bacterial colonies 
were counted and mutant BAC DNA was isolated from E. coli cultures with an alkaline 
lysis procedure (Sambrook et al., 2001) and purified with Nucleobond AX100 columns 
(Machery & Nagel) after overnight incubation. Table C 1 summarizes the primers used 
for the generation of mutants ΔATG-m139, ΔATG-m140, ΔATG-m140.1 and ΔATG-
m142. 
 
Tab. C 1 Overview of the generated mutant MCMV BAC plasmids. 
mutant ΔATG-m139 ΔATG-m140 ΔATG-m140.1 ΔATG-m142 
primers 5´-ΔATG-m139 
3´-ΔATG-m139 
5´-m140-nt-
197427 
3´-m140-nt-
197517 
5´-ΔATG-m139 
3´-m140-nt-
197477 
5´-ΔATG-m142 
3´-ΔATG-m142 
Deleted viral  
sequence  
(nt position) 
 
195 931 - 196 016 
 
(197 427 - 197 517)* 
* Estimated deletion 
 
(197 430 - 195 931)* 
* Estimated deletion 
 
200 476 - 200 478 
The used primers and the deleted viral sequences are listed for mutants ΔATG-m139, ΔATG-
m140, ΔATG-m140.1, and ΔATG-m142. 
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Mutagenesis of ORF m139 and m142 was successful. The viral sequences from nuc-
leotide 195 931 to 196 016 were deleted from the m139 ORF and the viral sequences 
from nucleotide 200 476 to 20 478 were deleted from the m142 ORF. Correct mutage-
nesis was confirmed by restriction pattern analysis (Fig. C 4, Fig. C 5) and sequencing. 
The first two start codons of ORF m139 were deleted and replaced by the kanamycin 
cassette introducing an additional EcoRI cleavage site into the 4.7 kbp EcoRI fragment. 
This rendered a single 4.7-kbp band, a triple band at 2.4 kbp, and an additional 3.4 kbp-
band on the ethidium bromide-stained gels (see ΔATG-m139+kan in Fig. C 4). In ORF 
m142 only the first start codon was deleted and replaced by the kanamycin cassette. 
Due to the insertion of the kanamycin cassette the 9 kbp band disappeared and was re-
placed by a 7.7 fragment and a triple band at 2.4 kbp (see ΔATG-m142+kan Fig. C 5). 
Site-directed mutagenesis of the first two in-frame start codons of the m140 ORF 
was not possible. Only isolated bacterial colonies could be recovered after transforma-
tion of the PCR-m140 fragment into electro-competent DH10 B. The purified low-scale 
BAC DNA was contaminated with plasmid DNA that could not be eliminated by re-
transformation. In the process, the MCMV BAC plasmid was lost repeatedly. BAC mu-
tagenesis with the PCR fragment PCR-m140.2, constructed to delete an alternative not 
in-frame start codon at position 197 479, did not produce bacterial colonies. 
1.3 The kanamycin cassette was excised from mutant ΔATG-m139+kan and mu-
tant ΔATG-m142+kan 
The kanamycin resistance cassette, flanked by the minimal FRT sites, was excised with 
the FLP recombinase expressed from plasmid pCP20 (Fig. C 4). Fifty colonies plated 
simultaneously on agar plates with both chloramphenicol and kanamycin or chloram-
phenicol only grew on the later (see Material and Methods, chapter B 2.5.5). This con-
firmed the successful excision of the kanamycin resistance marker. 
Digest analysis of mutant ΔATG-m139+kan with EcoRI produced a 3,386 and 2,402 
bp DNA fragment. After excising the kanamycin cassette, the 3,386 bp fragment disap-
peared (see Fig. C 4). The MCMV sequence from nucleotide 196 016 to nucleotide 195 
931 was deleted rendering the mutant ΔATG-m139. This viral sequence includes the 
first two in-frame ATGs of ORF m139.  
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Restriction digest analysis of mutant ΔATG-m142+kan with EcoRI produced two 
additional DNA fragments of 7,706 and 2,452 kbp. After excising the kanamycin cas-
sette the 7,706 band disappeared and was replaced by a 6,706 kbp DNA fragment (Fig. 
C 5). Nucleotides 200 476, 200 477 and 200 478 representing the first ATG in ORF 
m142 were deleted. This rendered the mutant ΔATG-m142. 
 
 
 
Fig. C 4 Mutant ΔATG-m139 was generated by site-directed mutagenesis of ORF m139. 
(A) Ethidium bromide-stained agarose gel of EcoRI-digested BAC plasmids pSM3fr, ΔATG-
m139 + Kan and ΔATG-m139 isolated from E. coli. Digestion of mutant ΔATG-m139+kan with 
EcoRI produced a 3,386 and 2,402 bp DNA fragment. After excising the kanamycin cassette 
the 3,386 bp fragment disappeared. (B) EcoRI (black line) restriction enzyme pattern after ex-
cising the kanamycin cassette (red box) from mutant ΔATG-m139+kan. Mutant ΔATG-m139 
contains a FRT site (yellow box) and the priming region (grey box) at the position of the inserted 
mutation. MCMV BAC DNA is shown as a green box. 
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Fig. C 5 Mutant ΔATG-m142 was generated by site-directed mutagenesis of ORF m142. 
(A) Ethidium bromide-stained agarose gel of EcoRI digested BAC plasmids pSM3fr, ΔATG-
m142 + Kan and ΔATG-m142 isolated from E. coli. Restriction analysis of mutant ΔATG-m142 + 
Kan with EcoRI produced additional DNA fragments at 7,706 and 2,452 kbp. After excising the 
kanamycin cassette, the 7,706 band disappeared and was replaced by a 6,706 kbp DNA frag-
ment (B) EcoRI (black line) restriction pattern after excising the kanamycin cassette (red box) 
from ΔATG-m142 + Kan. Mutant ΔATG-m139 contains a FRT site (yellow box) and the priming 
region (grey box) at the position of the inserted mutation. MCMV BAC DNA is shown as a green 
box. 
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1.4 Site-directed mutagenesis of ORF m139 and m142 introduces a minimal ge-
netic alteration 
In mutant ΔATG-m139 the first two putative start codons of ORF m139 that are 84 bp 
apart were replaced with an 86-bp extraneous sequence (Fig. C 6). The MCMV se-
quence from nucleotide 195 931 to nucleotide 196 016 was replaced by the 34-bp mi-
nimal FRT site and the priming sequence in plasmid pSLFRTkan. Site-directed muta-
genesis of ORF m139 was confirmed by sequencing (Fig. C 6). In mutant ΔATG-m142 
the native ATG of ORF m142 was deleted and replaced by an 86-bp sequence that con-
tains the 34-bp FRT flanked by a 23-bp sequence of priming in plasmid pSLFRTkan. 
 
Fig. C 6 Traces of mutagenesis. (A) pSM3fr corresponds to the MCMV wt sequence. In mu-
tant ΔATG-m139 the first two start codons were deleted resulting in a deletion of 87 base pairs, 
while in mutant ΔATG-m142 only 3 base pairs were deleted. After excision of the kanamycin 
cassette, an 80-bp (grey and yellow box) sequence remained. MCMV sequence (green arrow), 
FRT (yellox box), priming region (grey box). (B) Sequence analysis of the HindIII fragment that 
contained the mutated region of ORF m139 revealed appropriate mutagenesis with a remaining 
minimal FRT site flanked by the priming sequence (grey box) in pSLFRTKan. The minimal FRT 
site consists of the spacer (yellow box) and two surrounding 13 bp symmetry elements ar-
ranged in inverse orientation (yellow arrows). 
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2 Mutant ΔATG-m139 has wild-type properties in NIH3T3 fibroblasts, but 
shows attenuated growth in IC-21 macrophages 
2.1 Growth kinetics in NIH3T3 fibroblasts 
The mutant  ΔATG-m139 was first tested with respect to growth on NIH 3T3 fibroblasts 
in comparison with wild-type virus. Table C 2 shows a representative experiment. 
Growth kinetics of mutant  ΔATG-m139 was compared to wild-type MCMV virus MW 
97.1. In order to see whether growth of mutant  ΔATG-m139 was comparable to the 
corresponding transposon mutant for ORF m139 Tn-m139, the wild-type virus Tn-152 
with a transposon insertion 300 bp downstream to the native ATG (nucleotide 211 077) 
of gene 152, which expresses green fluorescent protein, was added to the experiment as 
a control. Monolayers of NIH3T3 fibroblasts were infected in triplicate with a multi-
plicity of infection of 0.1 of the respective viral stock. Virus progeny in tissue culture 
supernatants was quantified by the TCID50 method on NIH 3T3 fibroblasts. After incu-
bation of the NIH3T3 monolayers with viral progeny for one hour the supernatant was 
harvested and fresh cell medium was added. This supernatant, that had been absorbed 
one hour post infection, represented day 0. The titers of cell-free viruses were deter-
mined on day 0, day 1, day 4 and day 6 postinfection. After absorption of the virus one 
hour post infection viral plaques and viral spread was detectable after day 1. By day 6 
multiple viral plaques had formed. 
 
Tab. C 2 Mean viral titers of wild-type MCMV (MW 97.01, Tn-m152), mutant ΔATG-m139, 
and transposon mutant Tn-m139 at day 0, 1, 4 and 6 post infection in NIH 3T3 fibroblasts. 
MCMV mutant day 0 day 1 day 4 day 6 
wt (MW 97.01) 1.6 x 104 1.3 x 102 1.1 x 104 3.3 x 104 
wt (Tn-m152) 1.4 x 104 1.0 x 102 7.5 x 104 9.0 x 104 
ΔATG-m139 1.0 x 104 1.5 x 102 6.0 x 103 1.3 x 104 
Tn-m139 1.9 x 104 1.8 x 102 3.7 x 104 5.7 x 104 
Monolayers of NIH 3T3 fibroblasts were infected with an MOI of 0.1 with wild-type or mutant 
MCMV. At day 0 to 6 post infection, supernatant was harvested from individual wells and infec-
tious virus was quantified on NIH3T3 fibroblasts by the TCID50 endpoint titration method. 
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Fig. C 7 shows the corresponding multistep growth curves of the MCMV mutants in 
these adherent cells. The results demonstrate that the growth rate of each mutant was 
similar to that of the corresponding wild-type MCMV. A difference in the range of less 
than one log unit compared to wild-type MCMV was detected. Thus there was no sig-
nificant difference between wild-type MCMV and the mutant ΔATG-m139 or transpo-
son mutant Tn-m139 with respect to growth on NIH 3T3 fibroblasts, confirming that the 
mutations introduced into this ORF do not negatively affect MCMV replication in cul-
tured fibroblasts. The transposon and the ATG mutant of ORF m139 acted similarly 
displaying a growth difference of less than one log unit. 
Taken together, neither the introduction of a transposon at ORF m139, as shown be-
fore (Menard et al., 2003), nor the deletion of the first two ATGs in ORF m139 impairs 
growth in fibroblasts. Both m139 mutants show wild-type properties in NIH3T3 fibro-
blasts. 
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Fig. C 7 In vitro growth of mutant ΔATG-m139 in NIH3T3 fibroblasts. Multistep growth 
curves of wild-type MCMV (MW 97.01, Tn-m152), mutant ΔATG-m139 and transposon mutant 
Tn-m139 were determined in NIH3T3 as described in Material and Methods. Each data point 
represents the average of three separate cultures and error bars indicate the standard devia-
tions between triplicates. 
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2.2 Growth kinetics in IC-21 macrophages 
As a complement to the studies described above, growth of wild-type MCMV and that 
of mutants ΔATG-m139 and Tn-m139 were compared in the fully permissive peritoneal 
macrophages cell line IC-21 (Mauel, 1971). As shown previously the transposon mutant 
of gene m139 and a deletion mutant for m139, that lacks almost the complete m139 
ORF, were impaired for growth on IC-21 macrophages compared with wild-type 
MCMV (Menard et al., 2003). The attenuation of these mutants for growth on IC-21 
macrophages was in the range of two to three log units compared to wild-type MCMV. 
 
Tab. C 3 Mean viral titers of wild-type MCMV (MW 97.01, Tn-m152), mutant ΔATG-m139 
and transposon mutant Tn-m139 at day 0, 1, and 6 postinfection in IC-21 macrophages. 
MCMV mutant day 0 day 1 day 6 
wt (MW 97.01) 3.6 x 103 3.9 x 101 2.6 x 105 
wt (Tn-m152) 1.9 x 103 3.7 x 101 1.6 x 105 
ΔATG-m139 1.9 x 103 3.7 x 101 2.9 x 102 
Tn-m139 4.3 x 103 3.4 x 101 3.2 x 103 
Monolayers of IC-21 macrophages were infected with an MOI of 0.1 with wild-type or mutant 
MCMV. At day 0 to 6 post infection, supernatant was harvested from individual wells and infec-
tious virus was quantified on NIH3T3 fibroblasts by the TCID50 endpoint titration method. 
 
Growth kinetics of mutant  ΔATG-m139 was compared to wild-type MCMV virus 
MW 97.1. Table C 3 shows a representative experiment. In order to see whether growth 
of mutant  ΔATG-m139 was comparable to the corresponding transposon mutant for 
ORF m139 Tn-m139, the wild-type virus Tn-152 with a transposon insertion 300 bp 
downstream to the native ATG (nucleotide 211 077) of gene 152, which expresses 
green fluorescent protein, was added to the experiment as a control. Monolayers of IC-
21 macrophages were infected with an MOI of 0.1 of the respective viral stock in tripli-
cate. Virus progeny in tissue culture supernatants was quantified by the TCID50 method 
on NIH 3T3 fibroblasts. After incubation of the IC-21 macrophages with viral progeny 
for one hour the supernatant was harvested and fresh cell medium was added. This su-
pernatant absorbed one hour post infection represented day 0. The titers of cell-free vi-
ruses were determined on day 0, day 1 and day 6 postinfection. After absorption of the 
virus one hour post infection viral plaques formation for wild-type virus was seen later 
in IC-21 macrophages than in NIH3T3 fibroblasts. The first viral plaques had formed 
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starting at days 3 to 4. The ATG and transposon mutant for ORF m139 both grew 
slowly in general. 
Figure C 8 shows the corresponding multistep growth graph of the MCMV mutants 
 ΔATG-m139 and Tn-m139. Both wild-type viruses grew similarly. As described 
above, the transposon mutant Tn-m139 showed a two log unit growth difference com-
pared to wild-type. A difference in the range of three log units compared to wild-type 
MCMV was detected for mutant ΔATG-m139. Thus there was a significant difference 
between wild-type MCMV and the mutant ΔATG-m139 or transposon mutant Tn-m139 
with respect to growth in IC-21. The mutations introduced into this ORF affects MCMV 
replication in cultured macrophages whether the ORF is deleted completely or just the 
start codon. 
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Fig. C 8 In vitro growth of mutant ΔATG-m139 in IC-21 macrophages. Multistep growth 
graphs of wild-type MCMV (MW 97.01, Tn-m152), mutant ΔATG-m139 and transposon mutant 
Tn-m139 were determined in IC-21 macrophages as described in Material and Methods. Each 
bar represents the average of three separate cultures and error bars indicate the standard devi-
ation of the geometric mean. 
In summary, both m139 mutants show wild-type properties in NIH3T3 fibroblasts, 
but are impaired for growth in IC-21 macrophages by two to three log units. These re-
sults show that inactivation of the m139 gene of the US 22 gene family affects growth 
on IC-21 macrophages. 
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3 The gene products of gene m139 interact with the gene products of genes m140 
and m141 
3.1 The complex translational region of m139 to m143 
The US22 gene members m139 to m143 are localized toward the right end at the Hin-
dIII-I and HindIII-J region of the MCMV genome (Rawlinson et al., 1996). The m139, 
m140 and m141 genes and m142 with m143 genes belong to a complex transcriptional 
unit and have 3´-coterminal transcripts (Fig. C 9). Such sets of 3´-coterminal transcripts, 
with alternative promoters, are found in multiple regions in HCMV (Stenberg et al., 
1989; Welch et al., 1991; Adam et al., 1995; Wing and Huang, 1995) and at least one 
other region in MCMV (Cranmer et al., 1996), suggesting that this is a common occur-
rence in cytomegaloviruses. 
 
Fig. C 9 Transcript map of genes m139 to m143. Black arrows denote the major transcripts 
of genes m139 to m141 and genes m142 and m143 according to Hanson et al. (1999b). Poten-
tial ORFs within the HindIII-J and –I regions are indicated by open boxes. The small arrow de-
picts the indicated restriction site. M or m designation indicates respectively the ORFs with or 
without sequence homology to HCMV genes (Rawlinson et al., 1996). IE, E and L denote im-
mediate-early, early, and late transcripts. Numbers above the arrows indicate sizes of the tran-
scripts in kb. The red boxes denote potential polyadenylation signals. Green boxes indicate po-
tential TATA boxes. 
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It is less likely that a transposon insertion in the m141 ORF would affect the tran-
scription of the downstream m139 and m140 genes, because they have independent 
transcription start sites downstream of ORF m141. However, a transposon insertion in 
the m139 ORF could affect the transcription rate or the transcript stability of the up-
stream m140 and m141 genes. To determine whether the transposon insertion in m139 
had an effect on expression of the neighboring genes, the targeted mutant of the m139 
ORF ΔATG-m139 was constructed by site-directed mutagenesis of the wild-type 
MCMV BAC plasmid pSM3fr as described above. The first 86 bp of m139 were de-
leted, thereby deleting both ATGs. After excision of the kanamycin resistance marker by 
FLP recombination, 86 bp of noncoding sequence was left behind in the MCMV BAC 
genome, corresponding exactly to the length of the deleted viral sequence. Thus, the 
first two start ATGs of m139 were deleted without altering the lengths of the m139 to 
m141 mRNA transcripts. Maintaining the same transcript length should reduce tran-
script instability. 
3.2 Mutant ΔATG-m139 reduces the presence of the m140 and m141 proteins 
We first tested whether the proteins encoded by m139, m140 and m141 interact 
posttranslationally. The transcripts and proteins are expressed at early times within the 
MCMV replication cycle (Hanson et al., 1999b; Vieirra et al., 1994). Western blot 
analysis of the mutants ΔATG-m139 and Tn-m139 MCMV was performed with m140-, 
and m141-specific polyclonal antibodies. For the m140 and m141 proteins, 15-aa pep-
tides at the C-terminus (SVLTTRPDRNRDTRT, starting at position 431) and the N-
Terminus (ATGGDQNARRRAIER, position 25), respectively, were used to generate 
rabbit polyclonal antibodies (Eurogentec, Belgium). 
wt
50kDa
Tn-m139 ΔATG-m139 mock
α-m140
 
Fig. C 10 Western blot analysis with polyclonal antisera against protein m140. NIH 3T3 
cells were infected at an MOI of 1 with wild-type MCMV (wt) or MCMV mutants ΔATG-m139 and 
Tn-m139. Cell lysates were harvested 24 h postinfection and separated by polyacrylamide gel 
electrophoresis. Western blot analyss with rabbit polyclonal antisera against protein m140 was 
performed. 
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The viral proteins were quantified using the bicinchoninic acid (BCA) protein assay 
reagent and comparable viral protein was loaded. The protein load was separated under 
denaturing conditions and then blotted. The peptide antisera to the m140 and m141 
products detected single viral proteins in wild-type MCMV-infected fibroblasts with the 
expected size of 56 kDa and 52 kDa, respectively. This is consistent with previous data 
(Hanson et al., 1999). In both the transposon mutant and the site-directed mutant of the 
ORF m139 the proteins expressed by m140 and m141 were marginally detectable. Thus 
mutation of gene m139 strongly reduced the presence of the m140 and m141 proteins 
(see Fig. C 10 and 11). 
 
Fig. C 11 Western blot analysis with polyclonal antisera against protein m141. NIH 3T3 
cells were infected at an MOI of 1 with wild-type MCMV (wt) or MCMV mutants ΔATG-m139 and 
Tn-m139. Cell lysates were harvested 24 h postinfection and separated by polyacrylamide gel 
electrophoresis. Western blot analysis with rabbit polyclonal antisera against protein m141 was 
performed. 
3.3 ΔATG-m139 expresses a truncated protein of m139 
Western blot analysis was then performed with antisera against the protein expressed 
from ORF m139. The MCMV m139 rabbit polyclonal antibody is directed against 
amino acids 57 to 644 of the m139 recombinant protein  and was kindly provided by 
Ann Campbell, Eastern Virginia Medical School. In wild-type MCMV-infected cells, 
two proteins of 72 and 61 kDa were detected with the m139-specific antiserum (Fig. C 
12), consistent with previous data (Hanson et al., 1999b). In cells infected with the Tn-
m139 MCMV, no m139-specific signal was seen, whereas with the ΔATG-m139 
MCMV mutant, a smaller protein of 61 kDa was still present, suggesting that this pro-
tein is encoded by the m139 transcript, probably originating at the third alternative start 
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ATG of the m139 ORF at nucleotide position 195767. The 61 kDa protein is thus a 
truncated protein expressed by the m139 ORF. 
 
Fig. C 12 Western blot analysis with polyclonal antisera against protein m139. NIH 3T3 
cells were infected at an MOI of 1 with wild-type MCMV (wt) or MCMV mutants ATG-m139 and 
Tn-m139. Cell lysates were harvested 24 h postinfection and separated by polyacrylamide gel 
electrophoresis. Western blot analysis with rabbit polyclonal antisera against m139 was per-
formed. 
3.4 Gene products of m139, m140, and m141 interact on the protein level 
These results indicate that the products of genes m139, m140, and m141 interact at 
the protein level and that the lack of parts of ORF m139 affects the steady-state level of 
the other proteins of m140 and m141. These data are consistent with previous reports 
that the m140 and m141 proteins form a stable complex within infected cells (Campbell 
et al., 2001, Karabekian et al., 2000). 
4 Gene m142 is essential for MCMV replication 
4.1 Is ORF m142 essential for viral growth? 
Genes m139 to m143 belong to a complex transcriptional region. The transcripts of 
m142 and m143 coterminate downstream of m142 (Fig. C 13). Previous work in our 
laboratory with transposon mutants showed that three mutant genomes with transposon 
insertions in m142 and m143 (Tn-m142.A, Tn-m142.B, and Tn-m143) and a targeted 
deletion mutant of m143 failed to generate infectious progeny (see Menard et al., 2003). 
Since a transposon insertion into ORF m142 should not have affected the transcription 
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of the downstream m143 gene, the no-growth-phenotype can be truly attributed to gene 
m143. But it was not clear, whether the observed lethal phenotype for ORF m142 was 
due to change in transcription for this gene or due to a destabilized m143 transcript. It is 
possible that the insertion of the additional 3-kb into gene m142 affected the transcrip-
tion rate or the transcript stability of the upstream m143 gene. In order to minimize the 
possible polar effects on m143 mRNA expression, mutagenesis was restricted to the 
m142 start codon in this thesis. The first ATG was deleted by site-directed mutagenesis 
of the wild-type MCMV BAC plasmid pSM3fr (See chapters C 1). 
 
Fig. C 13 Transcript map of genes m142 to m143. The HindIII map of the MCMV genome is 
shown at the top. The expanded map of the HindIII I fragment represents the gene region that 
encodes for 6 genes including m142 and m143. ORFs are indicated by open and grey boxes. 
Red and green boxes denote polyadenylation signals and TATA boxes, respectively. Grey ar-
rows denote the major transcripts of genes m142 and m143, according to Hanson et al. 
(1999b). Only immediate-early (IE) transcripts are shown. Transposon (Tn) insertions into the 
wild-type MCMV BAC pSM3fr are indicated as blue boxes. 
4.2 Construction of site-directed MCMV mutants of ORF m142 
Mutant ΔATG-m142 was constructed by site-directed mutagenesis of the parental 
MCMV BAC genome pSM3fr as described above (see chapter C 1.2, C 1.3, and Fig. C 
5). pSM3fr contains the complete MCMV genome cloned into a BAC vector. Its growth 
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Fig. C 14 Mutant ΔATG-m142/FRT was generated by site-directed mutagenesis of plasmid 
pSM3fr/GFP. (A) Ethidium bromide-stained agarose gel of EcoRI-digested BAC plasmids 
pSM3fr/GFP, ΔATG-m142 + kan/FRT, and ΔATG-m142/FRT isolated from E. coli. Restriction 
analysis of mutant ΔATG-m142 + kan with EcoRI produced additional DNA fragments at 7,706 
and 2,452 kbp. After excising the kanamycin cassette, the 7,706 band disappeared and was 
replaced by a 6,706 kbp DNA fragment. (B) EcoRI (black line) restriction pattern after excising 
the kanamycin cassette (red box) from ΔATG-m142 + kan/FRT. The yellow boxes depict FRT 
sites. 
properties are indistinguishable from wild-type MCMV (Wagner et al., 1999) after 
transfection into permissive cells. In order to be able to insert the entire ORF m142 in 
future experiments at an alternative position into the MCMV genome the parental virus 
pSM3fr/GFP was used. pSM3fr/GFP contains the green-fluorescent protein (GFP) and a 
FRT site at the position of the nonessential m152 gene. The FRT site at this position can 
be used to introduce a mutation and the expression of the GFP can facilitate the visuali-
zation of plaque formation. The pSM3fr/GFP BAC that contains an FRT site and the 
GFP gene in position of the nonessential gene m152 was first subjected to site-directed 
mutagenesis to delete the native ATG of ORF m142. The ATG codon was deleted by 
insertion of a kanamycin marker by PCR based mutagenesis with the same PCR frag-
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ment used for the generation of the ΔATG-m142 mutant genome. The kanamycin cas-
sette, flanked by minimal FRT sites, was subsequently excised by the expression of the 
FLP recombinase. The mutant ΔATG-m142/FRT with the deletion of the first ATG of 
ORF m142 (nucleotides 200 746, 200 747, 200 748) was constructed. This mutant also 
contains a GFP marker and a FRT site at the position of the nonessential m152 gene. 
Thus, the MCMV genome ΔATG-m142 should not be able to encode for functional 
m142 protein. The structure of the BAC plasmids was analyzed by digestion of plasmid 
DNA with restriction enzyme EcoRI followed by agarose gel electrophoresis (Fig. C 
14). The 9.0 kbp EcoRI fragment of the parental BAC plasmid pSM3fr/GFP was miss-
ing in the BAC plasmid ΔATG-m142+kan/FRT and was replaced by two new fragments 
of 2.4 and 7.7 kbp. Excision of the kanamycin cassette resulted in a shift of the 7.7 kbp 
fragment to a new 6.7 kbp fragment and generated ΔATG-m142/FRT. These results 
show that the intended excision of the kanamycin cassette between the two 34-bp FRT 
sites was introduced into the MCMV BAC plasmids and that no adventitious deletions 
or rearrangements could be detected anywhere else in the cloned genome. Specifically, 
no deletion or inversion was introduced between the 34-bp and 48-bp FRT site. 
4.3 ORF m142 has a lethal phenotype 
4.3.1 Rescuing essential genes 
Genes important for host-virus interaction are not directly involved in replication of the 
viral genome. These genes are dispensable for replication and are referred to as nones-
sential genes. Deletion of essential genes does not render viral progeny (Fig. C 15). In 
order to rescue these viruses, the essential gene has to be introduced in trans. Cotrans-
fection of either a small subgenomic fragment overlapping the mutant gene or the intro-
duction of the essential gene ectopically can rescue viral progeny (Fig. C 15 B and C). 
Subgenomic fragments that contain the disrupted sequence are able to complement the 
lethal mutation. The wild-type properties are restored by allelic exchange in E. coli and 
viral plaques are readily obtained. In this thesis, both ΔATG-m142 and ΔATG-
m142/FRT were tested for viral growth. Mutant ΔATG-m142/FRT was used to demon-
strate that ORF m142 is essential for viral growth. 
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Fig. C 15 Mutants of essential genes. (A) Transfection of mutated MCMV BAC plasmid into 
permissive cells leads to no viral progeny. (B) Cotransfection of small subgenomic fragments 
overlapping the mutant gene should rescue the defect MCMV BAC plasmid. (C) Construction of 
a revertant MCMV genome by homologous recombination in E. coli and transfection into fibro-
blasts will prove if the affected gene is essential. 
4.3.2 Mutant ΔATG-m142 and ΔATG-m142/FRT did not reconstitute viral prog-
eny after transfection 
Mutant ΔATG-m142 was transfected into MEFs with calcium-phosphate precipitation 
and ΔATG-m142/FRT was transfected into NIH3T3 cells with Superfect transfection 
reagent. Both cell lines are permissive for MCMV infection. Plasmids pSM3fr and 
pSM3fr/GFP were used as controls for viral infection for ΔATG-m142 and ΔATG-
m142/FRT, respectively. The results of the experiments are shown in table C 4. Trans-
fection of the parental BAC plasmid pSM3fr and pSM3fr/GFP reproducibly resulted in 
the formation of plaques. Plaques usually occurred around day 5 to 10 posttransfection 
for MEFs and around day 4 to 8 posttransfection on NIH 3T3 fibroblasts, afterwards the 
infection spread rapidly throughout the monolayers. Cells harbouring the mutant 
ΔATG-m142 and ΔATG-m142/FRT did not reconstitute viral progeny. These results 
were observed after multiple attempts and prolonged incubation. Identical results were 
obtained after transfection of the BAC plasmids into mouse embryonic fibroblasts and 
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NIH 3T3 fibroblasts. This suggested that ORF m142 is essential for the lytic replication 
cycle of MCMV. 
4.3.3 Fragment HindIII-I rescued ΔATG-m142/GFP 
In a first attempt to prove that the failure of the m142-deficient BAC plasmid to form 
plaques was due to the disrupted m142 gene, rescue experiments by cotransfection of a 
subgenomic fragment HindIII-I were performed. Fragment HindIII-I, that contains the 
complete wild-type ORF of m142, was isolated from plasmid pUC19-HindIII-I by di-
gestion with enzyme HindIII and gel elution. Recombination between the purified sub-
genomic fragment and the m142-deficient genome ΔATG-m142/FRT resulted in the 
reconstitution of replication-proficient genomes. A few plaques appeared after cotrans-
fection of ΔATG-m142/FRT with fragment HindIII-I. Typically the plaques were first 
seen at 7 to 8 days post transfection (Tab. C 4). The infection spread slowly throughout 
the tissue 
 
Tab. C 4. Initial plaque formation after transfection of the MCMV BAC plasmids. 
BAC plasmid ΔATG-m142* ΔATG-m142/FRT** ΔATG-m142/m142E**
BAC plasmid only 
Plaque formation 
n*** 
n*** 
n*** 
n*** 
+++*** 
day 6-7 
Cotransfection of 
HindIII I fragment 
Plaque formation 
+*** 
 
day 7-8 
++*** 
 
day 7-8 
- 
 
- 
* Transfection was performed on MEF with calcium-phosphate precipitation. 
** Transfection was performed on NIH3T3 with Superfect transfection reagent. 
*** Scoring of the transfection was as follows: +++ 10-20 plaques, ++ 5-10 plaques, + 1-5 
plaques, n no plaques, - not performed. 
 
culture after occurrence of the first plaques. Transfection with wild-type virus rendered 
plaques on day 5 which spread quickly. Infected cells in the culture displayed a green 
fluorescence. Thus, cotransfection ΔATG-m142/FRT with fragment HindIII-I provided 
the missing m142 protein. The reduced number of plaques as well as the delayed kinet-
ics in plaque formation was consistent with the expectation that reconstitution of repli-
cation–proficient genome by recombination with the complementing subgenomic frag-
 C. Results 71 
ment had to occur prior to plaque formation. Thus, fragment HindIII-I rescued the mu-
tant virus ΔATG-m142/FRT and led to the production of infectious virus. 
4.3.4 The ectopic gene m142 rescued the ΔATG-m142/GFP mutant 
In a next step gene m142 was introduced at an ectopic position into the MCMV BAC 
genome.  For this purpose mutant ΔATG-m142/FRT, that contains a GFP marker and a 
FRT site at the position of the nonessential m152 gene, was constructed by site-directed 
mutagenesis with the deletion of the first ATG of ORF m142, (see chapter 4.2, Fig. C 
14). 
For the insertion of ORF m142 at the additional FRT site at ORF m152 of ΔATG-
m142/FRT, a plasmid with the entire m142 gene and a promoter and polyadenylation 
site was constructed (Fig. C16). First, the ORF of m142 was amplified by PCR with 
primers 200748 up-m142-Eco and 199441down-m142-Xba using fragment HindIII-I as 
template DNA. The amplified DNA fragment with ORF m142 was inserted into plas-
mid pCR3 via the XbaI and EcoRI cleavage sites. The XbaI cleavage site of 
pORI6kZeo-m142 was sequenced with primer m142-199541-up and confirmed correct 
insertion. This plasmid and plasmid pORI6kZeo that contains a 48-bp FRT site, were 
then submitted to DrdI restriction enzyme digestion. After blunt end ligation of these 
DNA sequences, plasmid pORI6kZeo-m142 with the m142 gene, a promoter, a polya-
denylation site and a FRT site was generated. The desired mutant genome was con-
structed by homologous recombination of the mutant ΔATG-m142/FRT genome and 
plasmid pORI6kZeo-m142 in E. coli. Mutant ΔATG-m142/m142E lacks the m142 at its 
original position, but has a wild-type copy of the m142 gene instead at the original posi-
tion of the m152 gene. Correct insertion was analyzed by digestion of plasmid DNA 
with restriction enzyme HindIII followed by agarose gel electrophoresis (Fig. C 17). 
After recombination between ATG-m142/FRT and plasmid pORI6kZeo-m142 two ad-
ditional bands at 1,9 and 3,6 kbp could be detected. 
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Fig. C 16 Complementation of the ΔATG-m142 genome by insertion of the m142 gene at 
an ectopic position. The genome of ΔATG-m142/FRT is almost identical to that of ΔATG-
m142, but carries a 48-bp FRT site in gene m152. This FRT site was used for insertion of the 
m142 gene under the control of its native promoter (pro) by FLP recombinase (FLP). Zeocin 
(Zeo) was used for selection. The resulting genome, ΔATG-m142/m142E, gave rise to viral 
progeny. 
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Fig. C 17 Construction of mutant ΔATG-m142/m142E. Ethidium bromide-stained agarose gel 
of HindIII digested MCMV BAC plasmids pSM3fr/GFP, ΔATG-m142/FRT, and ΔATG-
m142/m142E isolated from E. coli. Restriction analysis of mutant ΔATG-m142/m142E with Hin-
dIII detected two additional fragments at 1,940 and 3,600 kbp. 
To confirm that m142 is essential for viral growth wild-type pSM3fr/GFP, mutant 
ΔATG-m142/FRT and ΔATG-m142/m142E were transfected into NIH 3T3 fibroblasts 
with Superfect transfection reagent. Transfection of NIH3T3 fibroblasts with wild-type 
pSM3fr/GFP and mutant ΔATG-m142/m142E produced infectious virus at day 5-7 (see 
Tab. C 4). Once viral plaques had formed infection spread quickly for both the wild-
type and the rescue virus. Mutant ΔATG-m142/FRT did not render viral progeny. 
Reconstitution of viral progeny after transfection of mutant ΔATG-m142/m142E 
into fibroblasts proved that the m142 gene that had been inserted at an ectopic position 
had rescued the missing ORF m142. Thus, ORF m142 is essential for viral growth. The 
US22 gene homolog family now harbors two genes, m142 and m143, that are essential 
for viral replication. A new essential gene was identified for MCMV in this thesis. 
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D. DISCUSSION 
1 Targeted and random mutagenesis strategies of BAC cloned herpesvirus ge-
nomes 
The propagation of herpesvirus genomes as infectious BACs in E.coli has made the 
genes of herpesviruses accessible to the tools of bacterial genetics (Messerle et al., 
1997). In the past mutagenesis of large genomes of CMVs was a time consuming task 
since slow replication in cell culture made mutagenesis by homologous recombination 
tedious (Mocarski et al., 1996). Approximately 75% of the gene functions of HCMV 
and MCMV are unknown, leaving 173 ORF of the estimated 230 ORF of HCMV and 
128 ORF of the estimated 170 ORF MCMV with an unknown function (Rawlinson et 
al., 1996). Thus, simple and straightforward methods to generate CMV mutants are vital 
to characterize the viral functions of MCMV and HCMV. 
BACs that contain the MCMV genome can be submitted to techniques of forward or 
reverse genetics. The aim of forward genetics is to identify mutations that produce a 
certain phenotype. Once mutants have been isolated, the mutated gene can be molecu-
larly identified. Using transposons that insert into BACs, a forward genetics procedure 
for MCMV has been developed (Brune et al., 1999). In reverse genetics, as applies to 
site-directed mutagenesis of BACs, one determines the phenotype that results from mu-
tating a given gene. 
Reverse genetic approaches allow candidate genes or genome regions to be tested by 
the generation of the corresponding deletion mutants. ATG mutants of ORF m139 and 
m142, both members of the US 22 gene family, were constructed in this thesis to con-
firm the phenotypes that had been observed for the transposon insertion mutants (see 
Menard et al., 2003). The applied transposable element had introduced an additional 3-
kbp gene sequence that could have possibly increased transcript length and altered pro-
tein folding. We hypothesized that this could be omitted by introducing a minimal 
change, as in the case of the generated ATG mutants. The desired deletion was intro-
duced by homologous recombination between the viral homologies of a linear PCR 
fragment and the MCMV BAC DNA. Oligonucleotides with a priming region to a tem-
plate plasmid that contained the kanamycin resistance marker and viral homologies of 
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were used to amplify the linear PCR fragment. The PCR fragment was then inserted by 
the flanking 45- to 50-bp viral homologies. 
The kanamycin cassette was inserted to select for the rare occurrence of double 
crossing-over between the corresponding viral sequences. The kanamycin cassette, 
flanked by short 34-bp FRT sites, was later excised with the Flp recombinase. Flp re-
combinase recognizes not only 48-bp but also 34-bp long FRT sites (Schlake and Bode, 
1994). As described previously homologies of 50 bp were sufficient for successful in-
sertion of the desired mutation (Murphy et al., 1998; Muyers et al., 1999). In contrast, 
the RecABCD recombination system requires homologies of 2 kbp on both sides for 
efficient homologous recombination. Since primers larger than 80 nt are costly, difficult 
to synthesize and PCR with long primers is difficult, primers with a length of 68-73 nt 
were used in this thesis. This was achieved by incorporating the resistance cassette into 
the template plasmid, choosing viral homologies not longer than to 45- to 50-bp, and 
using the shorter 34-bp FRT site. 
A recET recombination system which confers homologous recombination between 
short stretches of 27-60 bp of linear and circular DNA was previously described by 
Zhang et al. (1998). However, MCMV BACs were not stable in the recET system. Ho-
mologous recombination occurred between the 533 bp repeats which were introduced to 
delete the bacterial sequences in eukaryotic cells. As an alternative, the red recombina-
tion system of phage λ, encoded by plasmid pBADαβγ, was used in this thesis (Zhang 
et al., 1998). This system also confers homologous recombination between short DNA 
sequences (Szostak et al., 1983). To regulate the expression of the recombinases and 
thus the recombination activity, the inducible BAD promoter from Invitrogen was in-
troduced. Undesirable recombination between internal repeats was diminished with the 
induction of the BAD promoter with arabinose. Additionally, the plasmid pBADαβγ 
expresses the redγ-protein with an exonuclease inhibiting action. That is why it was 
possible to carry out the mutagenesis in exonuclease positive yet recA negative E. coli 
strain DH10B. To date BACs can be best propagated in DH10B (Shizuya et al., 1992). 
But if no candidate gene(s) or gene regions for a specific phenotype are known, un-
biased approaches have to be applied. In this case large libraries of mutant genomes 
must be established. Transposon libraries can provide first insight for analysis of pheno-
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types. A library of transposon insertion mutants was constructed for the analysis of the 
US 22 gene homolog family by Menard et al. (2003). A one-step procedure based on a 
TnMax16 transposon, bearing the enhanced green fluorescent protein, was used for in-
sertional mutagenesis of MCMV BACs. The distribution of transposon insertion sites 
was not completely random (Gutermann et al., 2002) and required a collection of 2600-
3000 mutants. The mutant genome was easily identified by direct sequencing from pri-
mer sites within the transposon (Brune et al., 1999; Hobom et al., 2000; Menard et al., 
2003). For rapid recovery of mutant viruses BAC DNA was directly transferred from 
E.coli to mammalian cells (Brune et al., 2001). The transfer of MCMV BAC DNA into 
eukaryotic cells was conferred by E.coli that express the invasion gene of Yersinia 
pseudotuberculosis and the listeriolysin O gene of Listeria monocytogenes of plasmid 
pGBΩinv-hly (Grillot-Courvalin et al., 1998). These bacteria invade eukaryotic cells 
and release the MCMV genome for virus replication. Without knowledge of the trans-
poson insertion site and without previous DNA preparation or transfection, virus mu-
tants can be generated. Viable mutants are easily detected, since they form green fluo-
rescent plaques. This approach allows the random generation of viable MCMV mutants 
in one step and has already been applied to another herpesvirus, the murine γ-
herpesvirus 68 (MHV-68) (Fuchs et al., 2001). The generation of a transposon library 
does not take more effort than the targeted mutagenesis of about a dozen genes. Trans-
poson libraries can be used to screen viable mutants for the alteration of a specific phe-
notype and allow the identification of so-far unknown viral gene functions. 
With the transposon mutant library one can rapidly determine which MCMV genes 
are essential for viral growth (Brune et al., 1999) and confirm the observed phenotype 
with site-directed mutagenesis. Essential genes are of particular importance, as they 
may serve as targets for antiviral chemotherapy (Benedict et al., 1999). The large size of 
the herpesvirus genomes is one of the properties that make herpesvirus attractive for 
gene therapy, and several herpesviruses have been used for gene transfer into mamma-
lian cells (Fink et al., 1997; Messerle et al., 2000; Sclimenti et al., 1998). The nonessen-
tial sequences can be replaced by therapeutic genes, and even large genes with their 
regulatory sequences can be incorporated into herpesvirus vectors (Benedict et al., 
1999). 
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BAC technology has been adapted to many DNA viruses, such as EBV, HSV, 
HCMV, and MHV-68 (Delecluse et al., 1998; Stavropoulos and Strathdee, 1998; Saeki 
et al. 1998; Smith and Enquist, 1999; Borst et al., 1999; Adler et al., 2000). Recently, a 
RNA-virus was cloned as a BAC (Almazan et al., 2000). Thus, BAC technology has 
introduced a feasible and straightforward method for the mutagenesis of not only her-
pesviruses and could lead to new developments in clinical virology and basic virology 
research. 
2 Analysis of the MCMV US22 gene family homologs m139 and m142 
In the past, constructing, isolating and testing individual mutants of herpesviruses was 
time consuming. In this thesis site-directed mutagenesis of MCMV BAC DNA, a rapid 
and straightforward approach, was used to confirm the observations of transposon mu-
tagenesis for mutants of the US 22 gene homolog family. Two members of the US 22 
gene homolog family, murine CMV gene m139 and m142, were analyzed. 
2.1 Mutant ΔATG-m139 has a macrophage specific growth defect 
CMV genes dispensable for growth in NIH3T3 fibroblasts, as seen with the ATG-
mutant of ORF m139, are likely to have important functions within the infected host: 
influencing tissue tropism, dissemination, or immunological responses against the host. 
These nonessential genes are conserved in herpesviruses, but some may also encode 
redundant functions in the intact host. The site-directed ATG-mutant of ORF m139 was 
dispensible for growth in NIH3T3 fibroblasts, but the mutant did not grow to wild-type 
titers in IC-21 macrophages. Thus, this nonessential gene and member of the US22 gene 
homolog family seemed to confer a macrophage phenotype. 
CMV infection occurs in a variety of cell types, including not only endothelial cells, 
epithelial cells, stromal cells, neuronal cells, smooth muscle cells, hepatocytes, but also 
macrophages (Schrier et al., 1985; Sinzger et al., 1995; Soderberg et al., 1993). Macro-
phages are believed to play a critical role in CMV pathogenesis (Bale and O´Neil, 1989; 
Brautigam et al., 1979; Collins et al., 1994; Ibanez et al., 1991; Kondo et al., 1994; 
Saltzman et al., 1988; Schrier et al., 1985; Stoddart et al., 1994; Taylor-Weideman et 
al., 1991). They have been implicated as sites of CMV latency and persistence (Jarvis et 
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al., 2002). First, peripheral blood monocytes function to disseminate virus during acute 
infection (Collins et al., 1994; Stoddart et al., 1994; Taylor-Weideman et al., 1991) and 
then monocytes and macrophages are the most likely cell types that harbor latent CMV 
infection (Kondo et al., 1994; Stoddart et al., 1994; Taylor-Weideman et al., 1991). The 
determinants of MCMV infection in macrophages represent an exciting area of re-
search. 
Strict species specificity has hindered the study of HCMV in animals, and infection 
of mice with MCMV has been used extensively as a model for studying the pathogene-
sis of CMV infection (Staczek, 1990). Mutations in the viral genome can result in cell 
tropism for specific cell types. Currently, viral genes associated with growth defect in 
macrophages have only been identified in the MCMV system. Gene products of M36, 
M45, m140, and m141 have been shown to be required for normal in vitro replication in 
macrophages (Brune et al., 2001; Hanson et al., 2001; Hanson et al., 1999a; Hanson et 
al., 1999b). Among these, genes m140, m141 and M36 are representatives of the US22 
gene homolog family. Macrophages are also proposed as ‘carrier cells’ responsible for 
the transport of Marek´s disease virus, HHV-6 and MHV-68, all herpesviruses, to lym-
phoid organs (Barrow et al., 2003; Kondo et al., 2002). 
In this thesis, the peritoneal macrophage cell line IC-21 was used to test for macro-
phage tropism of ORF m139. The IC-21 cell line is a simian virus 40-transformed peri-
toneal macrophage, which displays properties of a differentiated macrophage, including 
high phagocytic activity and lysozyme and acid phosphatase production (Mauel et al., 
1971). This cell line is highly permissive for growth of wild-type MCMV. Cavanaugh et 
al. (1996) first reported of a mutant RV7 with genes deleted from the HindIII-J frag-
ment that grew poorly in this macrophage cell line and not in bone marrow macrophag-
es. The inability of mutant RV7 to replicate to wild-type levels in IC-21 macrophages 
compared with the bone marrow macrophages was most likely related to differences in 
the state of differentiation of the two host cells. In mutant RV7 the genes m137, m138, 
and m139 of HindIII-J fragment were deleted, in addition to genes m140 and m141 of 
HindIII-I. All seven open reading frames have been shown to be nonessential for 
MCMV replication in NIH3T3 fibroblasts (Vieira et al., 1994). To date only the func-
tion of the transcript of m138 is known. It encodes for an Fc receptor for murine immu-
noglobulin G (Thale et al., 1994). 
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Preliminary data of Vieira et al. (1994) and Cavanaugh et al. (1996) had first indi-
cated that MCMV HindIII-J mutants disrupted in ORF m139 grew to high titers in IC-
21 macrophages. In subsequent studies Hanson et al. (1999b) could show a macrophage 
phenotype for a mutant with the deletion of the ORF m139, m140, and m141. In this 
thesis, mutation of the first two ATGs of m139 affected virus growth on IC-21 macro-
phages. The difference was in the range of three log units and comparable to the growth 
differences observed with the transposon and deletion mutant of m139. Thus, not only 
deletion of the entire ORF m139 or introduction of a transposon mutation into this ORF, 
but also deletions of minimal sequences of ORF m139 affect its replication in cultured 
macrophages. Furthermore, the truncated 61-kDa protein could not substitute for the 
full-length protein and its function. 
Apart from the observed macrophage phenotype for ORF m139 little is known about 
its function. ORF m139 contains all four motifs seen in US22 gene family members 
(Kouzarides et al., 1988; Nicholas and Martin, 1994). Motifs I and II contain hydro-
phobic residues. Motifs III and IV are less well defined and have stretches of nonpolar 
residues (Kouzarides et al., 1988). m139 has an additional acidic domain, common to 
herpesvirus transcriptional activators, and specifically common to MCMV immediate 
early proteins 1 and 2 (Cardin et al., 1995; Munch et al., 1992). ORF m139 encodes for 
a 72 and 68 kDa protein with unknown functions (Hanson et al., 2001) and has been 
shown to transcribe at early and late times in the nucleus and cytoplasm. Furthermore, 
the m139 gene product colocalizes to a perinuclear region of the cell juxtaposed to or 
within the cis-Golgi region, but is excluded from the trans-Golgi region. Gene products 
of m140 and m141 that are adjacent to m139 are also found at this location. There has 
been some debate on the interaction of these three genes and their contribution to the 
macrophage cell tropism. 
2.2 Gene products of m139, m140, and m141 interact 
To clarify how m139 is responsible for the observed phenotype, the targeted ATG dele-
tion mutant ΔATG-m139 was constructed. Deletion of a short sequence of the ORF 
m139 should minimize possible polar effects on the mRNA expression of m140 and 
m141. Since an alternative ATG in frame is located 86 bp downstream of the native 
ATG, the first 86 bp were deleted by site-directed mutagenesis of the MCMV-BAC. 
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The deleted sequence was replaced by 86 bp of noncoding sequence after the excision 
of the kanamycin cassette. Thus, the transcript length was not altered. 
All the transcripts characteristic of the 139-141 transcription unit and seen in the 
wild-type virus, as shown by Hanson et al. (1999b), were present in both fibroblasts and 
macrophages infected with the ΔATG-m139 mutant (see also Menard et al., 2003). 
Thus, there does not seem to be a difference in the regulation of IE/E phases of MCMV 
gene expression in different permissive cells as seen by Kerry et al. (1995) for HCMV 
in monocytes-derived macrophages. The protein product of ORF m139 must then influ-
ence replication in macrophages after transcription. ORF m139 is predicted to transcribe 
a 72 kDa protein (Rawlinson et al., 1996). In addition to this full-length product, a 61 
kDa product has been previously described (Hanson et al., 2001). The ΔATG-m139 
mutant produced the alternative smaller 61 kDa m139 product. This protein is probably 
encoded by the transcript that originates at the third alternative start codon of ORF 
m139 at nucleotide position 195 767. 
In Western blot analysis of the ΔATG-m139 mutant with polyclonal antibodies to 
m140 and m141 the predicted 56 kDa and 52kDa gene products for m140 and m141 
were scant. The mutation of the first two ATGs of ORF must have had an affect on the 
transcription or translation of the other 3´-collinearily transcribed ORF of m140 and 
m141. Campbell and colleagues had demonstrated in 2001 an interaction between m140 
and m141 at the protein level and showed that mutation of m140 and m141 had an ef-
fect on m139, whereas deletion of m139 did not lead to a detectable difference in the 
levels of the other two protein products. In immunoprecipitation of ΔATG-m139 in-
fected cells, the m141 protein was still synthesized (see also Menard et al., 2003). Nev-
ertheless, the expression of the 61 kDa product did not suffice to stabilize the steady 
state expression of m140, and m141. Thus, mutagenesis of one of the three genes affects 
the stability of the other two gene products. Lack of any of these genes affects the 
steady-state level of the other proteins and causes the common macrophage phenotype. 
In this work we confirmed that the m140 and 141 gene products act in cooperation and 
that in contrast to previous observations m139 also influences this protein complex. 
It is possible that the Smith substrains kept in the two laboratories have differences 
in this genomic region. This can be responsible for the divergent results in the two re-
search groups. The described observations may be due to continuous cultivation of cell 
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lines in vitro without physiological in vivo selection pressure. An alternative explana-
tion for the observed differences is that BAC cloning in E. coli requires fewer passages 
of progeny virus in cell culture than do former methods of cloning. It is possible that the 
repeated passages required to purify recombinant progeny from wild-type parental virus 
may select viruses with a compensatory mutation elsewhere in the genome by way of a 
growth advantage. Resequencing of the MCMV Smith substrains in this region should 
reveal the differences. 
2.3 Gene m142 is essential 
Essential genes are of particular importance as they may serve as targets for antiviral 
chemotherapy. Moreover, inactivation of at least one essential gene is required to create 
replication-incompetent herpesvirus vectors for gene therapy, while nonessential genes 
can be removed to gain space for insertion of therapeutic genes (Glorioso et al., 1995) 
or to generate attenuated vaccines. 
The first essential gene in MCMV was described by Messerle et al. in 2000. Mes-
serle and colleagues constructed mutant genomes of gene IE3 by BAC mutagenesis. 
The ie3-deficient mutant did not replicate in normal mouse fibroblasts, but growth could 
be restored by a complementing cell line that provided the IE3 protein in trans. Since 
then no other essential MCMV gene has been described. 
Cavanaugh et al. (1996) showed that mutant MCMV RV9 with a deletion spanning 
genes m137 through m143 could not be purified from wild-type virus, while mutants 
deleted of m137 through m141 were replication competent. This data suggested that 
either m142 or m143, as individual genes or in combination, might be essential for viral 
growth. 
Menard et al. (2003) could show that viral progeny could not be reconstituted for the 
transposon mutants of ORF 142 and m143 (mutants Tn-m142 and Tn-m143). In addi-
tion to the Tn-m142 and Tn-m143 mutant genomes, a deletion mutant of the complete 
m143 ORF also failed to produce viral progeny. The transcripts derived from the m142 
to m144 region use a common polyadenylation signal downstream of m142 (Hanson et 
al., 1999 b). It is therefore possible that transposon mutagenesis affects the neighboring 
ORF. Transcription of m142 is probably not affected by transposon insertion into m143 
 D. Discussion  82 
since m142 and m143 have independent transcripts and transposon insertion in the 
m143 mutant is located approximately 1.5 kb upstream of the m142 start ATG. It was 
not clear whether the transposon insertion within m142 could result in destabilization of 
the m143 transcript. That is why the lethal phenotype was controlled by a targeted mu-
tant of ORF m142. 
The first ATG of ORF m142 was deleted and replaced by an 86-bp extraneous se-
quence. This ATG mutant of the m142 ORF, which should not affect the m143 tran-
script, failed to produce viral progeny. A revertant virus in which the m142 ORF was 
restored was able to replicate with wild-type kinetics. This provided evidence that the 
defective growth phenotype of the m142 mutant was due to disruption in the m142 
gene. The m142 revertant, which contained the m142 gene in an ectopic position, res-
cued virus growth. Thus, not only is m143, but also m142, essential for virus replica-
tion. These two genes form a new subfamily of essential US22 family genes expressed 
at immediate-early times after infection. 
Still, not much is known about gene m142 apart from the fact that it is transcribed 
with immediate-early kinetics. Transcription of IE genes is carried out by the cellular 
RNA polymerase II and is not dependent on de novo synthesis of viral proteins. Viral 
transactivator proteins that are synthesized during the IE phase activate transcription of 
early genes and give rise to a more extensive gene expression program during the early 
phase of the replication cycle. However, a transactivating function has not been shown 
for m142. This makes it unique among the immediate-early genes of the US 22 gene 
homolog family. It also lacks motif II, which is present in all other MCMV US22 gene 
family members. Hanson et al. (2005) could show that the m142 gene product is not 
expressed until early times post infection and that the protein pm142 is predominantly 
cytoplasmatic and did not co-localize with markers for either the ER or Golgi. Protein 
pm142 was present in the nucleus as well and the virion and is predicted to be mem-
brane-associated by sequence analysis. 
The closest homolog in HCMV is US26. The m142 and m143 gene homologs in 
HCMV, US 23 and US 26, have not been classified as essential genes in functional 
transposon mutagenesis, but as augmenting genes (Dong et al., 2003). It is possible that 
these genes are actually essential, but the mutants in this study replicated to a limited 
extent due to the accumulation of a truncated protein, although the insertions were made 
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in the N-terminal region of ORFs. For the HCMV strain AD169 41 essential , 88 essen-
tial and 27 ORFs whose products augment viral growth in fibroblasts have been identi-
fied. In general, the essential and augmenting ORFs were located in the central region 
and the nonessential ORFs cluster at the ends of the viral genome. Over 90 % of the 
essential genes are conserved among all herpesviruses or beta herpesviruses (Dunn et 
al., 2003). These core genes represent the minimal genome of all herpesviruses. HCMV 
may have evolved from the progenitor genome through the acquisition of nonessential 
genes that are responsible of its infection and pathogeneses in various tissues. The func-
tions of most of the essential gene products still have to be analyzed. 
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E. SUMMARY 
 
Human cytomegalovirus is a ubiquitous human pathogen, causing disease in the immu-
nocompromised host. Most of its ORFs have not been well studied due to a limited host 
range and slow growth of HCMV in cultured cells. MCMV, a natural pathogen isolated 
from mice, constitutes the most amenable animal model for human β-herpesviruses. To 
date most of its approximately 200 genes have an unknown function. For the analysis of 
these genes straightforward mutagenesis methods are necessary. With the cloning of 
herpesviruses as an infectious bacterial artificial chromosome a novel approach of mu-
tagenesis has been established. Herpesviruses are now accessible to the tools of bacteri-
al genetics. Since then site-directed mutagenesis by homologous recombination using 
linear DNA fragments and random transposon BAC mutagenesis have been introduced 
to delineate the functions of viral ORFs. 
The purpose of this work was to analyze two members of the US 22 gene homolog 
family, genes m139 and m142, with site-directed mutagenesis. Members of this family 
are conserved in all herpesviruses and mostly have unknown functions. Transposon mu-
tants showed a macrophage phenotype for m139, whereas m142 was possibly essential 
for viral replication. Genes m139-m141 and m142-m143 have complex transcriptional 
regions and have 3´-coterminal transcripts. The insertion of a 3-kb large transposon 
could destabilize the upstream transcripts. Site-directed mutants of genes m139 and 
m142, where only the start codon is deleted, should not influence transcript stability and 
permit confirmation of the results obtained with transposon mutagenesis. 
Targeted mutants of MCMV BAC were constructed for ORF m139 (ΔATG-m139) 
and m142 (ΔATG-m142, ΔATG-m142/FRT) by homologous recombination using linear 
DNA fragments. Mutant ΔATG-m139 showed attenuated growth in peritoneal macro-
phages. This mutant, with the first two ATGs deleted, expressed a truncated protein of 
61 kDa. Gene m139 seems to act in cooperation with genes m140 and m141 on the pro-
tein level. The site-directed MCMV BAC mutant of ORF m142 on the other hand could 
not reconstitute viral progeny in eukaryotic cells. The ORF of m142 was inserted an 
ectopic position and viral progeny was reconstituted with this revertant. Thus, it was 
shown that gene m142 is essential for viral replication. 
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Further analysis of nonessential and essential genes of cytomegalovirus will be 
needed to understand CMV viral pathology and to develop vaccines for herpesvirus 
infection and vectors for gene therapy. 
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E. ZUSAMMENFASSUNG 
 
Humanes Zytomegalievirus ist ein human pathogenes Virus, das vor allem bei Personen 
mit eingeschränktem oder unreifem Immunsystem zur Erkrankung führt. Aufgrund sei-
ner strikten Speziesspezifität kann HCMV nur Menschen infizieren und ist damit ungee-
ignet für die Infektion im Mausmodell. Daher wird murines CMV benützt, um die 
Funktion der Gene des größten Herpesvirus zu erforschen. Die Mehrzahl der etwa 200 
CMV-Gene wurde noch nicht charakterisiert. Mit der Klonierung des gesamten CMV-
Genoms in ein bakterielles künstliches Chromosom (BAC) wurde eine neue Mutagene-
semethode basierend auf homologer Rekombination in E. coli etabliert. Herpesviren 
sind jetzt den Werkzeugen der Bakteriengenetik zugänglich. 
Im Rahmen dieser Arbeit wurden zwei Mitglieder der US22 Genfamilie, m139 und 
m142, mit zielgerichteter BAC-Mutagenese analysiert. Mitglieder dieser Genfamilie 
sind in allen Herpesviren konserviert und haben eine noch unbekannte Funktion. Trans-
posonmutanten dieser Gene zeigten einen Makrophagenphänotyp für das Gen m139 und 
eine mögliche Essentialität für die Virusreplikation für das Gen m142. Gene m139 bis 
m141 und m142 bis m143 haben eine komplexe Transkriptionsregion. Die Insertion 
eines 3-kb großen Transposons könnte die Transkription eines aufwärts transkribierten 
Gens einschränken. Deshalb wurden Mutanten, die lediglich eine Deletion des Startko-
dons tragen, hergestellt. 
Zielgerichtete Mutanten wurden durch homologe Rekombination zwischen einem linea-
ren DNA Fragment und dem MCMV BAC Genom für m139 und m142 hergestellt. Mu-
tante m139 zeigte attenuiertes Wachstum für peritoneale Makrophagen. Diese Mutante, 
bei der die ersten beiden ATGs deletiert wurden, exprimiert ein verkürztes 61 kDa Pro-
tein. Dabei scheinen Gene m139, m140 und m141 in Kooperation zu arbeiten. Zur Be-
stätigung, dass ORF m142 essentiell für die Replikation von MCMV ist, wurde das 
Startkodon von ORF m142 deletiert und der Offene Leserahmen von m142 an einer 
anderen Stelle im BAC CMV Genom inseriert. Mit dieser Mutante konnte das Virus 
rekonstitutiert werden. Damit ist neben m143 auch m142 essentiell für die virale Repli-
kation von MCMV. 
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Weitere Untersuchung von essentiellen und nicht-essentiellen Genen sind notwendig, 
um die Pathogenese von CMV zu erforschen, und um in Zukunft neue Impfstoffe und 
Vektoren für die Gentherapie entwickeln zu können. 
 G. Reference List 88 
G. REFERENCE LIST 
 
Adam, B. L., T. Y. Jervey, C. P. Kohler, G. L. Wright, J. A. Nelson, and R. M. 
Stenberg. 1995. The human cytomegalovirus UL98 gene transcription unit 
overlaps with the pp28 true late gene (UL99) and encodes a 58-kilodalton early 
protein. J. Virol. 69:5304-5310. 
Adler, H., M. Messerle, M. Wagner, and U. H. Koszinowski. 2000. Cloning and 
mutagenesis of the murine gammaherpesvirus 68 genome as an infectious bacte-
rial artificial chromosome. J. Virol. 74:6964-6974. 
Ahn, K., A. Angulo, P. Ghazal, P.A. Paterson, Y. Yang, K. Fruh, and K. Blaser. 
1996. Human cytomegalovirus inhibits antigen presentation by a sequential 
multistep process. Proc. Natl. Acad. Sci. U. S. A. 93:10990-10995. 
Akdis, C. A. and K. Blaser. 2001. Mechanisms of interleukin-10-mediated immune 
suppression. Immunology 103:131-136. 
Almazan, F., J. M. Gonzalez, Z. Penzes, A. Izeta, E. Calvo, J. Plana-Duran, and L. 
Enjuanes. 2000. Engineering the largest RNA virus genome as an infectious 
bacterial artificial chromosome. Proc. Natl. Acad. Sci. U. S. A. 97:5516-5521. 
Alp, N. J., T.D. Allport, J.V. Zanten, B. Rogers, J.G. Sissons, and L.K. Borysiewicz. 
1991. Fine specificity of cellular immune responses in humans to human cy-
tomegalovirus immediate-early 1 protein. J. Virol. 65:4812-4820. 
Atalay, R., A. Zimmermann, M. Wagner, E. Borst, C. Benz, M. Messerle, and H. 
Hengel. 2002. Identification and expression of human cytomegalovirus tran-
scription units coding for two distinct FCδ receptor homologs. J. Virol. 76:8596-
8608. 
Baldick-CJ, J. and T. Shenk. 1996. Proteins associated with purified human cy-
tomegalovirus particles. J. Virol. 70:6097-6105. 
Bale, J. F., Jr., J. A. Blackman, and Y. Sato. 1990. Outcome in children with symp-
tomatic congenital cytomegalovirus infection. J. Child Neurol. 5:131-136. 
 G. Reference List 89 
Bale, J. F., and M. E. O´Neil. 1989. Detection of murine cytomegalovirus DNA in 
circulating leukocytes harvested during acute infection of mice. J. Virol. 
63:2667-2673. 
Barrow A.D., S. C. Burgess, S. J. Baigent, K. Howes and V. K. Nair. 2003. Infection 
of macrophages by a lymphotropic herpesvirus: a new tropism for Marek's dis-
ease virus. J. Gen. Virol. 84: 2635-2645. 
Benedict, C. A., K. D. Butrovich, N. S. Lurain, J. Corbeil, I. Rooney, P. Schneider, 
J. Tschopp, and C. F. Ware. 1999. Cutting edge: a novel viral TNF receptor 
superfamily member in virulent strains of human cytomegalovirus. J. Immunol. 
162:6967-6970. 
Beninga, J., B. Kropff, and M. Mach. 1995. Comparative analysis of fourteen indi-
vidual human cytomegalovirus proteins for helper T response. J. Gen. Virol. 
76:153-160. 
Berg, C. M. 1989.  Transposable elements and the genetic engineering of bacteria, p. 
879-925. In D. E. Berg and M. Howe (eds.), Mobile DNA. ASM press. 
Boeckh, M. and R. Bowden. 1995. Cytomegalovirus infection in marrow transplanta-
tion. Cancer Treat. Res. 76:97-136. 
Boppana, S. B., K. B. Fowler, W. J. Britt, S. Stagno, and R. F. Pass. 1999. Sympto-
matic congenital cytomegalovirus infection in infants born to mothers with pre-
existing immunity to cytomegalovirus. Pediatrics 104:55-60. 
Borst, E. M., G. Hahn, U. H. Koszinowski, and M. Messerle. 1999. Cloning of the 
human cytomegalovirus (HCMV) genome as an infectious bacterial artificial 
chromosome in Escherichia coli: a new approach for construction of HCMV 
mutants. J. Virol. 73:8320-8329. 
Brautigam, A. R., F. J. Dutko, L. B. Olding, and M. B. Oldstone. 1979. Pathogenesis 
of murine cytomegalovirus infection: the macrophage as a permissive cell for 
cytomegalovirus infection, replication and latency. J. Gen. Virol. 44:349-359. 
 G. Reference List 90 
Britt, W. J. and C. A. Alford. 1996. Cytomegalovirus, p. 2493-2523. In B. N. Fields, 
D. M. Knipe, and P. M. Howley (eds.), Fields Virology. Lippincott-Raven Pub-
lishers, Philadelphia. 
Britt, W. J. and M. Mach. 1996. Human cytomegalovirus glycoproteins. Intervirology 
39:401-412. 
Britt, W. J. 1991. Recent advances in the identification of significant human cytomega-
lovirus-encoded proteins. Transpl. Proc. 23:64-69. 
Brody, A. R. and J. E. Craighead. 1974. Pathogenesis of pulmonary cytomegalovirus 
infection in immunosuppressed mice. J. Infect. Dis. 129:677-689. 
Brune, W., C. Menard, J. Heesemann, and U. H. Koszinowski. 2001. A ribonucleo-
tide reductase homolog of cytomegalovirus and endothelial cell tropism. Science 
291:303-305. 
Brune, W., C. Menard, U. Hobom, S. Odenbreit, M. Messerle, and U. H. Koszi-
nowski. 1999. Rapid identification of essential and nonessential herpesvirus 
genes by direct transposon mutagenesis. Nat. Biotechnol. 17:360-364. 
Campbell, A. E., Z. Karabekian, L. K. Hanson, and J. S. Slater. 2001. Abstr. 8th 
International Cytomegalovirus Conference. abstr. p. 26. 
Cardin, R. D., G. B. Abenes, C. A. Stoddart, and E. S. Mocarski. 1995. Murine cy-
tomegalovirus IE2, an activator of gene expression, is dispensable for growth 
and latency in mice. Virology 209:236-241. 
Cavanaugh, V. J., R. M. Stenberg, T. L. Staley, H. W. Virgin, M. R. MacDonald, S. 
Paetzold, H. E. Farrell, W. D. Rawlinson, and A. E. Campbell. 1996. Murine 
cytomegalovirus with a deletion of genes spanning HindIII-J and -I displays al-
tered cell and tissue tropism. J. Virol. 70:1365-1374. 
Cha, T. A., E. Tom, G. W. Kemble, G. M. Duke, E. S. Mocarski, and R. R. Spaete. 
1996. Human cytomegalovirus clinical isolates carry at least 19 genes not found 
in laboratory strains. J. Virol. 70:78-83. 
 G. Reference List 91 
Chee, M. S., A. T. Bankier, S. Beck, R. Bohni, C. M. Brown, R. Cerny, T. Horsnell, 
C. A. Hutchison, T. Kouzarides, J. A. Martignetti, and a. et. 1990. Analysis 
of the protein-coding content of the sequence of human cytomegalovirus strain 
AD169. Curr. Top. Microbiol. Immunol. 154:125-169. 
Cherepanov, P. P. and W. Wackernagel. 1995. Gene disruption in Escherichia coli: 
TcR and KmR cassettes with the option of Flp-catalyzed excision of the antibi-
otic-resistance determinant. Gene 158:9-14. 
Chong, K. T. and C. A. Mims. 1981. Murine cytomegalovirus particle types in relation 
to sources of virus and pathogenicity. J. Gen. Virol. 57:415-419. 
Chou, S. 1990. Newer methods for diagnosis fo cytomegalovirus infection. Rev. Infect. 
Dis. 12 Supp7: S727. 
Cicin-Sain L., W. Brune, I. Bubic, S. Jonjic, and U.H. Koszinowski. 2003. Vaccina-
tion of mice with bacteria carrying a cloned herpesvirus genome reconstituted in 
vivo. J. Virol. 77:8249-8255. 
Colberg, P. A. 1996. Functional roles of immediate early proteins encoded by the hu-
man cytomegalovirus UL36-38, UL115-119, TRS1/IRS1 and US3 loci. Intervi-
rology 39:350-360. 
Colberg, P. A., L. D. Santomenna, P. P. Harlow, P. A. Benfield, and D. J. Tenney. 
1992. Human cytomegalovirus US3 and UL36-38 immediate-early proteins 
regulate gene expression. J. Virol. 66:95-105. 
Collins, T. M., M. R. Quirk, and M.C. Jordan. Biphasic viremia and viral gene ex-
pression in leukocytes during acute cytomegalovirus infection of mice. J. Virol. 
68:6305-6311. 
Compton, T., D. M. Nowlin, and N. R. Cooper. 1993. Initiation of human cytomega-
lovirus infection requires initial interaction with cell surface heparan sulfate. Vi-
rology 193:834-841. 
 G. Reference List 92 
Compton, T., R. R. Nepomuceno, and D. M. Nowlin. 1992. Human cytomegalovirus 
penetrates host cells by pH-independent fusion at the cell surface. Virology 
191:387-395. 
Craighead, J.E., R.E. Kanisch, and J.D. Almedia. 1972. Nonviral microbodies with 
viral antigenicity produced in cytomegalovirus-infected cells. J. Virol. 10:766-
775. 
Cranmer, L. D., C. L. Clark, C.S. Morello, H. E. Farrell, W. D: Rawlinson, and D. 
H. Spector.  1996. Identification, analysis, and evolutionary relationships of the 
putative murine cytomegalovirus homologs of the human cytomegalovirus UL82 
(pp71) and UL83 (pp65) matrix phosphoproteins. J. Virol. 70:7929-39. 
Danesh J., R. Collins, and R. Peto. 1997. Chronic infections and coronary heart dis-
ease: is there a link? Lancet 350:430-436. 
Dankner, W.M., J. A. McCutchan, D. D. Richman, K. Hirata, S. A. Specter. 1990. 
Localization of human cytomegalovirus in peripheral blood leukocytes by in situ 
hybridization. J. Infect. Dis. 161: 31-36. 
Delecluse, H. J., T. Hilsendegen, D. Pich, R. Zeidler, and W. Hammerschmidt. 
1998. Propagation and recovery of intact, infectious Epstein-Barr virus from 
prokaryotic to human cells. Proc. Natl. Acad. Sci. U. S. A. 95:8245-8250. 
DeLuca, N. A., A. M. McCarthy, and P. A. Schaffer. 1985. Isolation and characteri-
zation of deletion mutants of herpes simplex virus type 1 in the gene encoding 
immediate-early regulatory protein ICP4. J. Virol. 56:558-570. 
Demmler, G. J. 1991. Infectious Diseases Society of America and Centers for Disease 
Control. Summary of a workshop on surveillance for congenital cytomegalovi-
rus disease. Rev. Infect. Dis. 13:315-29. 
Dong Y., C.S. Silva, and T. Shenk. 2003. Functional map of human cytomegalovirus 
AD169 defined by global mutational analysis. Proc. Natl. Acad. Sci. U. S. A. 
100:12396-12401. 
 G. Reference List 93 
Dunn W. and C. Chou, R. Hai, D. Patterson, V. Stolc, H. Zhu and F. Liu. 2003. 
Functional profiling of a human cytomegalovirus genome. Proc. Natl. Acad. Sci. 
U. S. A. 100: 14223-14228. 
Dworsky M., M. Yow, S. Stagno, R. F. Pass, and C. Alford. 1983. Cytomegalovirus 
infection of breast milk and transmission in infancy. Pediatrics 72:295-299. 
Ebeling, A., G. M. Keil, E. Knust, and U. H. Koszinowski. 1983. Molecular cloning 
and physical mapping of murine cytomegalovirus DNA. J. Virol. 47:421-433. 
Fink, D. J. and J. C. Glorioso. 1997. Engineering herpes simplex virus vectors for 
gene transfer to neurons. Nat. Med. 3:357-359. 
Fuchs O., C. Menard, U.H. Koszinowski and M. Wagner. 2001. Abstr. 26th Interna-
tional Herpesvirus Workshop, abstr. 3.26. 
Gerna, G., E. Percivalle, F. Baldanti, S. Sozzani, P. Lanzarini, E. Genini, D. Lilleri, 
and M. G. Revello. 2000. Human cytomegalovirus replicates abortively in po-
lymorphonuclear leukocytes after transfer from infected endothelial cells via 
transient microfusion events. J. Virol. 74:5629-5638. 
Gewurz, B. E., R. Gaudet, D. Tortorella, E. W. Wang, and H. L. Ploegh. 2001. Vi-
rus subversion of immunity: a structural perspective. Curr. Opin. Immunol. 
13:442-450. 
Gibson, W. 1996. Structure and assembly of the virion. Intervirology 39:389-400. 
Glorioso, J. C., M. A. Bender, W. F. Goins, D. J. Fink, and N. Deluca. 1995.  HSV 
as a gene transfer vector for the nervous system. Mol. Biotechnol. 4:87-99. 
Gonzalez-Armas, J. C., C. S. Morello, L. D. Cranmer, and D. H. Spector. 1996. 
DNA immunization confers protection against murine cytomegalovirus infec-
tion. J. Virol. 70:7921-7928. 
Goodpasture, E.W., and F.B. Talbot. Concerning the nature of “protozoan-like” cells 
in certain lesions of infancy. Am. J. Dis. Child. 21:415-425. 
 G. Reference List 94 
Gompels, U. A., J. Nicholas, G. Lawrence, M. Jones, B. J. Thomson, M. E. Martin, 
S. Efstathiou , M. Craxton, and H. A. Macaulay. 1995. The DNA sequence of 
human herpesvirus-6: structure, coding content, and genome evolution. Virology 
209:29-51. 
Grattan, M. T., C. E. Moreno-Cabral, V. A. Starnes, P. E. Oyer, E. B. Stinson, and 
N. E. Shumway. 1989. Cytomegalovirus infection is associated with cardiac al-
lograft rejection and atherosclerosis. J.A.M.A. 261:3561-3566. 
Greijer, A.E., J.M. van de Crommert, S.J:C. Stevens, and J.M. Middeldrop. 1999. 
Molecular fine-specificity analysis of antibody responses to human cytomega-
lovirus and design of novel synthetic-peptide based serodiagnostic assays. J. 
Clin. Microbiol. 37:179-188. 
Grillot-Courvalin, C., S. Goussard, F. Huetz, D. M. Ojcius and P. Courvalin. 1998. 
Functional gene transfer from intracellular bacteria to mammalian cells. Nat. 
Biotechnol. 16:862-866. 
Gutermann, A., A. Bubeck, M. Wagner, U. Reusch, C. Menard, and U. Koszi-
nowski. 2002. Strategies for the identification and analysis of viral immune eva-
sion genes-Cytomegalovirus as example. Curr. Top. Microbiol. Immunol. 269:1-
22. 
Hahn, G., R. Jores, and E. S. Mocarski. 1998. Cytomegalovirus remains latent in a 
common precursor of dendritic and myeloid cells. Proc. Natl. Acad. Sci. U. S. A. 
95:3937-3942. 
Hamilton, J. D. and B. J. Seaworth. 1985. Transmission of latent cytomegalovirus in a 
murine kidney tissue transplantation model. Transplantation 39:290-296. 
Handsfield H. H., S. H.Chandler, V. A. Caine, J. D. Meyers, L. Corey, E. Medeiros, 
and J. K. McDougall. 1985. Cytomegalovirus infection in sex partners: evi-
dence for sexual transmission. J. Infect. Dis. 151:344-348. 
 G. Reference List 95 
Hanson, L. K., B. L. Dalton, L.F. Cageao, R. E. Brock, J. S. Slater, J.A. Kerry and 
A. E. Campbell. 2005. Characterization and regulation of essential murine cy-
tomegalovirus genes m142 and m143. Virology. 334: 166-77. 
Hanson, L. K., J. S. Slater, Z. Karabekian, G. Ciocco-Schmitt, and A. E. Campbell. 
2001. Products of US22 genes M140 and M141 confer efficient replication of 
murine cytomegalovirus in macrophages and spleen. J. Virol. 75:6292-6302. 
Hanson, L. K., J. S. Slater, Z. Karabekian, H. W. Virgin, C. A. Biron, M. C. Ruzek, 
N. van Rooijen, R. P. Ciavarra, R. M. Stenberg, and A. E. Campbell. 1999a. 
Replication of murine cytomegalovirus in differentiated macrophages as a de-
terminant of viral pathogenesis. J. Virol. 73:5970-5980. 
Hanson, L. K., B. L. Dalton, Z. Karabekian, H. E. Farrell, W. D. Rawlinson, R. M. 
Stenberg, and A. E. Campbell. 1999b. Transcriptional analysis of the murine 
cytomegalovirus HindIII-I region: identification of a novel immediate-early 
gene region. Virology 260:156-164. 
Heise, M. T., M. Connick, and H. W. Virgin. 1998. Murine cytomegalovirus inhibits 
interferon gamma-induced antigen presentation to CD4 T cells by macrophages 
via regulation of expression of major histocompatibility complex class II-
associated genes. J. Exp. Med. 187:1037-1046. 
Hengel, H., P. Lucin, and S. Jonjic. 1994. Restoration of cytomegalovirus antigen 
presentation by gamma interferon combats viral escape. J. Virol. 68:289-297. 
Ho M. Cytomegalovirus Biology and Infection. 1991. New York: Plenum Press. 
Hobom, U., W. Brune, M. Messerle, G. Hahn, and U. H. Koszinowski. 2000. Fast 
screening procedures for random transposon libraries of cloned herpesvirus ge-
nomes: mutational analysis of human cytomegalovirus envelope glycoprotein 
genes. J. Virol. 74:7720-7729. 
Horsburgh, B. C., M. M. Hubinette, D. Qiang, M. L. MacDonald, and F. Tufaro. 
1999. Allele replacement: an application that permits rapid manipulation of her-
pes simplex virus type 1 genomes. Gene Ther. 6:922-930. 
 G. Reference List 96 
Hudson, J. B. 1979. The murine cytomegalovirus as a model for the study of viral 
pathogenesis and persistent infections. Arch. Virol. 62:1-29. 
Ibanez, C. E., R. Schrier, P. Ghazal, C. Wiley, J. A. Nelson. 1991. Human cytomega-
lovirus productively infects primary differentiated macrophages. J. Virol. 65: 
6581-6588. 
Irmiere, A. and W. Gibson. 1983. Isolation and characterization of a noninfectious 
virion-like particle released from cells infected with human strains of cytomega-
lovirus. Virology 130:118-133. 
Iskenderian, A. C., L. Huang, A. Reilly, R. M. Stenberg, and D. G. Anders. 1996. 
Four of eleven loci required for transient complementation of human cytomega-
lovirus DNA replication cooperate to activate expression of replication genes. J. 
Virol. 70:383-392. 
Ivarsson, S. A., B. Lernmark, and L. Svanberg. 1997. Ten-year clinical, developmen-
tal, and intellectual follow-up of children with congenital cytomegalovirus infec-
tion without neurologic symptoms at one year of age. Pediatrics 99:800-803. 
Jarvis, M. A., and J. A. Nelson. 2002. Human cytomegalovirus persistence and latency 
in endothelial cells and macrophages. Curr. Opin. Microbiol. 5:403-407. 
Jordan, M. C., J. D. Shanley, and J. G. Stevens. 1978. Immunosuppression reacti-
vates and disseminates latent murine cytomegalovirus. I.A.R.C. Sci. Publ. 769-
774. 
Jordan, M. C., W. E. Rousseau, and G. R. Noble et al. 1973. Association of cervical 
cytomegaloviruses with veneral disease. N. Engl. J. Med. 288:932. 
Karabekian, Z., L. K. Hanson, J. S. Slater, and A. E. Campbell. 2000. Abstr. 25th 
International Herpesvirus Workshop. abstr. 9.26.  
Kavanagh, D. G., M. C. Gold, M. Wagner, U. H. Koszinowski, and A. B. Hill. 
2001a. The multiple immune-evasion genes of murine cytomegalovirus are not 
 G. Reference List 97 
redundant: m4 and m152 inhibit antigen presentation in a complementary and 
cooperative fashion. J. Exp. Med. 194:967-978. 
Kavanagh, D. G., U. H. Koszinowski, and A. B. Hill. 2001b. The murine cytomega-
lovirus immune evasion protein m4/gp34 forms biochemically distinct com-
plexes with class I MHC at the cell surface and in a pre-Golgi compartment. J. 
Immunol. 167:3894-3902. 
Kerry, J. A., A. Sehgal, S. W., Barlow, V. J., Cavanaugh, K. Fish, J. A. Nelson, and 
R. M. Stenberg. 1995. Isolation and characterization of a low-abundance splice 
variant from the human cytomegalovirus major immediate-early gene region. J. 
Virol. 69: 3868-3872. 
Kinzler, E. R. and T. Compton. 2005. Characterization of human cytomegalovirus 
glycoprotein-induced cell-cell fusion. J. Virol. 79:7827-7837. 
Kondo, K., H. Kaneshima, and E. S. Mocarski. 1994. Human cytomegalovirus latent 
infection of granulocyte-macrophage progenitors. Proc. Natl. Acad. Sci. U. S. A. 
91:11879-11883. 
Kondo T., K. Shimada, K. Amo, H. Miyagawa, and K. Yamanishi. 2002. Strong 
interaction between human herpesvirus 6 and peripheral blood mono-
cytes/macrophages during acute infection. J. Med. Virol. 67:364-369. 
Kotenko, S. V., S. Saccani, L. S. Izotova, O. V. Mirochnitchenko, and S. Pestka. 
2000. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-
10). Proc. Natl. Acad. Sci. U. S. A. 97:1695-1700. 
Kouzarides, T., A. T. Bankier, S. C. Satchwell, E. Preddy, and B. G. Barrell. 1988. 
An immediate early gene of human cytomegalovirus encodes a potential mem-
brane glycoprotein. Virology 165:151-64. 
Kovacs, A., M. Schluchter, K. Easley, G. Demmler, W. Shearer,  P. La Russa, J. 
Pitt, E. Cooper, J. Goldfarb, D. Hodes, M. Kattan, and K. McIntosh. 1999. 
Cytomegalovirus infection and HIV-1 disease progression in infants born to 
HIV-1-infected women. Pediatric Pulmonary and Cardiovascular Complications 
 G. Reference List 98 
of Vertically Transmitted HIV Infection Study Group. N. Engl. J. Med. 341:77-
84. 
Kowalik, T. F., B. Wing, J. S. Haskill, J. C. Azizkhan, A. S. Baldwin, Jr., and E. S. 
Huang. 1993. Multiple mechanisms are implicated in the regulation of NF-
kappa B activity during human cytomegalovirus infection. Proc. Natl. Acad. Sci. 
U. S. A 90:1107-1111. 
Krmpotic, A., M. Messerle, M. I. Crnkovic, B. Polic, S. Jonjic, and U. H. Koszi-
nowski. 1999. The immunoevasive function encoded by the mouse cytomega-
lovirus gene m152 protects the virus against T cell control in vivo. J. Exp. Med. 
190:1285-1296. 
Lopper M. and T. Compton. 2004. Coiled-coil domains in glycoproteins B and H are 
involved in human cytomegalovirus membrane fusion. J. Virol. 78:8333-41. 
Manning, W. C., and E. S. Mocarski. 1988. Insertional mutagenesis of the murine 
cytomegalovirus genome: one prominent alpha gene (ie2) is dispensable for 
growth. Virology 167:477-484. 
Mauel, J., and W. Defendi. 1971. Infection and transformation of mouse peritoneal 
macrophages by simian virus 40. J. Ex. Med. 134:335-350. 
Mayo, D. R., J. A. Armstrong, and M. Ho. 1977. Reactivation of murine cytomega-
lovirus by cyclophosphamide. Nature 267:721-723. 
MacDonald, M. R., X. Y. Li, R. M. Stenberg, A. E. Campbell, and H. W. Virgin. 
1998. Mucosal and parenteral vaccination against acute and latent murine cy-
tomegalovirus (MCMV) infection by using an attenuated MCMV mutant. J. Vi-
rol. 72:442-451. 
McGregor, A. and M. R. Schleiss. 2001. Molecular cloning of the guinea pig cy-
tomegalovirus (GPCMV) genome as an infectious bacterial artificial chromo-
some (BAC) in Escherichia coli. Mol. Genet. Metab. 72:15-26. 
 G. Reference List 99 
Mcleod, M., S. Craft, and J. R. Broach. 1986. Identification of the crossover site dur-
ing FLP-mediated recombination in the Saccharomyces cerevisiae plasmid 2 mi-
crons circle. Mol. Cell. Biol. 6: 3357-3367. 
Menard, C., M. Wagner, Z. Ruzsics, K. Holak, W. Brune, A. E. Campbell, and U. 
H. Koszinowski. 2003. Role of murine cytomegalovirus US22 gene family 
members in replication in macrophages. J. Virol. 77:5557-5570. 
Messerle, M., I. Crnkovic, W. Hammerschmidt, H. Ziegler, and U. H. Koszinowski. 
1997. Cloning and mutagenesis of a herpesvirus genome as an infectious bacte-
rial artificial chromosome. Proc. Natl. Acad. Sci. U. S. A. 94:14759-14763. 
Messerle, M., G. Hahn, W. Brune, and U. H. Koszinowski. 2000. Cytomegalovirus 
bacterial artificial chromosomes: a new herpesvirus vector approach. Adv. Virus 
Res. 55:463-478. 
Mettenleiter, T. C. 2002. Herpesvirus assembly and egress. J. Virol. 76:1537-1547. 
Michelson, S. 1997. Interaction of human cytomegalovirus with mono-
cytes/macrophages: a love-hate relationship. Pathol. Biol. (Paris) 45:146-158. 
Mocarski, E. S. 2001. Cytomegalovirus and their replication, p. 2629-2673. In B. N. 
Fields, D. M. Knipe, and P. M. Howley (eds.), Fields Virology, Lippincott-
Raven Publishers, Philadelphia. 
Mocarski, E.S. and G. W. Kemble. 1996. Recombinant cytomegaloviruses for study 
of replication and pathogenesis. Intervirology 39:320-330. 
Mocarski E. S., L. Pereira, and A. L. McCormick. 1988. Human cytomegalovirus 
ICP22, the product of the HWLF1 reading frame, is an early nuclear protein that 
is released from cells. J. Gen. Virol. 69 :2613-2621. 
Mocarski, E. S., L. E. Post, and B. Roizman. 1980. Molecular engineering of the her-
pes simplex virus genome: insertion of a second L-S junction into the genome 
causes additional genome inversions. Cell 22:243-255. 
 G. Reference List 100 
Montgomery R., L. Youngblood, and D. N. Jr Medearis DN. 1972. Recovery of cy-
tomegalovirus from the cervix in pregnancy. Pediatrics 49:524-531.  
Munch, K., M. Messerle, B. Plachter, and U. H: Koszinowski. 1992. An acidic re-
gion of the 89K murine cytomegalovirus immediate early protein interacts with 
DNA. J. Gen. Virol. 73:499-506. 
Murphy, K.C. 1998. Use of bacteriophage lambda recombination functions to promote 
gene replacement in Escherichia coli. J. Bacteriol. 180:2063-2071. 
Mustakangas, P., S. Sarna, P. Ammala, M. Muttilainen, P. Koskela, and M. Koski-
niemi. 2000. Human cytomegalovirus seroprevalence in three socioeconomi-
cally different urban areas during the first trimester: a population-based cohort 
study. Int. J. Epidemiol. 29:587-591. 
Muyrers, J. P., Y. Zhang, and A. F. Stewart. 2000. ET-cloning: think recombination 
first. Genet. Eng. 22:77-98. 
Nicholas, J. 1996. Determination and analysis of the complete nucleotide sequence of 
human herpesvirus 7. J. Virol. 70:5975-5989. 
Nicholas, J. and M. E. Martin. 1994. Nucleotide sequence analysis of a 38.5-kilobase-
pair region of the genome of human herpesvirus 6 encoding human cytomega-
lovirus immediate-early gene homologs and transactivating functions. J. Virol. 
68:597-610. 
Nigro, G., S. P. Adler, R. La Torre, and A. M. Best. 2005. Passive immunization dur-
ing pregnancy for congenital cytomegalovirus infection. N. Engl. J. Med. 
353:1350-1362. 
Orange, J. S. and C. A. Biron. 1996. Characterization of early IL-12, IFN-alphabeta, 
and TNF effects on antiviral state and NK cell responses during murine cy-
tomegalovirus infection. J. Immunol. 156:4746-4756. 
Ostrowski, M. A., D. C. Krakauer, Y. Li, S. J. Justement, G. Learn, L. A. Ehler, S. 
K. Stanley, M. Nowak, and A. S. Fauci. 1998. Effect of immune activation on 
 G. Reference List 101 
the dynamics of human immunodeficiency virus replication and on the distribu-
tion of viral quasispecies. J. Virol. 72:7772-7784. 
Pass, R. F. 1985. Epidemiology and transmission of cytomegalovirus. J. Infect. Dis. 
152:243-248. 
Pass, R. F., C. Hutto, M. D. Lyon, and G. Cloud. 1990. Increased rate of cytomega-
lovirus infection among day care center workers. Pediatr. Infect. Dis. J. 9:465-
470. 
Penfold, M. E., D. J. Dairaghi, G. M. Duke, N. Saederup, E. S. Mocarski, G. W. 
Kemble, and T. J. Schall. 1999. Cytomegalovirus encodes a potent alpha che-
mokine. Proc. Natl. Acad. Sci. U. S. A. 96:9839-9844. 
Pereira, L. H., J. A. Embil, D. A. Haase, and K. M. Manley. 1990. Cytomegalovirus 
infection among women attending a sexually transmitted disease clinic: associa-
tion with clinical symptoms and other sexually transmitted diseases. Am. J. Epi-
demiol. 131:683-692. 
Plachter B, C. Sinzger, and G. Jahn. 1996. Cell types involved in replication and dis-
tribution of human cytomegalovirus. Adv. Virus Res. 46:195-261. 
Pollock, J. L., R. M. Presti, S. Paetzold, and H. W. Virgin. 1997. Latent murine cy-
tomegalovirus infection in macrophages. Virology 227:168-179. 
Post, L. E. and B. Roizman. 1981. A generalized technique for deletion of specific 
genes in large genomes: alpha gene 22 of herpes simplex virus 1 is not essential 
for growth. Cell 25:227-232. 
Preiksaitis, J. K., L., Brown, and M. McKenzie. 1998. The risk of cytomegalovirus 
infection in seronegative transfusion recipients not receiving exogenous immu-
nosupression. J. Infect. Dis. 157:523-529. 
Radsak, K., M. Eickmann, T. Mockenhaupt, E. Bogner, H. Kern, A. Eis-Hubinger, 
and M. Reschke. 1996. Retrieval of human cytomegalovirus glycoprotein B 
from the infected cell surface for virus envelopment. Arch. Virol. 141:557-572. 
 G. Reference List 102 
Ramsay, M. 1994.  Yeast artificial chromosome cloning. Mol. Biotechnol. 1:181-201. 
Rawlinson, W. D., H. E. Farrell, and B. G. Barrell. 1996. Analysis of the complete 
DNA sequence of murine cytomegalovirus. J. Virol. 70:8833-8849. 
Reddehase, M. J., M. Balthesen, M. Rapp, S. Jonjic, I. Pavic, and U. H. Koszi-
nowski. 1994. The conditions of primary infection define the load of latent viral 
genome in organs and the risk of recurrent cytomegalovirus disease. J. Exp. 
Med. 179:185-193. 
Roizman, B., L. E. Carmichael, F. Deinhardt, G. De-The, A. J. Nahmias, W. Plow-
right, F Rapp, P. Sheldrick, M. Takahashi, and K. Wolf. 1981. 
Herpesviridae. Definition, provisional nomenclature, and taxonomy. The 
Herpesvirus Study Group, the International Committee on Taxonomy of Vi-
ruses. Intervirology. 16:201-217. 
Romanowski, M. J. and T. Shenk. 1997. Characterization of the human cytomegalovi-
rus irs1 and trs1 genes: a second immediate-early transcription unit within irs1 
whose product antagonizes transcriptional activation. J. Virol. 71:1485-1496. 
Rudolph, J., D. J. O'Callaghan, and N. Osterrieder. 2002. Cloning of the genomes of 
equine herpesvirus type 1 (EHV-1) strains KyA and racL11 as bacterial artificial 
chromosomes (BAC). J. Vet. Med. B Infect. Dis. Vet. Public Health 49:31-36. 
Saederup, N., and E. S. Mocarski, Jr. 2002. Fatal attraction: cytomegalovirus-
encoded chemokine homologs. Curr. Top. Microbiol. Immunol. 269:235-256. 
Saeki, Y., T. Ichikawa, A. Saeki, E. A. Chiocca, K. Tobler, M. Ackermann, X. O. 
Breakefield, and C. Fraefel. 1998. Herpes simplex virus type 1 DNA amplified 
as bacterial artificial chromosome in Escherichia coli: rescue of replication-
competent virus progeny and packaging of amplicon vectors. Hum. Gene Ther. 
9:2787-2794. 
Saltzman, R. L., M. R. Quirk, and M. C. Jordan. 1988. Disseminated cytomegalovi-
rus infection. Molecular analysis of virus and leukocyte interactions in viremia. J 
Clin Invest. 81:75-81. 
 G. Reference List 103 
Sambrook, J., T., Maniatis, and E. F. Fritsch. 1989. Molecular cloning: a laboratory 
manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 
N.Y. 
Schaffer, P. A. 1975. Temperature-sensitive mutants of herpesviruses. Curr. Top. Mic-
robiol. Immunol. 70:51-100. 
Schlake, T., and J. Bode. 1994. Use of mutated FLP recognition target (FRT) sites for 
the exchange of expression cassettes at defined chromosomal loci. Biochemistry. 
33:12746-12751. 
Schleiss, M. R. and T. C. Heineman. 2005. Progress toward an elusive goal: current 
status of cytomegalovirus vaccines. Expert. Rev. Vaccines. 4:381-406. 
Scholz, H. 2000. Häufigkeit der konnatalen Zytomegalie in der Bundesrepublik 
Deutschland. Monatsschr Kinderheilkd. 148:887-890. 
Schoppel, K., B. Kropff, C. Schmidt, and M. Mach. 1997. The humoral immune re-
sponse against human cytomegalovirus is characterized by a delayed synthesis 
of glycoprotein-specific antibodies. J. Infect. Dis. 178:533-544. 
Schrier, R. D., J. A: Nelson, and M. B: Oldstone. 1985. Detection of human cy-
tomegalovirus in peripheral blood lymphocytes in a natural infection. Science 
230:1048-1051. 
Schumacher, D., B. K. Tischer, W. Fuchs, and N. Osterrieder. 2000. Reconstitution 
of Marek's disease virus serotype 1 (MDV-1) from DNA cloned as a bacterial 
artificial chromosome and characterization of a glycoprotein B-negative MDV-1 
mutant. J. Virol. 74:11088-11098. 
Sclimenti, C. R. and M. P. Calos. 1998. Epstein-Barr virus vectors for gene expression 
and transfer. Curr. Opin. Biotechnol. 9:476-479. 
Shellam G.R., J. E: Allan, J. M. Papadimitriou, and G. J. Bancroft. 1981. Increased 
susceptibility to cytomegalovirus infection in beige mutant mice. Proc. Natl. 
Acad. Sci. U. S. A. 78:5104-5108. 
 G. Reference List 104 
Shizuya, H., B. Birren, U. J. Kim, V. Mancino, T. Slepak, Y. Tachiiri, and M. 
Simon. 1992. Cloning and stable maintenance of 300-kilobase-pair fragments of 
human DNA in Escherichia coli using an F-factor-based vector. Proc. Natl. 
Acad. Sci. U. S. A. 89:8794-8797. 
Sinzger, C. and G. Jahn. 1996. Human cytomegalovirus cell tropism and pathogenesis. 
Intervirology 39:302-319. 
Sinzger, C., B. Plachter, A. Grefte A. S. Gouw, T. H. The, and G. Jahn. 1996. Tis-
sue macrophages are infected by human cytomegalovirus in vivo. J. Infect. Dis. 
173:240-245. 
Sinzger, C., A. Grefte, B. Plachter, A. S. Gouw, T. H. The, and G. Jahn. 1995. Fi-
broblasts, epithelial cells, endothelial cells and smooth muscle cells are major 
targets of human cytomegalovirus infection in lung and gastrointestinal tissues. 
J. Gen. Virol. 76:741-750. 
Smith, G. A., and L. W. Enquist. 1999. Construction and transposon mutagenesis in 
Escherichia coli of a full- length infectious clone of pseudorabies virus, an al-
phaherpesvirus. J. Virol. 73:6405-6414. 
Soderberg-Naucler, C. and J. Y. Nelson. 1999. Human cytomegalovirus latency and 
reactivation - a delicate balance between the virus and its host's immune system. 
Intervirology 42:314-321. 
Soderberg-Naucler, C., K. N. Fish, and J. A. Nelson. 1997. Reactivation of latent 
human cytomegalovirus by allogenic stimulation of blood cells from healthy do-
nors. 91:119-26. 
Soderberg, C., S. Larsson, S. Bergstedt-Lindqvist, and E. Moller. 1993.- Definition 
of a subset of human peripheral blood mononuclear cells that are permissive to 
human cytomegalovirus infection. J. Virol. 67:3166-3175. 
Spaete, R. R. and E. S. Mocarski. 1987. Insertion and deletion mutagenesis of the hu-
man cytomegalovirus genome. Proc. Natl. Acad. Sci. U. S. A. 84:7213-7217. 
 G. Reference List 105 
Speir, E., R. Modali, E. S. Huang, M. B. Leon, F. Shawl, T. Finkel, and S. E. Ep-
stein. 1994. Potential role of human cytomegalovirus and p53 interaction in 
coronary restenosis. Science 265:391-394. 
Staczek., J. 1990. Animal cytomegaloviruses. Microbiol. Rev. 54:247-265. 
Stagno, S. and R. J. Whitley. 1985. Herpesvirus infections of pregnancy. Part I: Cy-
tomegalovirus and Epstein-Barr virus infections. N. Engl. J. Med. 313:1270-4. 
Stavropoulos, T. A. and C. A. Strathdee. 1998. An enhanced packaging system for 
helper-dependent herpes simplex virus vectors. J. Virol. 72:7137-43. 
Stenberg, R. M., A. S. Depto, J. Fortney, and J. A. Nelson. 1989. Regulated expres-
sion of early and late RNAs and proteins from the human cytomegalovirus im-
mediate-early gene region. J. Virol. 63:2699-708. 
Stoddert, C. A., R. D. Cardin, J. M. Boname, W. C. Manning, G. B. Abenes, and E. 
S. Mocarski. 1994. Peripheral blood mononuclear phagocytes mediate dissemi-
nation of murine cytomegalovirus. J. Virol. 68:6243-6253. 
Sutherland, C. L., N. J. Chalupny, and D. Cosman. 2001. The UL16-binding pro-
teins, a novel family of MHC class I-related ligands for NKG2D, activate natu-
ral killer cell functions. Immunol. Rev. 181:185-192. 
Szostak, J. W., T. L. Orr-Weaver, R. J. Rothstein, and F. W. Stahl. 1983. The dou-
ble-strand-break repair model for recombination. Cell 33:25-35. 
Taylor-Wiedemann, J., J. G. Sissons, L. K. Borysiewicz, and J. H. Sinclair. 1991. 
Monocytes ar a major site of persistence of human cytomegalovirus in periph-
eral blood mononuclear cells. J. Gen. Virol. 72: 2059-2064. 
Thale, R., P. Lucin, K Schneider, M. Eggers, and U. H. Koszinowski. 1994. Identifi-
cation and expression of a murine cytomegalovirus early gene coding for an Fc 
receptor. J. Virol. 68:7757-7765. 
Tomasec, P., V. M. Braud, C. Rickards, M. B. Powell, B. P. McSharry, S. Gadola, 
V. Cerundolo, L. K. Borysiewicz, A. J. McMichael, and G. W. Wilkinson. 
 G. Reference List 106 
2000. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced 
by human cytomegalovirus gpUL40. Science 287:1031. 
Tomazin, R., J. Boname, N. R. Hegde,  D. M. Lewinsohn, Y. Altschuler, T. R. 
Jones, P. Cresswell, J. A. Nelson, S. R. Riddell, and D. C. Johnson. 1999. Cy-
tomegalovirus US2 destroys two components of the MHC class II pathway, pre-
venting recognition by CD4+ T cells. Nat. Med. 5:1039-1043. 
van Zijl, M., W. Quint, J. Briaire, T. de Rover, A. Gielkens, and A. Berns. 1988. 
Regeneration of herpesviruses from molecularly cloned subgenomic fragments. 
J. Virol. 62:2191-2195. 
Vieira, J., H. Farrell, W. D. Rawlinson, and E. S. Mocarski. 1994. Genes in the Hin-
dIII J fragment of the murine cytomegalovirus genome are dispensable for 
growth in cultured cells: insertion mutagenesis with a lacZ/gpt cassette. J. Virol. 
68:4837-46. 
Vink, C., E. Beuken, and C. A. Bruggeman. 2000. Complete DNA sequence of the rat 
cytomegalovirus genome. J. Virol. 74:7656-7665. 
Wagner, M. and U. H. Koszinowski. 2003. Mutagenesis of viral BAC plasmids with 
linear DNA fragments (ET recombination) In S. Zhao and M. Stodolsky (eds.), 
Bacterial Artificial Chromosomes. 
Wagner, M., A. Gutermann, J. Podlech, M. J. Reddehase, and U. H. Koszinowski. 
2002a. Major histocompatibility complex class I allele-specific cooperative and 
competitive interactions between immune evasion proteins of cytomegalovirus. 
J. Exp. Med. 196:805-816. 
Wagner, M., Z. Ruzsics, and U. H. Koszinowski. 2002b. Herpesvirus genetics has 
come of age. Trend. Microbiol. 10:318-324. 
Wagner, M., D. Michel, P. Schaarschmidt, B. Vaida, S. Jonjic, M. Messerle, T. 
Mertens, and U. H. Koszinowski. 2000. Comparison between human cy-
tomegalovirus pUL97 and murine cytomegalovirus (MCMV) pM97 expressed 
 G. Reference List 107 
by MCMV and vaccinia virus: pM97 does not confer ganciclovir sensitivity. J. 
Virol. 74:10729–10736. 
Wagner, M., S. Jonjic, U. H. Koszinowski, and M. Messerle. 1999. Systematic exci-
sion of vector sequences from the BAC-cloned herpesvirus genome during virus 
reconstitution. J. Virol. 73:7056-7060. 
Wang, X.; S.-M. Huong, M. L. Chiu, N. Raab-Traub N and E.-S. Huang. 2003. 
Epidermal growth factor receptor is a cellular receptor for human cytomegalovi-
rus. Nature 424: 456–461 
Welch, A. R., L. M. McGregor, and W. Gibson. 1991. Cytomegalovirus homologs of 
cellular G protein-coupled receptor genes are transcribed. J. Virol. 65:3915-
3918. 
Weston, K. and B. G. Barrell. 1986. Sequence of the short unique region, short re-
peats, and part of the long repeats of human cytomegalovirus. J. Mol. Biol. 
192:177-208. 
Wing, B. A. and E. S. Huang. 1995. Analysis and mapping of a family of 3'-coterminal 
transcripts containing coding sequences for human cytomegalovirus open read-
ing frames UL93 through UL99. J. Virol. 69:1521-31. 
Wong A, K. H. Tan, C. S. Tee, and G. S. Yeo. 2000. Seroprevalence of cytomegalovi-
rus, toxoplasma and parvovirus in pregnancy. Singapore Med. J. 41:151-155. 
Zhang, Y., F. Buchholz, J. P. Muyrers, and A. F. Stewart. 1998. A new logic for 
DNA engineering using recombination in Escherichia coli. Nat. Genet. 20:123-
128. 
Zhou Y.F., M. B. Leon, M. A. Waclawiw, J .J. Popma, Z. X. Yu, T. Finkel, and S. 
E. Epstein. 1996. Association between prior cytomegalovirus infection and the 
risk of restenosis after coronary atherectomy. N. Engl. J. Med. 335:624-630. 
Zhu, H., Y. Shen, and T. Shenk. 1995. Human cytomegalovirus IE1 and IE2 proteins 
block apoptosis. J. Virol. 69:7960-7970. 
 G. Abbreviations 108 
 
G. ABBREVIATIONS 
 
AS  amino acid 
ATCC  American type culture collection 
BAC  bacterial artificial chromosome 
bp  base pairs 
cam  chloramphenicol 
CMV  cytomegalovirus 
CTL  cytotoxic T-cells 
dGTP  deoxyguanosine triphosphate  
DMEM Dulbecco´s modified Eagle´s medium 
DNA  deoxyribonucleic acid 
EBV  Epstein-Barr virus 
Fig.  figure 
FRT  FLP recombinase target 
GFP  green fluorescent protein 
gp  glycoprotein 
HCMV human CMV 
HHV-6, 7, 8 human herpesvirus-6, 7, 8 
HSV  herpes simplex virus 
IFN  interferon 
IL  interleukin 
KAc  potassium acetate 
Kan  kanamycin 
KCl  potassium chloride 
kb  kilobase pairs 
kDa  kilo dalton 
M  molar 
Mbp  mega base pairs 
ml  mililiter 
mM  milimolar 
MCMV murine CMV 
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MEF  murine embryo fibroblasts 
MHC  major histocompatibility complex 
MHV-68 murine herpesvirus 68 
MOI  multiplicity of infection 
NK  natural killer 
NCS  new born calf serum 
nt  nucleotide 
ORF  open reading frame 
PCR  polymerase chain reaction 
PEC  peritoneal exudate cells 
PFU  plaques forming units 
pi  post infection 
SDS  sodium dodecyl sulphate 
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis 
Tab.  table 
Tn  transposon 
VZV  Varicella zoster virus 
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